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ABSTRACT 
Giulia Ghibellini 
IN VIVO AND IN VITRO METHODS TO DETERMINE BILIARY CLEARANCE 
OF DRUGS IN HUMANS 
 
(Under the direction of Kim L.R. Brouwer, Pharm.D., Ph.D.) 
 
Biliary excretion is an important route of hepatic elimination of drugs and metabolites that is 
investigated commonly using in vitro or in vivo animal models.  However, changes in biliary 
clearance due to drug-drug interactions, genetic polymorphisms and/or disease state may be 
species-specific, and animal data may be difficult to extrapolate to humans.  This dissertation 
research focused on the development and refinement of a specialized clinical protocol and 
novel oroenteric tube to accurately quantify biliary clearance of drugs in humans and the 
comparison of these values with predicted biliary clearance values determined in sandwich-
cultured human hepatocytes.  Hepatocytes cultured between two layers of extracellular 
matrix express and correctly localize functional transport proteins on the canalicular as well 
as the basolateral domains, and enable determination of drug excretion into bile by 
quantifying accumulation within the hepatocyte and bile canalicular networks.  Experiments 
were devised and performed to establish the utility of this model to predict hepatobiliary drug 
disposition in humans.  The biliary clearance of three model probes, Tc-99m mebrofenin, Tc-
99m sestamibi, and piperacillin, was evaluated in healthy humans.  These model compounds 
exhibited high, intermediate and low biliary clearance, respectively.  Pharmacokinetic 
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modeling and simulations of the disposition of Tc-99m mebrofenin in humans, combined 
with results of in vitro systems transfected with hepatic transport proteins, revealed that 
disease states and drug interactions would impact the hepatobiliary disposition of this probe.  
Moreover, the recovery of piperacillin metabolites in bile samples obtained during the 
clinical studies suggested that the clinical methodology developed is useful for the 
identification of metabolites unique to the human species.   Finally, the biliary clearance 
values obtained in vivo were compared to those calculated using sandwich-cultured human 
hepatocytes.  The in vitro system proved to be a reliable model for predicting biliary 
clearance of xenobiotics in humans. 
Collectively, the results of this research provide new tools, both in vivo and in vitro, to study 
and characterize biliary clearance of drugs in the most relevant species, humans.  
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A portion of this Chapter is in press in Molecular Pharmaceutics Volume 3, Issue 3, 2006.
ABSTRACT:  
Determining the biliary clearance of drugs in humans is very challenging because bile in not 
readily accessible due to the anatomy of the hepatobiliary tract.  The collection of bile 
usually is limited to post-surgical patients with underlying hepatobiliary disease.  In healthy 
subjects, feces typically are used as a surrogate to quantify the amount of drug excreted via 
non-urinary pathways.  Nevertheless, it is very important to characterize hepatobiliary 
elimination because this is a potential site of drug interactions that might result in significant 
alterations in systemic or hepatic exposure.  In addition to the determination of in vivo biliary 
clearance values of drugs, the availability of in vitro models that can predict the extent of 
biliary excretion of drugs in humans may be a powerful tool in the pre-clinical stages of drug 
development.  In this review, recent advances in the most commonly used in vivo methods to 
estimate biliary excretion of drugs in humans are outlined.  Additionally, in vitro models that 
can be employed to investigate the molecular processes involved in biliary excretion are 
discussed to present an updated picture of the new tools and techniques that are available to 
study the complex processes involved in hepatic drug transport.  
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INTRODUCTION:  
With the advent of combinatorial chemistry, an increasing number of new chemical entities 
that are more lipophilic and characterized by high molecular weight are being synthesized 
and screened during the drug discovery process.1   Drugs with these physicochemical 
characteristics often are associated with significant hepatic metabolism and/or excretion via 
the biliary route.2,3   The threshold molecular weight for drugs and metabolites to be excreted 
preferentially into bile varies between species, ranging from ~235 in rats up to 500-600 in 
humans.  Biliary excretion of compounds can significantly impact the systemic exposure, 
pharmacological effect and toxicity of certain drugs.  Drugs excreted into bile often undergo 
some degree of reabsorption along the gastrointestinal tract (e.g., mycophenolic acid4, 
warfarin5, and digoxin3).  Enterohepatic recycling is also a very important physiological 
process for bile salt homeostasis.  In humans, the intestinal reabsorption of bile salts is very 
efficient; more than 95% of the bile salt pool is reabsorbed in the distal ileum.6,7  So far, 
limited in vivo information has been available regarding the extent of biliary elimination of 
drugs and metabolites in humans, primarily due to the difficulty in obtaining bile samples 
from healthy human subjects.  An accurate measure of biliary clearance and of the extent of 
biliary excretion of compounds would be extremely valuable in evaluating the contribution of 
biliary clearance to total systemic clearance, elucidating potential mechanisms of 
hepatobiliary toxicity, predicting drug-drug interactions, and identifying enterohepatic versus 
enteroenteric recirculation.   Several clinical studies have shown that drug-drug interactions 
can result in changes in drug absorption due to inhibition of transport proteins [increased 
exposure to talinolol after P-glycoprotein (P-gp, gene symbol ABCB1) inhibition8, or 
inhibition of intestinal secretion resulting in improved therapeutic efficacy of paclitaxel9].  
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Important modifications in the pharmacokinetics/pharmacodynamics of digoxin, another P-
gp substrate, have been observed with co-administration of other P-gp substrates/inhibitors, 
which are thought to cause interactions in intestinal10, biliary11,12 and/or renal13,14 levels.  
However, drug-drug interactions influencing biliary clearance of compounds have not been 
investigated systematically due to technical difficulties in performing these experiments in 
humans.  The inhibition of hepatobiliary transport processes can affect the ability of the liver 
to extract bile salts from the bloodstream or, potentially more importantly, can affect the 
metabolism and biliary excretion of bile salts.  Although mechanisms of hepatotoxicity are 
believed to be multifactorial, it has been demonstrated that inhibition of bile salt biliary 
excretion by drugs (e.g., troglitazone15 and bosentan16) can affect hepatocyte viability due to 
the accumulation and direct toxicity of detergent-like bile salts.17 
The contribution of biliary excretion to the overall disposition and pharmacological effect 
of some drugs has been underestimated due to the lack of methodologies to accurately 
quantify the amount of drug subjected to enterohepatic recirculation, and a poor 
understanding of the processes involved in hepatic excretion and reabsorption of drugs from 
the canalicular space, bile ducts and intestine.  Several animal models, primarily rodent, have 
been used to study genetic diseases affecting biliary clearance and drug-drug interactions.  
Mouse and rat isolated perfused liver experiments and bile duct cannulated animals are 
useful tools for studying biliary disposition of drugs in the early phases of drug development.  
The availability of rodent models genetically deficient in specific transport proteins has 
improved understanding of the complex molecular processes involved in excretion of 
endogenous and exogenous compounds into bile.18-22  However, accumulating evidence 
suggests that significant inter-species differences exist in the function and regulation of 
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transport proteins, in addition to the already thoroughly characterized species differences in 
metabolism; these findings complicate the direct extrapolation of animal data to humans.23-25  
Enterohepatic recirculation of drugs has been studied extensively in experimental animals 
where cannulation of the bile duct allows for interruption of bile flow into the intestine.  The 
importance of enterohepatic recirculation also has been investigated with a similar study 
design in humans.  The pharmacokinetic profiles of drugs have been compared in patients 
with bile duct obstruction, before and after removal of nasobiliary drainage.  This design 
allows complete collection of bile and interruption of enterohepatic recirculation while the 
drainage is in place.26  However, since the subjects studied in this type of experimental 
design are affected by hepatobiliary disease, it is not possible to account for changes in the 
hepatobiliary tract that might have followed the resolution of bile duct obstruction.  
Mechanisms for Excretion of Endogenous and Exogenous Compounds into Bile: 
Several recent reviews have been published on the transporters involved in hepatobiliary 
disposition of drugs and bile salts.27-31  The liver (Figure 1.1) plays a central role in the 
biotransformation and removal of xenobiotics and endogenous compounds from the blood.  
While the majority of small, lipophilic compounds enter the hepatocyte from the Space of 
Disse on the basolateral membrane by simple passive diffusion, more polar and bulky 
molecules require transport systems to cross the sinusoidal membrane (Figure 1.2 A).  Once 
inside the hepatocyte, compounds can be transported into bile either unchanged or as more 
hydrophilic metabolites after phase I and/or phase II biotransformations, or can be excreted 
into blood by basolateral transport proteins (Figure 1.2 B).  The presence of several transport 
proteins on the canalicular domain of hepatocytes results in the excretion of solutes into the 
bile canaliculi, which are dilated intercellular spaces.  One of the many functions of the liver 
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is the synthesis of bile acids from cholesterol32. The major bile acids present in human bile 
are cholic and chenodeoxycholic acids conjugated with glycine and taurine.33  Bile salts are 
excreted into bile by the bile salt export pump (BSEP/ABCB11, Figure 1.2 B).  Bile salts 
facilitate the absorption of nutrients in the intestine by emulsifying lipophilic molecules due 
to their surfactant characteristics.34  Once this function is served, bile salts are very efficiently 
reabsorbed into the cells of the distal ileum by the apical sodium-dependent bile salt transport 
protein (ASBT/IBAT/SLC10A2 35) and excreted across the basolateral membrane into portal 
blood by the recently identified organic solute transport proteins OST α and β.36,37  In 
addition to bile salt transport, hepatic transport proteins facilitate excretion of end-products 
of metabolism, such as bilirubin and/or xenobiotics, into bile for subsequent removal via the 
intestine, and thus act as an important clearance mechanism.  
Bile Formation and Excretion: 
Bile formation includes uptake of bile components from the sinusoidal blood and secretion of 
these substances into the canalicular space.  Water and other small ions also diffuse into bile 
due to the differential osmotic pressure between bile and the hepatocyte cytoplasm.  
Subsequently, bile is drained into the biliary tree along the liver lobules and reaches the 
hepatic ducts.  In humans, a fraction of this hepatic bile is secreted continuously into the 
duodenum while the majority of the ~800 mL of bile secreted per day is concentrated and 
stored in the gallbladder (Figure 1.1).  Bile freely flows into the gallbladder, because this 
organ has a much lower internal pressure than the intra-hepatic ducts, common bile duct and 
the Sphincter of Oddi (Figure 1.1).  The gallbladder fills to its maximum capacity (40-70 
mL) in approximately 6 hours, while re-absorbing water and electrolytes from hepatic 
bile.3,38-40  After ingestion of a meal, fats, proteins and acid reach the duodenum and 
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endogenous neurohormones such as cholecystokinin (CCK) and secretin are released by 
endocrine cells in the small intestine.41   CCK, acting on the CCK-A type receptors of smooth 
muscle fibers, contracts the gallbladder and relaxes the Sphincter of Oddi.  A similar effect 
can be obtained by intravenous infusion of physiological amounts of CCK analogs (e.g., 
CCK-8).42,43  CCK blood concentrations are decreased to minimal values during fasting, 
which promotes contraction of the Sphincter of Oddi and relaxation of the gallbladder walls, 
facilitating storage of bile in the gallbladder.  CCK also delays gastric emptying in order to 
coordinate the digestive postprandial process.  In the blood of humans and animals, CCK-33, 
8 and 58 are the predominant active forms of this polypeptide 44 generated by differential 
post-translational modifications of the same gene; functional activity is dependent upon the 
last seven amino acids at the carboxyl terminus.  In addition to the role of CCK in gallbladder 
contraction, CCK also functions as a neurotransmitter in the cerebral cortex to regulate 
satiety, and on the peripheral nerves of the GI tract to regulate bowel movement.45,46 
Methods Used to Determine In Vivo Biliary Clearance: 
Several preclinical tools involving in vivo or ex vivo rodent models can be utilized to evaluate 
the extent of biliary excretion of drugs and the interaction of xenobiotics with bile salt 
transport proteins. These tools employ animal species with well characterized differences 
from humans, making the prediction/extrapolation to humans less accurate.47  Determination 
of the extent of biliary excretion can be attained in human subjects with different 
methodologies as described in detail below.  However, only a few studies have been 
performed in vivo in humans to evaluate biliary clearance of drugs, and little is known about 
the contribution of biliary clearance to the overall systemic clearance for most drugs.  Table 
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1.1 summarizes those studies published in the literature along with the techniques used for 
the determination of the amount of drug and metabolites excreted into bile. 
I. Patients as Study Subjects 
Historically, there has been little success in the development of valid and reliable techniques 
to quantify biliary excretion of drugs or endogenous compounds in healthy human 
volunteers.  Such data is obtained more easily from patients diagnosed with diseases of the 
gallbladder and biliary tract who require medical procedures that allow measurements of 
drug concentrations in bile.  Usually these patients suffer from cholestasis and/or occlusion 
of the biliary or cystic ducts, and some may have undergone liver transplantation.  
i. Cholecystectomy  
Several groups have investigated gallbladder bile concentrations and disposition of 
drugs into bile by administering the compound of interest to patients prior to 
cholecystectomy.  Drug concentrations in the gallbladder bile and tissue after removal are 
quantified and compared to the plasma concentrations.  Although this approach only allows 
the determination of drug content in bile and tissue at a single time point, it is still very useful 
and has been employed to establish whether an antibiotic reaches the necessary therapeutic 
concentrations to treat bacterial infections of the gallbladder and biliary tract.48,49 
ii. T-tube 
Patients that require a temporary bile shunt (T-tube) that diverts part of the bile 
flowing from the liver to a transcutaneous port for external collection have been employed 
commonly to study biliary excretion of drugs.  T-tubes are used primarily in patients with 
cholangitis, distal bile duct obstruction or edema, and often are inserted after 
cholecystectomy and choledochotomy.  T-tubes allow for partial collection of liver bile, and 
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provide an estimate of the biliary excretion of  administered drugs during the  time that the 
shunt is in place.50-55   A limitation of this technique is that bile collection in these patients is 
not complete.  Furthermore, the composition of bile may be very different in patients due to 
underlying hepatobiliary disease.56 
iii. Nasobiliary Drainage 
Patients with bile duct stenosis can be treated with the temporary insertion of a 
nasobiliary tube.  This patient population has been recruited less frequently for drug 
disposition studies, probably due to the fact that this procedure is relatively new.  This 
intervention theoretically allows for complete collection of bile while the tube is in place.  
The nasobiliary drainage interrupts delivery of bile into the duodenum and can be used to 
evaluate the influence of enterohepatic recirculation on the plasma concentration-time profile 
for the drug of interest.  In these studies, the same patients have been used as their own 
control when the stricture has resolved and the tube has been removed thus restoring the  
enterohepatic recycling process.26,50 
Less commonly, bile has been collected from patients equipped with other types of 
drainage devices such as biliary-enteric diversions or percutaneous transhepatic 
cholangiodrainage.51  Although the details of the surgical procedures are beyond the scope of 
this review, all these techniques allow free access to partial or complete collection of hepatic 
bile from patients. 
In recent years laparoscopic cholecystectomy with duct exploration and endoscopic 
retrograde cholangiopancreatography (ERCP) have largely replaced more invasive methods 
for removing common duct stones.  As a result, many fewer patients with T-tubes have been 
available to enroll in studies examining the biliary excretion of drugs.  The relatively few 
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patients who are treated with nasobiliary drainage are seldom well enough or maintain the 
tube long enough to be suitable study candidates. 
II. Healthy Volunteers as Study Subjects 
One of the major limitations of the techniques described above is the use of subjects with 
significant hepatobiliary disease.  Disease status may significantly influence transport protein 
expression, function, localization and/or bile flow, thereby altering drug excretion and 
reabsorption patterns.57,58  It is well known that biliary obstruction decreases the expression 
of BSEP and MRP2 (ABCC2) in hepatocytes, and increases P-gp, MDR3 (ABCB4) and 
MRP3 (ABCC3) expression.59,60 Moreover, cholestatic syndromes may be associated with 
genetic polymorphisms in transport proteins.61,62  More relevant information may be obtained 
by enrolling healthy volunteers as study subjects.  In this case, the physiology of the 
hepatobiliary tract is intact and healthy.  However, the collection of bile from the gallbladder 
or upon immediate secretion into the intestine is more challenging, due to the difficulty of 
accessing the gallbladder and the anatomy of the human hepatobiliary tract.  
i. Fecal Recovery 
The approach most commonly used in the determination of biliary excretion as a 
route for drug elimination is the quantification of the drug of interest in feces.  Often these 
studies are performed with a radiolabeled compound in order to increase the selectivity and 
the recovery of drug and unknown metabolites, resulting in good mass balance.63-69  More 
recently, sensitive analytical techniques such as HPLC coupled with mass spectrometry have 
been applied widely to the analysis of biological matrices to identify the excretion routes of 
parent drugs and metabolites.  Several drawbacks are associated with the quantification of 
drugs in feces.  Most importantly, this method does not distinguish between biliary excretion 
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and intestinal secretion processes.  For orally administered drugs, this method does not 
distinguish between unabsorbed drug and that secreted by the liver and/or gut back into the 
intestinal lumen, thus, the percentage of the dose in feces does not necessarily reflect the 
dose excreted into bile.  Moreover, relatively unstable drugs, or compounds that are 
transformed into unstable metabolites, may not be recovered in feces due to the long 
exposure to the intestinal contents and colonic flora.  Finally, drugs subjected to entero-
hepatic or entero-enteric recycling, such as glucuronide conjugates, can be reabsorbed in the 
colon upon intestinal degradation by β-glucuronidases of the microbial flora, and will not be 
recovered in the feces.  
ii. Aspiration of Duodenal Fluids 
An ideal methodology would provide information on the amount of parent drug and 
metabolites excreted into bile, and would be flexible enough to allow for studies examining 
potential drug-drug interactions.  This type of information can be obtained by sampling 
duodenal fluids to collect bile upon discharge from the biliary tract into the small 
intestine.11,12,70,71  Duodenal bile is representative of gallbladder bile in terms of bile 
composition, although it is more dilute.72  The use of oroenteric tubes to withdraw 
pancreatico-biliary secretions from the duodenum is a common practice in the medical field, 
and has been used to study the biliary excretion of endogenous compounds such as 
radiolabeled bile acids.35,73  Some of these investigations have utilized occlusive balloons to 
facilitate more complete bile collection, along with the perfusion of a marker to evaluate 
leakage of bile or duodenal fluids distal to the balloon seal.74  Other groups have corrected 
for any incomplete bile collection by perfusing non-absorbable markers, such as polyethylene 
glycol or sulphobromophthalein, into the duodenum.71,75,76  Modified versions of these 
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methodologies have been applied successfully to the determination of intestinal absorption 
and secretion of drugs, thus enhancing the knowledge regarding intestinal processes, which 
complements information acquired regarding biliary excretion of drugs.77-82   All the methods 
cited are particularly sophisticated, and the execution of these studies is not trivial.  These 
clinical studies often require custom-made catheters, specialized personnel and equipment, 
and they need to be approved by local Institutional Review Boards and Research Ethics 
Committees.  For these reasons, these methods are not used widely.  Although a direct 
comparison of methods has not been published, it is reasonable to believe that the 
information obtained is, in many cases, an estimate of the amount of drug excreted via the 
biliary route.  Nevertheless, many of the studies conducted in healthy human volunteers have 
resulted in incomplete and highly variable recovery of compounds excreted in bile.  This is 
primarily due to the difficulty in obtaining and assessing the completeness of bile collection, 
and an inherent lack of control over gallbladder contraction. 
A novel method to increase the recovery of biliary secretions and correct for the degree of 
gallbladder contraction, with the intention of reducing the level of complexity of the 
procedure, has been developed recently by our group.83  This method assures the quantitative 
collection of bile secreted into the duodenum by temporary occlusion of the intestine with an 
inflatable balloon.  At the same time, the administration of a hepatobiliary imaging agent 
(e.g. Tc-99m mebrofenin) is used to evaluate the degree of gallbladder contraction in 
response to pharmacological stimulation, and to detect any leakage of bile due to partial 
occlusion of the intestine.  One of the major factors affecting the variability in the 
determination of biliary excretion in humans is related to differences in the amount of bile 
and drug delivered into the duodenum during the collection interval.  Partial spontaneous 
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contractions of the gallbladder during fasting are not uncommon, and can deliver over 25% 
of total gallbladder bile into the intestine.  To obtain more complete gallbladder contraction, 
CCK-8 can be administered intravenously to pharmacologically stimulate gallbladder 
emptying.  CCK-8 administered at a low dose (0.02 μg/Kg) infused slowly over 30-60 min 
has been reported to provide the most complete gallbladder contraction43; however, inter-
individual response is variable, and possibly influenced by the collection procedure.  
Therefore, it is important to assess the degree of gallbladder contraction in each subject.  The 
administration of trace amounts of a gamma-emitting probe that accumulates quickly in bile, 
such as Tc-99m mebrofenin, can assist in the determination of the overall gallbladder 
response, and indicate when intestinal occlusion is not complete.  Alternatively, ultrasound 
may be used to determine the extent of gallbladder contraction together with perfusion of the 
occluded tract with a non-absorbable marker to identify leakages.  A gallbladder ejection 
fraction (EF) can be calculated from the abdominal gamma images of the volunteers during 
gallbladder contraction, and this number can be incorporated as a correction factor when 
determining the amount of bile (containing drug) excreted into the duodenum and collected 
by aspiration.83  This method has been shown to correct reasonably well for the high 
variability in the gallbladder contraction which influences the amount of drug excreted into 
the duodenum.84  Quantification of parent drug and metabolites in bile aspirated directly from 
the duodenum rather than in feces can be extremely advantageous in the identification of 
unknown metabolites, uniquely formed in humans, that are unstable and would not be found 
after prolonged contact with intestinal enzymes (such as unstable glucuronides).  
Finally, the possibility of repeating a pharmacokinetic study in the same volunteers 
with and without the balloon inflated enables an evaluation of the importance of biliary 
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excretion in systemic drug exposure, and in studying the enterohepatic recirculation 
process.85   Biliary excretion and intestinal reabsorption may be one explanation for multiple 
peaks in the plasma concentration-time profiles of some drugs.86,87  Often, pharmacokinetic 
modeling of these data with a model that incorporates enterohepatic recycling has been used 
to explain these experimental observations.88  Unfortunately, this approach does not provide 
direct evidence for biliary excretion, and does not allow for precise quantification of the 
biliary clearance parameter.  Experimentally, the pharmacokinetic disposition of drugs and 
glucuronide conjugates have been compared in patients before and, upon removal of 
nasobiliary drainage, after the restoration of enterohepatic recirculation.26   Other studies 
have interrupted enterohepatic recirculation with antibiotics, to eliminate the colonic flora, 
and/or cholestyramine, a resin that prevents the availability of lipophilic compounds for 
absorption in the gut lumen.4,89   Improved methods for studying drug disposition in healthy 
volunteers in the presence or absence of enterohepatic recirculation should enable the 
investigation of hepatobiliary disposition mechanisms in much more depth than what has 
been attempted to date.  
Methods Used to Determine In Vitro Biliary Excretion 
Several in vitro models are available to investigate the processes governing biliary excretion 
and potential interactions of drugs with the hepatic uptake and excretion of bile salts and 
other endogenous and exogenous substances.  These tools span from the whole hepatocyte to 
membrane vesicles prepared from cell lines transfected with specific transport proteins.  Such 
techniques complement human and animal in vivo studies, and allow characterization of 
transport processes at the molecular level.  Unfortunately, the results obtained with in vitro 
models are difficult to compare to human in vivo data.  This is primarily due to the fact that 
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the data generated in vitro are used to determine values for the intrinsic biliary clearance of a 
drug. In contrast, in vivo studies often are designed to obtain more crude estimates such as 
the percentage of the dose excreted into bile rather than pharmacokinetic parameters.  The in 
vivo biliary clearance values in humans usually are not reported (Table 1.1).  Whole liver 
perfusion, a common technique in rodent models to obtain biliary clearance values, is rarely 
possible in humans due to limited availability of viable whole human livers. 
i. Sandwich-Cultured Hepatocytes 
Primary hepatocytes isolated from humans and animals are useful tools for studying 
hepatic metabolism and transport due to the expression of the full array of proteins involved 
in these processes.  In conventional culture, a rapid decline in expression of both 
metabolizing enzymes and transport proteins occurs over time after cell isolation.90   In 
addition, collagenase digestion of liver, required for hepatocyte isolation results in the 
disruption of the canalicular membrane and consequently, the cellular internalization of 
transport proteins expressed at this membrane.91   A novel in vitro model system using 
primary hepatocytes from various species, including rat and human, cultured in a collagen-
sandwich configuration (SC) has several distinct advantages over conventional hepatocyte 
culture.  For example, SC hepatocytes develop functional and extensive bile canalicular 
networks, acquire and maintain normal cell polarity, and allow direct access to the 
hepatocyte and adjacent biliary compartment.92-96  Thus, hepatocytes maintained under these 
culture conditions offer a unique opportunity to study basolateral uptake and canalicular 
efflux transport processes.  Using simple alterations in buffer components, accumulation of 
substrates of interest can be measured in hepatocytes alone, or in hepatocytes plus canalicular 
networks.  This allows determination of the in vitro intrinsic biliary clearance.  To date, most 
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SC experiments have been conducted using rat hepatocytes. 93,96-100  Recently, SC human 
hepatocytes also have been characterized; uptake and efflux transport proteins are expressed, 
properly localized on the apical and basolateral membranes and functional.91,101  Since SC 
human hepatocytes  also retain metabolic capabilities, this model allows for investigation of 
the interplay between many of the processes that take place in vivo.  Additionally, these cells 
can be maintained in culture for several days allowing for the study of drug interactions 
involving induction mechanisms.  Human hepatocytes are not readily available and are 
associated with high costs.  Furthermore, each culture is performed with cells from a single 
donor reflecting the inherent variability among donors in protein expression, function, and 
canalicular network formation.  SC human hepatocytes serve as a unique, comprehensive tool 
to investigate hepatobiliary transport mechanisms.   
ii. Suspended Hepatocytes 
Viability of primary hepatocytes can be maintained for several hours in suspension 
when supplemented with appropriate culture media and oxygen.  Fresh or cryopreserved rat 
and human hepatocytes have been used extensively to determine the hepatic metabolic 
clearance of drugs. 102,103 Suspended hepatocytes are a useful tool to characterize hepatic 
uptake and metabolism processes and inhibition studies can be perfomed with this system.  
However, due to the limited viability of these cells, it is not possible to study induction 
processes.104-106   Additionally, internalization of canalicular transport proteins during 
collagenase perfusion limits the use of suspended hepatocytes to predict an overall value for 
biliary clearance when transport into bile is important. 
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iii. Vectorial Transport Using Polarized Cell Lines  
The Madin Darby Canine Kidney, strain II (MDCKII) cells are polarized cells that 
have been used extensively to express various combinations of recombinant uptake and 
efflux transport proteins.  Initially, MDCKII cells transfected with different combinations of 
a single basolateral uptake and a single canalicular efflux pump were established.107-109  More 
recently, MDCKII cells transfected with a single efflux pump (MRP2/ABCC2) and three 
basolateral uptake transport proteins (OATP1B1/SLCO1B1, OATP1B3/SLCO1B3 and 
OATP2B1/SLCO2B1) have been established in an attempt to mimic vectorial transport 
processes in human liver.110  The combination of quadruple, double and single transfected 
cells is very useful for determining the contribution of individual transport proteins to 
vectorial transport processes.  These cell lines can be transfected with transport proteins of 
interest, grown on a permeable membrane, and used to study the transcellular passage of 
selected substrates.  Many model substrates have been studied using MDCK cells, and 
correlated with biliary clearance values obtained from rats in vivo.108  Although the polarized 
transfected cell systems are powerful tools for studying vectorial transport, they lack a full 
complement of transport proteins, metabolic enzymes and co-factors present in hepatocytes, 
and expression levels of transport proteins may not be comparable to hepatocytes in vivo.    
These issues must be considered in data interpretation and when extrapolating to in vivo 
hepatic or biliary clearance values.  Nevertheless, transfected systems are simple to use and 
more readily available than primary human hepatocytes and are useful as a high-throughput 
screening tool.  
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iv. Whole Cells and Membrane Vesicles  
Whole cell expression systems such as Xenopus laevis oocytes or immortalized cell 
lines transfected with the transporter of interest are ideal tools when functional studies of the 
kinetics of transport for individual transport proteins are needed.111  Such expression systems 
have been used extensively in the literature to demonstrate substrate specificity and for 
functional characterization of mutant proteins, such as genetic polymorphisms.112,113  
Although oocytes are a transient expression system and need to be injected individually with 
cRNA of the protein of interest, oocytes often are used to study uptake processes.  The 
commercial availability of this model facilitates their use for transport studies.114  These 
expression systems are more applicable to studying the effect of genetic diseases and the 
molecular mechanisms of transport than for the determination of hepatobiliary clearance.115  
Because of technical difficulties in loading whole cells with a substrate of interest prior to 
measuring efflux, these models are more suitable for the study of uptake transport proteins.  
To circumvent this issue, the double transfected MDCKII cells have been used, or more 
commonly, efflux transport processes have been studied with inside-out membrane vesicles.  
Such vesicles can be prepared from primary hepatocytes or from cell lines transfected with a 
transport protein of interest.  Basolateral and apical membrane vesicles prepared from 
polarized cells such as primary hepatocytes can be isolated through various centrifugation 
steps and membrane fractions enriched in basolateral or canalicular transporters can be used 
to investigate drug transport and transport inhibition.116,117  Canalicular vesicles .are more 
commonly prepared from rat than human hepatocytes due to limited human tissue 
availability.  However, several recent studies have used canalicular membrane vesicles 
isolated from human hepatocytes.117-119  Membrane vesicles prepared from primary 
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hepatocytes have distinct advantages over transfected systems:  the native membrane 
environment is in place during isolation from the other cellular components, and all the 
hepatic transport systems are present.  Membrane vesicles can be prepared, stored frozen, and 
used as needed; however, isolation of basolateral and canalicular fractions is labor intensive 
and complete purity is never achieved.   
Membrane vesicles prepared from cell lines transiently and stably expressing 
membrane proteins of interest have been used extensively to characterize polymorphisms, 
substrate specificity and structure-function relationships of efflux transport proteins.120-122  
The expression systems used are many (insect cells: e.g., Sf9 cells 123,124; mammalian cells: 
e.g. HEK293 cell line 125) and expression of endogenous transporters may vary.  The 
background activity of membrane vesicles must be accounted for by performing control 
experiments in untransfected cells; moreover, post-translational protein modifications may be 
different depending on the host cells and may affect the affinity of the transport protein for 
the substrate of interest. 
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CONCLUSIONS: 
Novel and important technologies for evaluation of biliary excretion and the related 
toxicological/pharmacological issues derived from drug-drug interactions at the hepatobiliary 
transport level are under development.  Currently, several in vitro models are used as 
screening tools in drug discovery and early development to eliminate molecules that present 
challenges in this particular aspect of disposition.126-128   Comparison of results obtained 
using in vitro systems to data generated in vivo in humans would be extremely beneficial to 
substantiate in vitro observations.  Unfortunately, information on in vivo biliary excretion of 
drugs is not readily available, and studies in volunteers will continue to be challenging and 
limited to few subjects.  However, the findings of these studies can be extremely valuable, 
not only to explain results obtained using in vitro systems, but also to determine the 
importance of biliary excretion and enterohepatic recirculation in the overall disposition of 
drugs.  
In the future, it is possible that a more systematic comparison between in vivo and in 
vitro hepatobiliary clearance will confirm the accuracy of in vitro scaled predictions, and 
allow the development of accurate models to predict drug disposition in humans with a 
higher degree of confidence.  We believe that this combination of tools, together with 
extensive use of mathematical modeling and simulations, will not only improve our 
understanding of drug disposition, but will also help predict drug-drug interactions and/or the 
impact of genetic polymorphisms on drug exposure and toxicity. 
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PROJECT RATIONALE AND SPECIFIC AIMS 
This project is part of a long-term research effort to develop a method to accurately predict 
from in vitro data the biliary clearance of drugs measured in vivo in humans. This type of 
correlation is lacking in the current literature despite the extensive use of in vitro systems to 
predict disposition and metabolism of drugs in humans.  One of the major obstacles 
encountered in studying the biliary excretion of drugs is the difficulty in accessing the 
gallbladder and collecting bile from healthy volunteers.  This is why, for many drugs, very 
little is known about the actual fraction of the dose excreted in bile, and the portion of total 
clearance that can be attributed to the biliary route.  The development and validation of a 
technique to determine biliary clearance in healthy human volunteers would provide novel in 
vivo information which could be compared to biliary clearance values generated in vitro.  
Several in vitro models have been used to examine mechanisms of biliary clearance.  The 
most physiologically relevant in vitro system, which is characterized by the presence of both 
metabolic enzymes and transport proteins, is the sandwich-cultured human hepatocyte model. 
This in vitro system could be employed for moderate- to high-throughput screening of human 
hepatic clearance mechanisms, and perhaps more importantly, for investigating and 
predicting drug associated hepatotoxicity and drug-drug interactions.  
In summary, the first aim of this research project was to develop a method to quantitatively 
collect bile in healthy volunteers after administration of probe compounds.  These probes 
were specifically selected to exhibit various degrees of biliary excretion, in order to generate 
a range of in vivo biliary clearance values for these compounds.  A second objective was to 
utilize pharmacokinetic modeling and simulations, as well as in vitro systems expressing 
specific transport proteins, to elucidate the mechanisms involved in the hepatobiliary 
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disposition of the model compound Tc-99m mebrofenin, and to explore the effects of 
pathophysiological changes due to disease states or drug interactions on the disposition of 
this compound.  Additionally, the versatility of the clinical technique was demonstrated by 
collecting previously unknown metabolites that were excreted in bile, in addition to 
quantifying the biliary excretion of drugs.  Finally, the sandwich-cultured human hepatocyte 
model was used to investigate the in vitro biliary clearance of the model compounds 
previously studied in vivo, in order to evaluate the accuracy of the in vitro predictions. These 
Aims are described briefly in the next few pages and in depth results, analyses and discussion 
are reported in Chapters 2-5 and in Appendices A-D. 
 
HYPOTHESES:  A method to quantitatively estimate biliary clearance of drugs in healthy 
human volunteers can be developed and applied to model compounds exhibiting a wide 
range of biliary excretion (Aim #1).  Pharmacokinetic modeling and simulation studies with 
Tc-99m mebrofenin can explain in vivo observations in health and disease; information 
obtained with the aid of in vitro tools concerning the mechanisms underlying Tc-99m 
mebrofenin biliary excretion can be incorporated into the pharmacokinetic model (Aim #2). 
The clinical methodology developed in Aim #1 can be applied to the collection of labile 
metabolites in bile that are unique to the human species (Aim #3). The biliary clearance of 
the model compounds obtained in sandwich-cultured human hepatoyctes, once properly 
scaled, can accurately predict in vivo biliary clearance in humans (Aim #4). 
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Specific Aim #1 Hypothesis: It is possible to quantitatively collect bile secreted into the 
duodenum in healthy volunteers and obtain reliable estimates of biliary clearance for drugs 
that exhibit various degrees of biliary excretion. 
1.a. Design an oroenteric tube and a clinical protocol to quantitatively collect duodenal 
secretions in humans. 
1.b. Validate the oroenteric tube and clinical protocol in a study involving healthy human 
volunteers using Tc-99m mebrofenin. 
1.c. Utilize the technique developed in 1.a and 1.b to obtain biliary clearance values in 
healthy volunteers for piperacillin, Tc-99m sestamibi and Tc-99m mebrofenin, compounds 
expected to exhibit low, intermediate and high biliary clearance, respectively. 
 
Specific Aim #2 Hypothesis: The disposition of Tc-99m mebrofenin observed in the clinical 
studies can be characterized with the aid of pharmacokinetic modeling. The mechanisms of 
hepatobiliary transport of this probe can be clarified with the use of in vitro tools. 
2.a. Use pharmacokinetic modeling as an approach to evaluate the disposition of Tc-99m 
mebrofenin (a model compound that undergoes high biliary clearance) in humans and 
simulate alterations in disposition caused by drug interactions or disease states. 
2.b. Identify the human transport proteins involved in the hepatic basolateral uptake of Tc-
99m mebrofenin using Xenopus leavis oocytes transfected with OATP1B1 and OATP1B3. 
2.c. Elucidate the mechanism of canalicular and basolateral excretion of Tc-99m mebrofenin 
using inside-out membrane vesicles prepared from HEK293 cells transfected with MRP2 or 
MRP3. 
 24
2.d. Evaluate the contribution of Mrp2 in the biliary excretion of Tc-99m mebrofenin in the 
sandwich-cultured rat hepatocyte model using cells from control (Wistar) and TR- (Mrp2-
deficient) rats. 
 
Specific Aim #3 Hypothesis: The collection of bile as soon as it is secreted into the human 
intestine by utilizing the oroenteric tube and clinical protocol developed in Aim #1 allows for 
identification of labile metabolites unique to the human species. 
 3.a. Use LC-MS-MS to analyze bile and urine obtained from healthy volunteers after 
administration of piperacillin in order to investigate the formation and excretion of Phase I 
and Phase II metabolites. 
3.b. Demonstrate that the formation of labile metabolites identified in vivo can be generated 
in vitro.  
 
Specific Aim #4 Hypothesis: The sandwich-cultured human hepatocyte model is a useful 
tool for predicting biliary clearance values in humans.  
4.a. Customize experimental conditions for studying the cellular accumulation of model 
compounds in sandwich-cultured human hepatocytes. 
4.b. Determine the biliary excretion index (BEI) and in vitro biliary clearance parameters for 
Tc-99m mebrofenin, Tc-99m sestamibi and piperacillin in sandwich-cultured hepatocytes. 
4.c. Investigate the predictive capabilities of the sandwich-cultured human hepatoycte model 
by comparing in vitro data with in vivo data obtained in humans. 
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TABLES 
 
Table 1.1: Summary of human studies that report the amount of parent drug and/or 
metabolites excreted via the biliary route.  
The percentages of the dose excreted into bile and/or feces as parent drug or total 
radioactivity are summarized where possible. The administration route and methods used to 
obtain this information, the particular population of subjects studied, and systemic and biliary 
clearance values, if published also are listed. Antibiotics are a therapeutic class that has been 
studied in particular detail in terms of biliary excretion and distribution within the gallbladder 
tissue. In addition to the studies reported here, the reader is referred to comprehensive 
reviews on this topic.71,122-124 
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Therapeutic Class Compound Administration 
route 
Population 
studied 
Bile collection 
methodology 
(number of 
subjects) 
% of dose excreted 
in bile or feces 
(collection interval) 
Clearance 
parameters 
Reference 
132 Antineoplastic 
Agent 
Elsamitrucin IV Cancer  
patients 
Indwelling biliary 
catheter (n=1) 
~22  unchanged  
(51 hr) 
 
Cltotal=10-19 
L/h/m2
 Irinotecan IV (14C) Cancer  
patients 
Feces (n=7); T-tube 
bile and feces (n=1) 
54-75 total in feces, 
30 total in bile; 32.3 
unchanged, 14  total  
in feces 
 
Cltotal=13.5 
L/h/m2
67 
133 
134  Taxol IV Cancer  
patients 
Feces  (n=5) 5 and 71.1 
unchanged and total 
(4-5 days) 
 
N.D. 
 Vincristine aIV (3H) Cancer  
patients 
T-Tube bile and 
feces (n=1) 
a49.6 total in bile 
and 4.2 in feces (72 
hr), 46.5 of bile 
radioactivity at 2 hr 
as unchanged  
 
bCltotal=189 
mL/min/m2
a, 55
b, 135
41
83 Hepatobiliary 
Imaging Agent 
Tc-99m 
Mebrofenin 
IV Healthy  
volunteers 
Duodenal aspiration 
(n=4) 
67.1/84.2 
unchanged/ 
corrected by EF 
(3 hr) 
Cltotal=17.3  
Clbiliary=12.5 
in vivo Clbiliary 
=16.1 
mL/min/Kg 
 
136 Cardiac Imaging 
Agent 
Tc-99m 
Sestamibi 
IV Healthy  
volunteers 
Duodenal aspiration 
(n=7) 
14.7/ 21.5 
unchanged/ 
corrected by EF 
(3 hr) 
Cltotal=25.8 
Clbiliary=3.9 
in vivo 
Clbiliary=6.0 
mL/min/Kg 
 
50 NSAID Aspirin PO and IV Patients T-tube bile (n=3);  
nasobiliary tube bile 
(n=2) 
 
0.02-1.89 primarily 
conjugated (24 hr) 
N.D. 
 41
51  Diclofenac PO Patients Percutaneous 
transhepatic 
cholangiodrainage 
(n=2)  
 
4.6 total (24 hr), 1.1 
unchanged and 
active phase II 
metabolites 
N.D. 
51  Indomethacin PO Patients Percutaneous 
transhepatic 
cholangiodrainage 
(n=3)  
 
0.23-15 (24 hr) N.D. 
51  Ibuprofen PO Patients Percutaneous 
transhepatic 
cholangiodrainage  
(n=3) 
 
0.82 (24 hr), 0.15 
unchanged and 
active phase II 
metabolites 
N.D. 
Analgesic, 
Antipyretic 
Paracetamol/ 
Acetaminophen 
PO cPatients; 
 dhealthy 
volunteers  
cT-tube bile (n=6); 
dduodenal aspiration 
for 15 min post CCK 
administration(n=10) 
 
c2.6 total and  c0.57 
unchanged; d7.3 
total  
N.D. c,52  
d, 137
42
Antihyperlipidemic Ezetimibe PO (14C) Healthy  
males 
Feces (n=8) 78 mostly 
unchanged  
(10 days ) 
 
N.D. 138 
 Fluvastatin IV/PO (3H) Healthy  
volunteers 
Feces (n=6) 86-92 total (120 hr), 
1.8 of total 
radioactivity as 
unchanged 
 
Cltotal=0.97 
L/hr/Kg 
64 
139  Pravastatin IV Healthy  
volunteers 
Feces 34 total and 23 
unchanged 
 
Cltotal=13.5 
mL/min/Kg 
 Rosuvastatin PO (14C) Healthy  
volunteers 
Feces (n=6) 90 total at 10 days 
(~70 at 72hr); 78.8 
as unchanged (10 
days) 
 
N.D. 68 
 42
 Simvastatin PO (14C) Patients T-tube bile and feces 
(n=4)  
25 total in bile and 
20 in feces 
 
N.D. 53 
Antihistamine Desloratadine PO (14C) Healthy  
volunteers 
Feces 47 primarily 
metabolites 
 
N.D. 140 
141  Ebastine PO  Healthy  
volunteers 
Feces 6 total (24hr), 
28 total (312 hr) 
 
N.D. 
 Fexofenadine PO (14C) Healthy  
volunteers 
Feces 80 total (~95 of 
radioactivity as 
unchanged) 
Cl/F=1.10 
L/hr/Kg 
140,141 
 Levocetrizine PO (14C) Healthy  
volunteers 
Feces 13 total and 86 
unchanged 
 
N.D. 140 
 Mizolastine PO (14C) Healthy  
volunteers 
Feces 84-95 primarily 
glucuronidated 
 
Cl/F=0.69 
L/hr/Kg 
140,141 
43
Antihypertensive Eplerenone PO (14C) Healthy  
volunteers 
Feces (n=8) 32.0 primarily 
metabolites (96 hr) 
  
N.D. 63 
54  Ramipril PO Patients T-tube bile (n=8) ~17 total and 0.1 
unchanged ( 24 hr) 
 
N.D. 
 Spironolactone PO (3H) Healthy males Feces (n=5) 22.7 total  
(5 days) 
 
N.D. 66 
142  Valsartan IV Patients Biliary-enteric 
diversion (n=1)  
 
89 mostly 
unchanged 
N.D. 
Antidiabetic Rosiglitazone PO/IV (14C) Healthy 
volunteers 
Feces (n=4) 21.6 from PO, 25.2 
from IV ( 21 days) 
mostly metabolites 
 
N.D. 143 
Immuno 
Suppressant/ 
Modulator 
Leflunomide PO (14C) Healthy 
volunteers 
Feces (n=4) 48 (28 days ) as 
methylhydroxy-
metabolite (M1) 
 
Cltotal for 
M1=0.051 
L/h 
144 
 43
4 Immunosuppressant Mycophenolic 
acid 
PO Healthy 
volunteers; 
patients 
Feces (n=4); 
T-tube bile (n=17) 
5.5 in feces; 16.5-26 
in bile as 
glucuronide 
conjugate, <0.1 
unchanged in bile 
 
Cltotal=8.5-
11.6 L/min 
 Tacrolimus eIV /PO (14C) 
fIV 
eHealthy 
 males; fpatients 
eFeces (n=6) e0.29 (IV) and 0.12 
(PO)  unchanged, 
e5.4 (IV) and 92.6 
(PO) total (11 days) 
 
fCltotal= 0.3-
5.4 L/hr/Kg 
e, 69
 f, 145
146 Gastrointestinal 
Stimulant 
Metoclopramide PO Patients Nasobiliary tube 
(n=10), repeated 
with restored 
enterohepatic 
recirculation 
 
 
<1 as unchanged 
and conjugated 
metabolites 
Cl/F= 0.5 
L/hr/Kg 
Antiarrhythmic Digoxin PO gHealthy  
Males;  hpatients 
Intestinal perfusion 
(n=6) 
 gCltotal=255  
Clbile= g72-
163  
or h79-343  
or i58-142 
mL/min 
 
g, 147
h, 12 
44
i, 11
148 Antipsychotic Quetiapine PO   Feces 21 total, < 1 of total 
radioactivity as 
unchanged (168 hr) 
 
Cl/F=86-105 
L/hr 
Skeletal Muscle 
Relaxant 
Cyclobenzaprine IV and PO (14C) Healthy  
volunteers 
Feces  
(n=5, PO) 
(n=3, IV)  
13.5 (PO) and 15.1 
(IV) primarily as 
glucuronide (120 hr) 
 
N.D. 149 
Antifungal Ketoconazole  PO (3H) Healthy  
males 
Feces (n=3) 57 total, 20-65 of 
total radioactivity as 
unchanged ( 4 days) 
  
N.D. 150 
 44
26 Benzodiazepine Lormetazepam PO Patients Nasobiliary drainage 
bile (n=5) 
 
0.3-2.8 total (24 hr) Cltotal=1.9-6.2 
mL/min/Kg 
151 Analgesic Opioid Methadone PO (acute, 
intermediate, 
chronic 
administration) 
Post-addict 
volunteers 
Feces (n=12) 3.0, 7.4, 20.1 total 
and 
0.14, 0.47, 1.2 
unchanged (acute, 
intermediate, 
chronic, 
respectively) 
 
N.D. 
Anti-asthma Montelukast PO (14C) Healthy  
volunteers 
Duodenal secretions 
suction at 2-8 and 8-
12 hr post dose 
(n=6) 
  
3-20 total N.D. 152 
Antiretroviral Lopinavir PO (14C in 
combination 
with ritonavir) 
Healthy  
volunteers 
Feces (n=5) 82.6 total,  19.8 
unchanged 
(0-8 days) 
 
N.D. 153 
45
 Ritonavir PO (14C) Healthy  
males 
Feces (n=5) 86.3 total, 33.8 
unchanged 
(6 days) 
 
N.D. 154 
71 Antibiotic Azlocillin IV  Healthy  
volunteers 
Duodenal perfusion 
(n=5) 
3.4 as unchanged Cltotal=173-
375 
Clbile=1.4-
25.9 mL/min 
155  Ceftriaxone IV Healthy  
males 
Duodenal perfusion 
for 6-8 hr (n=5) 
11-65 total Cltotal=9-20  
Clbile=1-13  
mL/min 
 
71  Mezlocillin IV  Healthy 
volunteers 
Duodenal perfusion 
(n=5) 
29.9 unchanged Cltotal=187-
477 
Clbile=45.8-
122.8 mL/min 
 
 45
 Piperacillin IV jCholecystectomy 
patients; 
 khealthy  
volunteers 
jT-tube (n=5); 
kduodenal aspiration 
(n=3) 
j0.7 as total 
(12 hr);  k0.41/1.1 
unchanged/corrected 
by EF (6 hr) 
jCltotal=276  
jClbile=1.74 
mL/min 
kCltotal=2.9 
kClbiliary=0.012 
k in vivo 
Clbiliary= 0.032 
mL/min/Kg 
 
j, 48
k, 84
156  Quinupristin/ 
Dalfopristin 
IV Healthy  
volunteers 
Feces (n=24) 74.4-77.5 total, <15 
unchanged 
Cltotal=0.83-
0.87  
Cltotal=0.85-
0.82 L/hr/Kg 
 
70  Temocillin IV Healthy  
volunteers 
Duodenal perfusion 
(n=6)  
 
2.2 unchanged (6 
hr) 
N.D. 
 Trovafloxacin PO (14C) Healthy  
volunteers 
Feces (n=4) 63.3 total,  43.2 of 
total radioactivity as 
unchanged 
N.D. 157 
46
 
IV= intravenous administration 
PO= oral administration 
EF= gallbladder ejection fraction 
in vivo Clbiliary= biliary clearance corrected for EF 
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FIGURES 
Fig 1.1: Macro-anatomy of the hepatobiliary system.  
Bile flow into the gallbladder is facilitated by lower internal pressure when compared to the 
rest of the biliary tract (pressure values are in parenthesis40).  Water and solutes are 
reabsorbed within the gallbladder.  
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Fig 1.2:  Micro-anatomy of the hepatobiliary tract.  
(A)  At the cellular level, hepatocytes are organized in cords and bathed by sinusoidal blood 
from the basolateral side; the canalicular membranes form the bile canaliculi.  Bile flows in 
the opposite direction to blood and drains into bile ducts.   
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(B)  An enlarged view of two hepatocytes from Figure A.  Transport proteins are involved in 
the uptake and excretion of endogenous substances and xenobiotics into blood and bile.  
Filled symbols represent unidirectional primary active transport by ATP-binding cassette 
(ABC) transport proteins (Pgp, ABCB1; BSEP, ABCB11; BCRP, ABCG2; MRP2, ABCC2; 
MRP3, ABCC3; MRP4, ABCC4; MRP5, ABCC5; MRP6, ABCC6; ABCG5, ABCG5; 
ABCG8, ABCG8).  Open symbols represent transport by members of the solute carrier 
protein families including the SLC family (OAT2, SLC22A7; OCT1, SLC22A1; NTCP, 
SLC10A1) and the SLCO family (OATP1B1, SLCO1B1; OATP1B3, SLCO1B3; OATP1A2, 
SLC01A2; OATP2B1, SLCO2B1).  Each functional hepatocyte contains all the transport 
proteins depicted in this figure. Adjacent hepatocytes form tight junctions (TJ) to seal the 
canalicular domain from the basolateral domain. 
B
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CHAPTER 2 
 
 
 
A NOVEL METHOD FOR THE DETERMINATION OF BILIARY CLEARANCE IN 
HUMANS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter was published in The AAPS Journal Volume 6, Issue 4, 33, 2004 
ABSTRACT 
Biliary excretion is an important route of elimination and the biliary tract is a potential site of 
toxicity for many drugs and xenobiotics.  Quantification of biliary excretion in healthy 
human volunteers is logistically challenging and is rarely defined during drug development.  
The current study uses a novel oroenteric tube coupled with a specialized clinical protocol to 
examine the pharmacokinetics of 99mTechnetium (Tc-99m) mebrofenin, a compound that 
undergoes rapid hepatic uptake and extensive biliary excretion.  A custom-made multi-lumen 
oroenteric tube was positioned in the duodenum of healthy human volunteers.  Subjects were 
positioned under a gamma camera and 2.5 mCi of Tc-99m mebrofenin was administered 
intravenously.  Duodenal aspirates, blood samples, and urine were collected periodically for 
3 hours.  Two hours after Tc-99m mebrofenin administration, the gallbladder was contracted 
with an intravenous infusion of cholecystokinin-8.  Gamma scintigraphy was used to 
determine the gallbladder ejection fraction in each subject.  Total systemic clearance of Tc-
99m mebrofenin approximated liver blood flow (Cltotal 17.3 ± 1.7 mL/min/kg) and 35 to 84% 
of the Tc-99m mebrofenin dose was recovered in bile. However, when the data were 
corrected for the gallbladder ejection fraction, 71 to 92% of the excreted Tc-99m mebrofenin 
dose was recovered.  This novel oroenteric tube and clinical protocol provide a useful 
method to quantify biliary excretion of xenobiotics in healthy human volunteers. 
 
 
 
Keywords: oroenteric tube, gallbladder, Tc-99m mebrofenin, biliary excretion, biliary 
clearance 
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INTRODUCTION 
    With the advent of combinatorial chemistry, an increasing number of new chemical 
entities characterized by high molecular weight and lipophilicity are being synthesized and 
screened during the drug discovery process.1  Drugs with these physicochemical 
characteristics often are associated with significant hepatic metabolism and excretion via the 
biliary route.2  Therefore, new tools and techniques are needed to investigate and predict 
biliary excretion of investigational drugs in healthy human volunteers.  Currently, limited 
information is available regarding the extent of biliary elimination of drugs and metabolites, 
primarily due to the difficulty in obtaining bile samples from healthy human subjects.  
Biliary excretion data would be extremely valuable in evaluating the contribution of biliary 
clearance to total systemic clearance, elucidating potential mechanisms of hepatobiliary 
toxicity, and examining enterohepatic recirculation.  In addition, the FDA recently published 
guidelines detailing the requirements for drug-drug interaction studies necessary in New 
Drug Application submissions.  These guidelines suggest that mechanisms of interactions 
should be explored, rather than simply performing observational studies.3  Therefore, a 
method to investigate drug interactions that may occur during biliary elimination may 
increase the quality of information provided to registration agencies and help avoid the 
withdrawal of drugs from the market due to a serious, but foreseeable, drug interaction.   
    One valuable preclinical tool to investigate biliary clearance of drugs is the sandwich-
cultured hepatocyte model.  This model has been developed using rat and human hepatocytes 
to examine biliary excretion in vitro, and has been validated with in vivo data collected from 
rats.4  However, the human in vivo data required to develop in vitro-in vivo correlation in 
biliary clearance for humans is lacking.  This shortcoming is primarily a result of the 
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difficulty in obtaining biliary excretion data in humans, particularly in healthy human 
volunteers. 
    Historically, there has been little success in the development of valid and reliable 
techniques to quantify biliary excretion of drugs or endogenous compounds in humans.   
Such data may be obtained from patients suffering from gallbladder disease requiring 
removal of the gallbladder.  Typically, patients are administered the drug of interest prior to 
surgery, and the amount of drug found in the gallbladder after removal is quantified.5, 6  This 
approach only allows a single time point determination of drug content in bile.  More 
commonly, studies employ patients that require a temporary bile shunt (T-tube) that diverts 
bile from the liver to a transcutaneous port for external collection.7, 8  With this method, 
biliary excretion may be determined over time while the shunt is in place. 
    The major limitation of both of the above techniques is the use of patients with significant 
hepatobiliary disease as study subjects.  Several studies have employed healthy human 
volunteers and oroenteric tubes to withdraw pancreatic-biliary secretions from the 
duodenum.9  These studies have utilized occlusive balloons to facilitate more complete bile 
collection,10 or have perfused non-absorbable markers into the duodenum to evaluate 
recovery.11, 12  A significant advantage of these techniques is the ability to conduct studies in 
healthy human volunteers, particularly in light of the role of hepatobiliary transport proteins 
in hepatic drug disposition.  Certain disease states may significantly influence transport 
protein expression, function, localization and/or bile flow along the bile canaliculi and bile 
ducts, thereby altering drug secretion and excretion patterns.13-15  
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Previous studies conducted in healthy human volunteers have resulted in incomplete and 
highly variable recovery of compounds excreted in bile.10, 16  This is primarily a result of 
difficulties in obtaining and assessing the completeness of bile collection, and a lack of 
control over gallbladder contraction.  Described here is a method using a novel oroenteric 
tube and specialized clinical protocol that facilitates efficient recovery of biliary secretions 
and optimal gallbladder refilling status and contractibility.  The use of the gamma emitter 
99mTechnetium (Tc-99m) mebrofenin as a probe compound in this study allowed real-time 
assessment of biliary excretion, gallbladder ejection fraction, and the efficiency of bile 
collection.  This compound is available for intravenous administration, is not significantly 
metabolized, and is principally excreted unchanged in bile. 
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MATERIALS AND METHODS 
Catheter design: A commercially available oroenteric catheter extrusion was modified 
according to the design in Figure 2.1 to aspirate secretions from the gastric and duodenal 
regions of the human gastrointestinal tract (Dentsleeve, Wayville, Australia).  Briefly, the 
tube is a silicone multi-lumen extrusion 4.5 mm in diameter, 128 cm long, with 3 tungsten tip 
weights to facilitate passage of the tube through the pyloric sphincter.  The distal/terminal 
end of the tube was fitted with a welded polyethylene balloon to facilitate migration of the 
tube during placement, and to ensure occlusion of the intestine during the bile collection 
period.  The balloon (9 cm long x 4.7 cm wide uninflated) was single use and fitted to metal 
balloon attachment rings using 1.0 silk suture.  Two of the large lumens of the extrusion 
(Figure 2.1, Panel A, lumens A and C) were dedicated to aspiration of secretions from the 
duodenal region, while lumen E was used for aspiration from the gastric region.  Aspiration 
vacuum relief was provided by lumens B, D, and F.  Lumen G was used to inflate/deflate the 
polyethylene balloon and lumen H provided a saline flush to reduce viscosity of the duodenal 
secretions.  A radio-opaque pyloric marker was positioned 100 cm from the syringe 
connectors to facilitate correct placement of the tube under fluoroscopy. 
Clinical Protocol:  Four non-smoking volunteers (20-24 years of age; 3 male, 1 female) 
within 20% of ideal body weight (64.5-84.4 kg) completed the study.  All procedures were 
approved by the Clinical Research Advisory Committee and the Committee on the Protection 
of the Rights of Human Subjects of the University of North Carolina (UNC) at Chapel Hill 
School of Medicine.  Subjects provided written informed consent prior to participation in the 
study, and were healthy as indicated by their medical history, physical examination, routine 
laboratory tests, and electrocardiogram.  Subjects were asked to abstain from any medication 
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(with the exception of oral contraceptives) for 2 weeks prior to the study, and to abstain from 
caffeine and alcohol during the study.  Subjects were admitted to the General Clinical 
Research Center of UNC Hospitals the evening before the study and given a high fat meal 
(~55 grams of fat) at 18:00 hours and a high fat snack (~45 grams of fat) at 23:00 hours.  
Subjects then remained fasted until the end of the study.  At 06:00 the following morning, the 
oroenteric tube was passed through the mouth and positioned with the aid of dynamic 
fluoroscopic radiography (ICONOS R200, Siemens, Hoffman Estates, IL).  Correct 
placement of the tube was judged by the position of the pyloric marker (right hand margin of 
spine) and the tip weights (immediately distal to the Ligament of Treitz) (Figure 2.2).  
Subjects were then positioned supine under a gamma camera (E-CAM Dual Head Gamma 
Camera, Siemens), baseline blood, urine and bile samples were collected; and the occlusive 
polyethylene balloon was inflated with ~ 20 mL of air until the subjects experienced mild 
discomfort.  Subjects were then administered a 2.5 mCi IV bolus dose of  Tc-99m 
mebrofenin (Squibb Diagnostics, Princeton, NJ) via a forearm vein indwelling catheter 
(specific activity 0.8-1.1 mCi/mg at time of preparation).  Blood samples (3 mL) were 
collected at 1, 2.5, 5, 7.5, 10, 20, 40, 60, 80, 100, 120, 140, 165 and 180 minutes post-dose 
from the contralateral arm.  Biliary secretions collected from the occluded duodenal region 
were continuously aspirated and pooled over the following intervals:  0-5, 5-10, 10-30, 30-
50, 50-70, 70-90, 90-110, 110-120, 120-130, 130-150, 150-180 minutes post-dose.  Anterior 
gamma scintigraphic images of the abdomen were acquired under dynamic mode at 1-minute 
intervals and analyzed using ESOFT 2.5 software (Siemens).  Two hours post Tc-99m 
mebrofenin administration, cholecystokinin-8 (sincalide, 0.02 μg/kg, Bracco Diagnostics, 
Princeton, NJ) was administered as an IV infusion over 30 minutes to facilitate contraction of 
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the gallbladder.  Cholecystokinin-8 is an octa-peptide derived from cholecystokinin and has a 
very short duration of action (half-life in blood of 2.5 minutes).17, 18  Urine was collected at 
the conclusion of the sampling period (180 minutes).    
Whole blood radioactivity was determined by gamma scintillation counting (Quantum-8 
Multichannel Analyzer, Oak Ridge, TN).  Bile collected over each interval, and an aliquot of 
urine, were analyzed by a CRC-15R dose calibrator (Capintec, Ramsay, NJ).  All samples 
were corrected for decay based on the Tc-99m half-life of 6.01 hours.  Linearity of the 
gamma camera response was assessed utilizing 250 mL saline bags injected with pre-
determined amounts of radioactivity (0.5 - 3 mCi) measured with a CRC-15R dose calibrator.  
Data Analysis:  A duplicate dose of Tc-99m mebrofenin was prepared at the same time as the 
dose administered to the subject and used for calculation of the “theoretical dose”.  This 
reference standard also was used to convert the units of the whole blood radioactivity from 
counts per minute (cpm) to nCi, in order to obtain a more quantitative measurement of the 
amount of radioactivity present in blood.  After assessing the radioactivity remaining in the 
syringe, IV tubing, and catheter, the “administered dose” was then calculated by difference.  
Biliary recovery and urinary recovery were calculated as the percentage of the administered 
dose that accumulated in bile and urine, respectively, 180 minutes after dosing.  A 
gallbladder ejection fraction (EF) was calculated from planar scintigraphic images using the 
following equation: 
( ) ( )( )min120
min150min120
  
GB
GBGBFractionEjection −=      (1) 
where GB represents the counts per minute in the gallbladder region of the image pre- 
(time=120 minutes) and post- (time=150 minutes) infusion of cholecystokinin-8. 
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In order to account for the variable contractile response of the gallbladder, the total amount 
of radioactivity collected from the duodenal region during the 30 minute infusion of 
cholecystokinin-8 was divided by the ejection fraction.  This correction accounted for the Tc-
99m mebrofenin remaining in the gallbladder after contraction.  Addition of this value to the 
cumulative amount of Tc-99m mebrofenin collected in the first 120 minutes of the study 
represented the total amount of Tc-99m mebrofenin transported from the liver into bile, and 
the amount that would have been collected if the gallbladder were to contract completely.   
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +×=
−
−
EF
XX
X
100%Dose Excreted ofRecovery  %
min150120
Bilemin1200
Bile0    (2) 
where X0 represents the administered dose; XBile the amount of Tc-99m mebrofenin 
recovered in biliary secretions collected over the time interval specified; and EF is the 
ejection fraction.  Therefore, 
EF
X min150-120Bile  estimates the total amount of Tc-99m mebrofenin 
that would have been collected from the duodenal region if the EF=1.  This corrected 
amount, expressed as a percentage of the administered dose, represented the recovery of Tc-
99m mebrofenin excreted from the gallbladder during the study, and assumes that no 
additional Tc-99m mebrofenin remains to be excreted into the duodenum from 150 to 180 
minutes. Therefore this value can therefore provide an estimate of recovery efficiency and 
performance of the oroenteric tube. 
Pharmacokinetic data analysis: Blood activity-time profiles were analyzed by non-
compartmental analysis using WinNonlin (version 4.1, Pharsight Corp., Mountain View, 
CA).  The frequency of the blood sampling at the beginning of the experiment and the slow 
clearance of radioactivity from the injection site allowed the characterization of Tc-99m 
mebrofenin distribution into the systemic circulation.  Therefore, the kinetics of 
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administration were modeled as an IV infusion of duration Tmax to account for this 
observation.  The area under the blood concentration time curve (AUC) was calculated using 
the linear trapezoidal rule, and where appropriate, extrapolated to infinity using the slope 
obtained from linear regression of the last 5 to 6 time points.  Total blood clearance of Tc-
99m mebrofenin was determined as the ratio of the administered dose and the AUC 
extrapolated through infinite time.  Biliary clearance was determined as the ratio of the 
cumulative amount of Tc-99m mebrofenin recovered in bile from 0 to 180 minutes (not 
corrected for EF) and the AUC from 0 to 180 minutes.  
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RESULTS 
    Proper positioning of the oroenteric tube required between 0.5 and 2 hours.  However, 1 
subject failed to pass the tube through the pylorus and into the duodenum in the allocated 
time and, therefore, did not complete the study.  Correct positioning of the oroenteric tube 
was confirmed by fluoroscopic radiography.  A representative image of the tube located in 
the correct anatomical position is shown in Figure 2.2.  The marker at the pyloric sphincter 
and the tungsten tip weights just beyond the Ligament of Treitz (immediately preceded by 
the 2 balloon attachment rings) are clearly visible. 
    As expected, rapid and extensive biliary excretion of Tc-99m mebrofenin was observed.  
As evident in animated Figure 2.3 (Panels A, B, C and D), after IV administration Tc-99m 
mebrofenin was rapidly taken up into the liver, secreted into the canalicular space, and 
collected in the common bile duct and gallbladder.  Despite the consistency in the rate and 
extent of Tc-99m mebrofenin accumulation in the gallbladder, each subject exhibited a 
different pattern of bile secretion into the intestine, presumably due to differing spontaneous 
contraction patterns of the gallbladder.19  These differing release patterns of Tc-99m 
mebrofenin in bile are evident in animated Figure 2.3 and in the profiles shown in Figure 2.4.   
Subject 1 did not expel Tc-99m mebrofenin from the gallbladder until administration of 
cholecystokinin-8 at 120 minutes, whereas subjects 2 and 4 exhibited partial spontaneous 
contraction of the gallbladder prior to cholecystokinin-8.  Of interest, Subject 3 immediately 
ejected bile and Tc-99m mebrofenin into the intestine before accumulation in the gallbladder, 
and did not respond to cholecystokinin-8 as quickly or to the same extent as the other 
subjects. 
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The gamma camera images obtained during the study allow a visual, subjective assessment 
of tube performance and indicate that the biliary and duodenal secretions were efficiently and 
entirely removed via the duodenal aspiration ports.  Specifically, Tc-99m mebrofenin and 
bile accumulated in a small segment of the duodenum and were not visible in more distal 
regions of the intestinal tract (Figure 2.3, Panels B, C, and D).  At times, Tc-99m mebrofenin 
was recovered as quickly as it was expelled from the gallbladder, resulting in little 
accumulation of radioactivity in the duodenal region (Figure 2.3, Panel D).  In subject 1, the 
scintigraphic images also allowed visualization of a small amount of Tc-99m mebrofenin that 
leaked beyond the occlusive balloon after cholecystokinin-8 administration (Figure 2.3, Panel 
A).  This observation corresponded with a lower recovery of Tc-99m mebrofenin in subject 1 
(Table 2.1).  Static gamma camera images of subject 2 pre-cholecystokinin-8 and post-
cholecystokinin-8 (Figure 2.5) clearly illustrate the efficiency of the oroenteric tube in 
removing Tc-99m mebrofenin and bile from the duodenum. 
    At the conclusion of the sampling period (180 minutes post dose), residual radioactivity 
was evident in the gallbladder, consistent with incomplete emptying of the gallbladder after 
contraction.18, 20  Using planar images obtained before and after cholecystokinin-8 
administration, the gallbladder ejection fraction was determined (Table 2.1).  With the 
exception of subject 3, remarkably large and consistent ejection fractions were obtained.  The 
extent of Tc-99m mebrofenin recovered in aspirated bile exhibited high inter-subject 
variability (35-84% of the administered dose); however, once corrected for the gallbladder 
ejection fraction, the recovery of excreted Tc-99m mebrofenin was consistently high (84.2 ± 
9.3%, Table 2.1). 
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The blood concentration-time profiles, bile amount-time profiles and the amount in urine at 
180 minutes for subjects 1, 2, 3, and 4 are shown in Figure 2.4, Panels A, B, C, and D, 
respectively.  The blood profiles are similar in all subjects; Cmax was followed by a rapid 
distributional phase and polyexponential decay.  A terminal monoexponential decay phase 
was not clearly evident after 3 hours of sampling.  Table 2.1 summarizes the pharmacokinetic 
parameters obtained.  Systemic exposure and total body clearance were comparable in all 
subjects, and biliary clearance ranged from 7.8 to 15.6 mL/min/kg (Table 2.1).  The fraction 
of total clearance that can be attributed to biliary excretion is numerically equivalent to the 
biliary recovery (expressed as percentage of dose) of Tc-99m mebrofenin reported in Table 
2.1, averaging 78% in subjects that responded to cholecystokinin-8 (subjects 1, 2, and 4).  
The variability in biliary clearance was due primarily to incomplete excretion of Tc-99m 
mebrofenin from the gallbladder during the collection period.  The total amount of Tc-99m 
mebrofenin recovered in urine 3 hours post dose was very low (0.6 % ± 0.2%).   
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DISCUSSION 
    This study used a customized oroenteric tube and tailored clinical protocol to validate 
successfully an experimental procedure that allowed efficient collection of biliary secretions 
from healthy human volunteers.  In a previous pilot study, only modest outcomes were 
obtained: gallbladder ejection fractions after cholecystokinin-8 administration were 
abnormally low, and the oroenteric tube utilized failed to completely collect biliary 
secretions.  It was hypothesized that the lack of response to cholecystokinin-8 in the pilot 
study was a result of the prolonged fasting period required by the protocol (the intubation 
procedure took place the night before the study), while the incomplete biliary recovery was 
due to the design of the tube and the absence of an occlusive balloon.  The clinical protocol 
designed in the present study sought to maintain a more physiologically normal gallbladder 
refilling state, thereby maximizing the response to cholecystokinin-8.  With the exception of 
subject 3, subjects responded to the infusion of cholecystokinin-8 in a manner typical for 
healthy volunteers, with gallbladder ejection fractions greater than 0.8.17  To optimize the 
filling status of the gallbladder during the study, subjects received a high fat evening meal 
and snack ~ 15 and 9 hours, respectively, prior to Tc-99m mebrofenin administration.  This 
proved to be a successful method to ensure refilling of the gallbladder the following day, as 
evidenced by the rapid accumulation of Tc-99m mebrofenin in the gallbladder.  These results 
suggested that the gallbladder was not overfilled, a state often associated with reduced bile 
flow, poor accumulation of cholecystographic agents in the gallbladder, and in some cases, 
significant spontaneous contraction of the gallbladder in inter-digestive states.21  
The oroenteric tube design utilized in the current study, and the presence of an occlusive 
balloon, allowed for more complete recovery of biliary secretions; a high percentage of the 
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administered dose was collected in bile in subjects 1, 2, and 4 (Table 2.1).  Unfortunately, 
only the theoretical dose was determined for subject 1, and a small amount of bile containing 
Tc-99m mebrofenin leaked past the occlusive balloon (Figure 2.3), thus a lower than 
expected recovery of Tc-99m mebrofenin was determined for this subject (Table 2.1).   
    The calculated ejection fraction theoretically represents the fraction of gallbladder content 
that is expelled into the intestine following infusion of cholecystokinin-8.  Radioactivity 
remaining in the gallbladder after contraction, therefore, represents the amount of Tc-99m 
mebrofenin irreversibly removed from the systemic circulation that has not yet been excreted 
into the intestine.   By correcting the amount of Tc-99m mebrofenin collected in the bile 
during the infusion of cholecystokinin-8 by the ejection fraction, and adding this value to the 
biliary recovery from 0 to 120 minutes, the subsequent recovery of Tc-99m mebrofenin 
represents the proportion of the administered dose that was collected by the oroenteric tube 
and is defined as excreted dose.  The recovery of excreted Tc-99m mebrofenin was high and 
exhibited less variability, ranging from 70.9% to 91.9% of the administered dose across all 
subjects.  These results are consistent with the extent of biliary excretion of Tc-99m 
mebrofenin in humans (98% in 24 hours).22  The correction for incomplete gallbladder 
ejection takes into account a poor or incomplete response to cholecystokinin-8 (as observed 
for subject 3), and demonstrates the efficiency of the oroenteric tube to collect excreted Tc-
99m mebrofenin from the duodenal region.  
The Tc-99m mebrofenin blood concentration-time profiles exhibited polyexponential decay 
(Figure 2.4), and a non-compartmental approach was employed to obtain primary 
pharmacokinetic parameters (Table 2.1).  The total systemic clearance of Tc-99m mebrofenin 
(17.3 ± 1.7 mL/min/kg) approximated liver blood flow in humans (21 mL/min/kg)23, and was 
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in agreement with previously published animal and human data.24  The calculated biliary 
clearance for subjects 1, 2, and 4 was 14.0 ± 2.2 mL/min/kg, consistent with the high biliary 
excretion of Tc-99m mebrofenin, and represented over 66% of the total body clearance 
observed in these subjects.  The poor ejection fraction observed in subject 3 resulted in a 
lower recovery of Tc-99m mebrofenin, and subsequently, a lower biliary clearance (7.8 
mL/min/kg), representing only 35% of the total body clearance for this subject.  It is clear 
that if bile could be collected for a longer time period, eventually all but a fraction of the 
dose would be recovered in bile.  However, owing to practical constraints, it is not possible 
to keep the balloon inflated for more than 3 to 4 hours. Therefore, quantitative assessment of 
the gallbladder ejection fraction is vital to the correct interpretation of the biliary clearance 
value obtained in time-constrained studies such as those described here.  Similarly, although 
samples were collected only for 180 minutes, the cumulative amount of Tc-99m mebrofenin 
excreted in the urine (0.6 % ± 0.2%) was consistent with that reported in the literature (2% 
over 24 hours).22   
     In conclusion, the oroenteric tube and clinical protocol developed in this study represent a 
useful method to investigate the biliary excretion of the probe drug Tc-99m mebrofenin.  The 
custom-made oroenteric tube fitted with an occlusive balloon allowed extremely efficient 
recovery of biliary secretions from the duodenum. The approach described in this study uses 
a combination of gamma scintigraphy and a carefully designed clinical protocol to overcome 
variability in biliary excretion and gallbladder responsiveness to cholecystokinin-8 observed 
in previous studies.10, 16  A similar experimental design may be used to investigate the biliary 
excretion of a variety of endogenous compounds and xenobiotics (including investigational 
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drugs) and to calculate biliary clearance, a pharmacokinetic parameter that previously has 
been difficult to estimate or predict in healthy human subjects.  
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TABLES 
Table 2.1: Summary of Tc-99m mebrofenin dose, recovery, gallbladder ejection 
fraction, and pharmacokinetic parameters for Subjects 1, 2, 3, and 4. 
 Subject 1 Subject 2 Subject 3 Subject 4 Mean S.D. 
Theoretical Dose (μCi) 2188 2498 2500 2497 2421 155 
Administered Dose (μCi) -a 2072 2282 2476 2277 202 
Biliary Recovery (% of doseb) 65.5 84.3 35.2 83.5 67 23 
Urinary Recovery  
(% of doseb) 
0.7 0.5 0.8 0.5 0.6 0.2 
Total Recovery (% of doseb) 66.2 84.8 36 84 67.8 22.8 
Ejection Fraction (EF) 0.82 0.86 0.03 0.86 0.64 0.4 
Recovery of Excreted Dose 
 (% of doseb ) 
70.9 89.1 91.9 -84.9 84.2 9.3 
AUC0-∞ (nCi.min/mL) 1466 1613 1422 2305 1701 410 
Cltotal (mL/min/kg) 16.4 16.2 19.9 16.7 17.3 1.7 
AUC0-180 (nCi.min/mL) 1371 1462 1279 2054 1542 350 
Clbiliary (mL/min/kg) 11.5 15.0 7.8 15.6 12.5 3.6 
aNot determined, all calculations based on theoretical dose. 
bAdministered dose, where available. 
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FIGURES 
Figure 2.1: (A) Cross-sectional diagram of the oroenteric tube.  Lumen labels correspond 
to the following functions: A, duodenal aspiration 1;  B, duodenal aspiration 1 vacuum relief; 
C, duodenal aspiration 2; D, duodenal aspiration 2 vacuum relief; E, gastric aspiration; F, 
gastric aspiration vacuum relief; G, balloon inflation; H, saline flush.   
A 
 
  
 
 
 
(B) Schematic of oroenteric tube.  Syringe connector labels correspond to the following 
channels: I, duodenal aspiration 1 and 2; II, gastric aspiration; III, duodenal aspiration 1 and 
2 vacuum relief; IV, gastric aspiration vacuum relief; V, balloon inflation/deflation; VI, 
saline flush. 
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Figure 2.2: A representative fluoroscopic image of the oroenteric tube correctly 
positioned.  Arrows indicate the following: A, radio-opaque marker at the pyloric sphincter; 
B, balloon attachment rings; C, tungsten tip weights positioned at the Ligament of Treitz. 
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Figure 2.3: Animated gamma scintigraphic images of Tc-99m mebrofenin disposition 
(from 0 to 180 minutes): A, subject 1; B, subject 2; C, subject 3; D, subject 4.  Hepatic 
uptake of Tc-99m mebrofenin was rapid, followed by excretion into the canalicular space and 
accumulation in the gallbladder.  Gallbladder contraction, facilitated by cholecystokinin-8 IV 
infusion at 120 minutes, resulted in expulsion of bile containing Tc-99m mebrofenin from the 
gallbladder into the duodenum and subsequent aspiration via the oroenteric tube. Online link 
to animation: http://www.aapsj.org/articles/aapsj0604/aapsj060433/aapsj060433_figure3.htm
  
 A) Subject 1 
D) Subject 4 C) Subject 3 
B) Subject 2 
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Figure 2.4: Tc-99m mebrofenin blood concentration (circles) and amount in bile 
(triangles) vs. time profiles, and the amount in urine at 180 minutes (diamonds):  
A, Subject 1; B, Subject 2; C, Subject 3; D, Subject 4.  Cholecystokinin-8 was administered 
at 120 minutes as a 30 minute IV infusion to facilitate contraction of the gallbladder 
 
B) Subject 2
0 50 100 150 200
0.1
1
10
100
1000
0
200
400
600
800
1000
1200
A) Subject 1
0 50 100 150 200
0.1
1
10
100
1000
0
200
400
600
800
1000
1200
C) Subject 3
0 50 100 150 200
0.1
1
10
100
1000
0
200
400
600
800
1000
1200
D) Subject 4
0 50 100 150 200
0.1
1
10
100
1000
0
200
400
600
800
1000
1200
Time (min)
C
on
ce
nt
ra
tio
n  
(n
C
i /m
L)
A
ct
iv
ity
 (μ
C
i)
C
on
ce
nt
ra
tio
n  
(n
C
i /m
L)
A
ct
iv
ity
 (μ
C
i)
 
 
 
 74
Figure 2.5: Static gamma camera images of Subject 2 at 80 and 160 minutes after 
administration of Tc-99m mebrofenin.  Tc-99 mebrofenin accumulation in the intestine 
after 80 minutes was aspirated efficiently via the oroenteric tube as limited radioactivity was 
present in the intestine by 160 minutes. 
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CHAPTER 3 
 
 
 
IN VITRO CHARACTERIZATION AND PHARMACOKINETIC MODELING OF 
TC-99m MEBROFENIN HEPATOBILIARY DISPOSITION IN HUMANS AND 
RELEVANCE IN DISEASE STATES 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to Pharmaceutical Research and is presented in the style of 
that journal. 
ABSTRACT  
Purpose: This study was conducted to characterize the disposition of the hepatobiliary 
scintigraphy agent Tc-99m mebrofenin in humans using in vitro tools and pharmacokinetic 
modeling. 
Methods: Four healthy volunteers received 2.5 mCi of Tc-99 mebrofenin intravenously and 
blood, urine and bile were collected over time.  Xenopus laevis oocytes and membrane 
vesicles prepared from HEK293 cells were used to identify transport proteins involved in Tc-
99m mebrofenin transport.  Several compartmental pharmacokinetic models were developed 
to describe the clinical data.  The pharmacokinetic model was used to simulate patho-
physiological changes in drug disposition due to drug interactions and disease states. 
Results: In vitro studies demonstrated that Tc-99m mebrofenin is a substrate for OATP1B1, 
OATP1B3, MRP2 and MRP3.  These data support the hypothesis that OATPs are involved in 
the hepatic uptake of Tc-99m mebrofenin while MRP2 and MRP3 are responsible for 
excretion into bile and blood, respectively.  Systemic and hepatic exposure to Tc-99m 
mebrofenin would be influenced markedly by hyperbilirubinemia, or altered canalicular or 
basolateral excretion based on simulations of disease states (e.g., Dubin-Johnson syndrome) 
or drug interactions at the level of the transport protein (e.g., inhibition or induction). 
Conclusions: The pharmacokinetic model developed to describe Tc-99m mebrofenin 
disposition in humans can be used to predict drug interactions and alterations associated with 
disease states in Tc-99m mebrofenin disposition. 
 
Keywords: Tc-99m mebrofenin, hepatobiliary disposition, pharmacokinetic modeling, 
Dubin-Johnson syndrome, OATP1B1, OATP1B3, MRP2, MRP3 
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INTRODUCTION 
Tc-99m mebrofenin is an imino diacetic acid derivative (HIDA) commonly used in 
hepatobiliary scintigraphy (Fig 3.1).  This class of agents was developed to couple selective 
liver uptake and rapid transit into bile with the gamma emitting properties of technetium-99m 
(1).  Tc-99m mebrofenin is used commonly in nuclear medicine to evaluate hepatobiliary 
dysfunction associated with the gallbladder, although broader uses, such as the evaluation of 
hepatocyte viability in vivo (2, 3) and the detection of genetic diseases that could affect 
excretion of compounds into bile (4, 5), have been proposed by several investigators.  The 
kinetics of hepatic uptake, secretion into bile and systemic disposition of Tc-99m mebrofenin 
and analogs have been studied using invasive techniques in animals (6, 7).  However, only 
gamma images have been used to derive these kinetic parameters in clinical studies, typically 
performed in patients undergoing a hepatobiliary scan for diagnostic reasons.  Thus, these 
data may not reflect normal disposition of these compounds (1, 8, 9).  During the 
development of a clinical protocol to determine biliary excretion of drugs in humans, Tc-99m 
mebrofenin was administered as a model high biliary clearance compound to healthy 
volunteers (10).   
Dubin-Johnson syndrome is an autosomal recessive genetic disease.  Although 
generally asymptomatic, these patients present with mild icterus, bilirubinuria and an 
elevated serum bilirubin concentration with half of the serum bilirubin in the conjugated 
form (mainly as diglucuronide) (11, 12).  Dubin-Johnson syndrome is caused by mutations in 
the MRP2 (ABCC2) gene, including several in the region coding for the nucleotide binding 
domains (13-16) and in other domains affecting expression, maturation and appropriate 
localization of the protein (17, 18).  In these patients, MRP3 (ABCC3), an ABC transport 
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protein which is closely related to MRP2 and expressed on the basolateral membrane of 
hepatocytes, is present at higher levels than normal (19).  Upregulation of MRP3 
compensates for the lack of MRP2, and protects the liver from bilirubin conjugates and other 
organic anions that cannot be excreted into bile.  TR- rats are a naturally occurring strain of 
Mrp2-deficient Wistar rat that have impaired bilirubin excretion (absence of canalicular 
Mrp2) and enhanced basolateral expression of Mrp3 (20, 21).  
Despite the extensive diagnostic use of Tc-99m mebrofenin, its hepatobiliary 
disposition has not been investigated fully.  The involvement of MRP2/Mrp2 in the biliary 
excretion of Tc-99m mebrofenin and analogs is suggested by case reports indicating lack of 
visualization of the hepatobiliary tree after Tc-99m mebrofenin injection in Dubin-Johnson 
patients (4, 5, 22), and by reduced biliary excretion of Tc-99m HIDA  in TR- rats (23).  The 
implication of OATP family members in the hepatic uptake of Tc-99m mebrofenin is 
supported by the finding that Tc-99m disofenin, an analog of mebrofenin, is taken up actively 
into the liver by a sodium-independent transport protein (24, 25).   
The purpose of the current study was to characterize the mechanisms of hepatic uptake and 
excretion of Tc-99m mebrofenin using in vitro systems such as Xenopus laevis oocytes 
expressing OATP1B1 or 1B3, and membrane vesicles prepared from HEK293 cells 
transfected with MRP2 or MRP3.  Moreover a pharmacokinetic model was developed to 
describe the kinetics of distribution and elimination of Tc-99m mebrofenin in healthy 
subjects, and to simulate changes in Tc-99m mebrofenin disposition that are associated with 
disease states such as hyperbilirubinemia and Dubin-Johnson syndrome.  Changes in 
disposition of this agent that might occur due to drug-drug interactions also were simulated.  
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MATERIALS AND METHODS 
Chemicals  
Tc-99m mebrofenin (Choletec®, Bracco Diagnostics, Princeton, NJ) was prepared at the 
Nuclear Medicine pharmacy, UNC Hospital, and radiochemical purity was evaluated by TLC 
using instant thin layer chromatography with polysilicic acid (ITLS-SA) as a the stationary 
phase and 20% sodium chloride as the mobile phase.  Solutions employed in the in vitro 
experiments had a radiochemical purity ≥ 90% (26).  β-Estradiol 17-β-D-glucuronide 
(E217βG), rifampicin, AMP, ATP, pyruvic acid and gentamicin sulfate were purchased from 
Sigma Chemical Co (St. Louis, MO), creatine phosphate, creatine kinase, protease inhibitor 
cocktail (Complete™) were purchased from Roche Diagnostics (Indianapolis, IN), MK571 
was purchased from Cayman Chemical Co (Ann Arbor, MI), [3H]E217βG (39.8 Ci/mmol, 
purity > 97%) was obtained from Perkin Elmer Life Sciences (Boston, MA, USA), all other 
chemicals were of reagent grade and were readily available from commercial sources. 
Oocyte Uptake Studies 
Xenopus laevis oocytes injected with hOATP1B1 and hOATP1B3 cRNA were acquired from 
BD Bioscience (Transportocytes, BD Gentest™, Woburn, MA).  In preliminary experiments, 
the suitability of uninjected oocytes versus water injected oocytes as controls was 
established.  Upon receipt, oocytes were inspected visually and the viable cells were 
maintained for 24 hr at 18°C in oocyte Ringer's 2 buffer (OR-2: 82.5 mM NaCl, 2.5 mM 
KCl, 1 mM Na2HPO4, 3 mM NaOH, 1 mM CaCl2, 1 mM MgCl2, 1 mM pyruvic acid, and 5 
mM HEPES, pH 7.6) supplemented with 0.05 mg/ml gentamicin sulfate, 1.5 mM sodium 
pyruvate and 5% heat-inactivated horse serum. Uptake was determined according to the 
method described in Bow et al. (27).  In brief, oocytes were incubated at 18 to 22°C over 60 
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min in OR-2 containing Tc-99m mebrofenin (9-10 µCi/ml).  Subsequently, the oocytes were 
rinsed three times in ice-cold OR-2 and placed into individual vials for immediate analysis of 
associated radioactivity by gamma scintillation counting using a TN-1750 Multichannel 
Analyzer (Tracor Northen, Middleton, WI).  Tc-99m mebrofenin uptake was calculated in 
picoCi per oocyte. The effect of rifampicin (50 µM), a well-characterized inhibitor of OATP 
proteins, on Tc-99m mebrofenin uptake was measured at the 60-min time point.  
MRP2 and MRP3 Expression Vectors and Transfections in HEK293 Cells 
The construction of vectors containing MRP2 [pcDNA3.1(-)MRP2] and MRP3 
[pcDNA3.1(+)MRP3] has been described previously (28, 29).  pcDNA3.1(-)MRP2 and 
pcDNA3.1(+)MRP3 were a kind gift of Dr. Susan P.C. Cole (Queen’s University, Kingston, 
ON, Canada) and were transfected into SV40 transformed human embryonic kidney cells 
(HEK293).  HEK293 cells were seeded at 5.8x106 cells per 162 cm2 flask and transfected 24 
hrs later with 16.8 μg of plasmid DNA using FuGENE 6 (Roche Diagnostics) according to 
the manufacturer’s instructions.  After 72 hr, cells were harvested as described previously 
(30). 
Membrane Vesicle Preparation and Immunoblotting   
Plasma membrane vesicles from MRP2 and MRP3 transfected HEK293 cells were prepared 
as described, with modifications (30).  Briefly, cells were homogenized in buffer containing 
250 mM sucrose, 50 mM Tris pH 7.5, 0.25 mM CaCl2 and protease inhibitor cocktail tablets.  
Cells were disrupted by N2 cavitation (5 min equilibration at 200 psi) and then released to 
atmospheric pressure and EDTA was added to 1 mM.  The suspension was centrifuged at 
800xg at 4˚C for 10 min and the supernatant was layered onto 10 ml of a 35% (w/w) sucrose, 
50 mM Tris pH 7.4 cushion.  After centrifugation at 10,000xg at 4˚C for 1 h, the interface 
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was removed and placed in a 25 mM sucrose, 50 mM Tris, pH 7.4 solution and centrifuged at 
100,000xg at 4˚C for 30 min.  The membranes were washed with Tris sucrose buffer (250 
mM sucrose, 50 mM Tris, pH 7.4) and then resuspended by vigorous syringing with a 27-
gauge needle.  Protein concentrations were determined using a BCA protein assay (Pierce 
Chemical, Rockford, IL) and aliquots of membrane vesicles were stored at –80˚C.  
[3H]E217βG  and Tc-99m mebrofenin Transport Studies  
Transport assays were carried out by a rapid filtration method as described previously (31).  
Membrane vesicles (8 μg of protein per time point) were incubated at 37 ˚C in a final volume 
of 60 μl.  The transport assay buffer used was Tris (50 mM, pH 7.5)/sucrose (250 mM), and 
contained ATP or AMP (4 mM), MgCl2 (10 mM), creatine phosphate (10 mM), creatine 
kinase (100 μg/ml), and E217βG (120 nCi, 400 nM) or Tc-99m mebrofenin (2 μCi).  At the 
indicated time points, 19 μl (for time courses) or 60 μl (single time points) of transport 
reaction mixture was removed and placed in 800 μl of Tris sucrose buffer and filtered 
through glass fiber filters (type A/E; Pall Life Sciences, East Hills, NY), washed twice, and 
radioactivity was quantitated by liquid scintillation counting (Packard Tricarb, Packard 
Corp., Meriden, CT,).  Transport in the presence of AMP was subtracted from transport in 
the presence of ATP and reported as ATP-dependent E217βG or Tc-99m mebrofenin 
transport.  The effects of potential modulators of Tc-99m mebrofenin transport [MK571 (50 
μM) and E217βG (100 μM)] were measured at a single time point of 3 min. 
In vitro Tc-99m mebrofenin protein binding  
Plasma samples containing a range of concentrations of Tc-99m mebrofenin between 1 and 
160 nCi/mL were obtained from a healthy subject participating in the clinical study described 
below.  Samples were centrifuged (1000xg) at room temperature using Centrifree® 
 82
ultrafiltration devices equipped with YMT membranes (Millipore Corporation, Bedford, 
MA). Centrifugation in a fixed angle rotor varied from 3 to 5 min, depending on the time 
required to yield approximately 10% of the sample volume as ultrafiltrate.  Initial studies 
were conducted to validate that Tc-99m mebrofenin did not bind to the device or the 
membrane. 
Clinical study   
Details on the study design and results have been reported previously (10). In brief, four 
healthy non-smoking volunteers within 20% of ideal body weight participated in this study.   
All procedures were approved by the Clinical Research Advisory Committee and the 
Committee on the Protection of the Rights of Human Subjects of the University of North 
Carolina at Chapel Hill School of Medicine.  Subjects provided written informed consent 
prior to participation in the study.  After an overnight fast, a custom-made oroenteric tube 
was passed through the mouth and positioned in the upper portion of the duodenum with the 
aid of dynamic fluoroscopic radiography.  The oroenteric tube used in these studies was a 
silicone multi-lumen extrusion fitted at the distal end with a polyethylene balloon to occlude 
the intestine during bile collection; this tube has been described in detail previously (10).  
Subjects received a 2.5-mCi IV bolus dose of Tc-99m mebrofenin (Squibb Diagnostics, 
Princeton, NJ).   Blood samples were collected at predetermined time points up to 180 min 
post dose.  Biliary secretions were aspirated continuously and pooled over predetermined 
intervals up to 180 min post dose.   Urine was collected at 180 min.  Anterior gamma 
scintigraphic images of the abdomen were acquired under dynamic mode at 1-min intervals 
using a gamma camera (E-CAM Dual Head Gamma Camera, Siemens), and analyzed using 
ESOFT 2.5 software (Siemens, Hoffman Estates, IL).   Two hr post Tc-99m mebrofenin 
 83
administration, cholecystokinin-8 (CCK-8; sincalide; 0.02 μg/kg; Bracco Diagnostics, 
Princeton, NJ) was administered as an IV infusion over 30 min to facilitate contraction of the 
gallbladder.  A gallbladder ejection fraction (EF) value was calculated from the abdominal 
images.   
Whole blood radioactivity was determined by gamma scintillation counting (Quantum-8 
Multichannel Analyzer, Oak Ridge, TN).   Bile and urine were analyzed by a CRC-15R dose 
calibrator (Capintec, Ramsay, NJ).   All samples were corrected for decay based on the Tc-
99m half-life of 6.01 hr.  
Biliary and urinary recovery were calculated as the percentage of the administered dose that 
accumulated in bile and urine, respectively, 180 min after dosing.   The biliary recovery of 
Tc-99m mebrofenin was corrected by EF to obtain the percentage of the excreted dose.  This 
corrected value was used in the modeling to minimize inter-subject variability among 
volunteers associated with gallbladder response to CCK-8.  
Pharmacokinetic modeling 
A series of multicompartmental models was developed using the concentration- and mass-
time profiles from subject 4, who had the most complete data set, to describe Tc-99m 
mebrofenin hepatobiliary disposition in healthy volunteers.  The final model is shown in Fig 
3.2.  This model included a central compartment (Vc, Cc) that described the blood activity-
time profiles, a peripheral compartment that represented the liver (Xliver), from which 
unidirectional elimination into bile (collected in the duodenum) was characterized by k20.  
Urinary elimination was described by unidirectional elimination from the central 
compartment (k10).  k21 described the egress of Tc-99m mebrofenin from the liver into the 
central compartment.  All processes were assumed to be linear and were represented by first-
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order rate constants.  Tc-99m mebrofenin was administered as a single IV bolus; although 
intense blood sampling at early time points captured the distribution into the systemic 
circulation, initial data points up to Cmax were not considered in development of the 
pharmacokinetic model.  The terminal elimination phase of the plasma profiles was truncated 
at 140 min because inclusion of concentrations beyond this time point in the regression 
analysis resulted in decreased values of R-square and the slope of the fitted line.  Differential 
equations describing the mass balance of the compound in the compartments depicted in Fig 
3.2 were fit simultaneously to blood, urine and bile activity time profiles using nonlinear 
least-squares regression (WinNonlin Pro version 4.2; Pharsight, Mountain View, CA).  
Model selection was based on Akaike’s Information Criterion, the residual sum of squares, 
visual inspection of the residual plots and of model fitting to the concentration- and mass-
time profiles.  A weighting scheme was developed to account for the relative contribution of 
each data set to the overall number of data points, due to the disparity in the number of 
observations among the data-supported functions.  Each data point was assigned a weight of 
)1(1 n
y
−×  where n is the fraction of total number of data points that support a particular 
function.  The following differential equations described Tc-99m mebrofenin disposition in 
healthy volunteers:  
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Pharmacokinetic Simulations 
Simulations were performed to explore the potential effect of disease states such as 
hyperbilirubinemia and Dubin-Johnson syndrome on the disposition of trace amounts of Tc-
99m mebrofenin.  Moreover, several potential clinical interactions with other xenobiotics at 
the hepatic uptake or efflux level were simulated.  Using transfected in vitro systems, 
transport proteins that may play a role in the Tc-99m mebrofenin hepatobiliary disposition 
were identified.  However, it was not possible to characterize the transport kinetic parameters 
(Vmax  and Km values) with increasing concentrations of Tc-99m mebrofenin because of the 
amount of radioactivity that would be required to conduct these studies.  For the simulations 
it was assumed that the rate constant k12 was associated with OATP-mediated hepatic uptake, 
k20 described MRP2-dependent canalicular efflux, and k21 was associated with hepatic 
basolateral efflux of Tc-99m mebrofenin.  The effect of high blood levels of bilirubin and its 
conjugates on Tc-99m mebrofenin hepatobiliary disposition in the presence and absence of 
physiologic changes associated with Dubin-Johnson syndrome or extra-hepatic cholestasis 
was simulated through changes in the first-order rate constants obtained from 
pharmacokinetic modeling of the data from healthy subjects.   Additionally, the potential 
effects of alterations in uptake and biliary excretion of Tc-99m mebrofenin in healthy 
subjects due to drug-drug interaction were investigated in cases in which agents such as 
cyclosporin A (MRP2 and OATP inhibitor), gemfibrozil (OATP1B1 inhibitor) and 
phenobarbital (Mrp3 inducer and Mrp2 inhibitor in the rat) would be co-administered with 
Tc-99m mebrofenin.  The renal excretion of Tc-99m mebrofenin was assumed to be due only 
 86
to glomerular filtration.  Therefore, k10 was not expected to be modified by the disease states 
or drug interactions investigated in these simulations. 
In order to simulate the effect of the described pathologies or co-treatments on the disposition 
of Tc-99m mebrofenin, the following alterations were made: 
1) Elevated plasma bilirubin may be associated with elevated Tc-99m mebrofenin 
plasma concentrations at 10 min, resulting in increased renal excretion at 3 and 24 hr 
(32).  To describe competitive inhibition of Tc-99m mebrofenin uptake in the liver, 
k12, the rate constant associated with hepatic uptake, was lowered 10-, 5- and 2.5- 
fold.   
2) MRP3 protein expression is induced in patients with Dubin-Johnson syndrome (19).  
Additionally, a 7-fold induction in Mrp3 has been observed in TR- rats (20).   The 
mean estimate for k21 (reflecting MRP3 basolateral efflux) was increased 7-fold to 
simulate expected alterations in Tc-99m mebrofenin disposition in patients with 
Dubin-Johnson syndrome.  To account for the absence of functional MRP2 at the 
canalicular membrane, as well as the delayed gallbladder and intestinal visualization 
that has been observed in Dubin-Johnson patients’ scans after Tc-99m mebrofenin 
analogs administration, k20 (reflecting canalicular efflux) was diminished 100-fold.  
Jaundice is observed in most patients with Dubin-Johnson syndrome.  Additional 
simulations were conducted for these patients incorporating mild hyperbilirubinimia 
(k12  lowered by 2.5-fold) in addition to impaired MRP2 function (k20 lowered of 100-
fold) and induction of MRP3 (k21 increased 7-fold).  
3) Extra-hepatic or obstructive cholestasis can cause changes in hepatic transport 
proteins similar to Dubin-Johnson syndrome.  Mrp2 expression has been reported to 
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be reduced and Mrp3 enhanced in response to stasis of bile in bile-duct ligated rats 
(33).  Similar changes in patients affected by obstructive cholestasis were simulated 
by diminishing k20 3-fold and increasing k21 5-fold. 
4) Finally, the effect of drug interactions at the level of the transport proteins on blood 
and hepatic concentration of Tc-99m mebrofenin were investigated.  Cyclosporin A is 
known to inhibit Oatps (34) and to inhibit modestly Mrp2-dependent transport in rats 
(35).  Acute co-administration of Tc-99m mebrofenin and cyclosporine A was 
simulated by lowering k20 2-fold and k12 5-fold.   Inhibition of Tc-99m mebrofenin 
uptake might be observed with xenobiotics  that are known to inhibit OATP1B1 [e.g. 
gemfibrozil (36)], this scenario was simulated by decreasing k12 5-fold.  
Phenobarbital treatment increases Mrp3 expression (>10-fold induction) without 
altering the expression of Mrp2 in rats (37).  A similar scenario was simulated to 
investigate changes in the disposition of Tc-99m mebrofenin in patients chronically 
treated with phenobarbital (k21 was increased 10- and 100-fold).  
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RESULTS 
Tc-99m mebrofenin transport by OATP1B1 and OATP1B3 
Published in vitro studies have implicated a Na+-independent process in the uptake of Tc-
99m mebrofenin analogs into hepatocytes (25).  Additionally, elevated bilirubinemia 
enhances Tc-99m mebrofenin urinary excretion (32).  Since OATP1B1 and OATP1B3 are 
responsible for the hepatic uptake of bilirubin and its glucuronide metabolites, these clinical 
observations might be due an interaction in hepatic uptake between bilirubin and  Tc-99m 
mebrofenin (38).  For these reasons, Xenopus laevis oocytes expressing OATP1B1 and 
OATP1B3 were utilized to investigate the potential role of these transport proteins in the 
hepatic uptake of Tc-99m mebrofenin.  Tc-99m mebrofenin uptake by uninjected, 
OATP1B1- and OATP1B3- expressing oocytes was measured over 60 min (Fig 3.3A).  
Transport was linear up to 30 min in oocytes expressing OATPs.  After 30 min, OATP1B1 
transport reached a plateau.  Uninjected oocytes did not show any significant transport of Tc-
99m mebrofenin.  Rifampicin is used commonly as a potent inhibitor of OATP-dependent 
transport (39).  Co-incubation of the oocytes with 50 μM rifampicin inhibited Tc-99m 
mebrofenin uptake over 60 min to ~90% and ~96% of untreated control values in OATP1B1- 
and OATP1B3- expressing oocytes, respectively (Fig 3.3B). 
Tc-99m mebrofenin transport by MRP2 and MRP3 
Previously reported clinical observations in patients with Dubin-Johnson syndrome, and 
experiments using TR- rats, have suggested that Tc-99m mebrofenin is transported into bile 
by MRP2/Mrp2.  Thus, to determine whether Tc-99m mebrofenin is a substrate for MRP2, 
and for another important hepatic transport protein, MRP3, ATP-dependent uptake of Tc-
99m mebrofenin by inside-out membrane vesicles prepared from HEK293 cells transiently 
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transfected with MRP2 or MRP3 was measured (Fig. 3.4).  Control experiments to measure 
the uptake of [3H]E217βG, a well-characterized substrate for both MRP2 and MRP3, were 
performed at a single time point (3 min) to ensure that membrane vesicles were functional 
(Fig. 3.4A).  Consistent with previously published observations, uptake of [3H]E217βG in 
membrane vesicles prepared from untransfected, MRP2 and MRP3 transfected HEK293 cells 
was 6.2, 16.1 and 102.3 pmol/mg protein, respectively (28).  Tc-99m mebrofenin uptake in 
inside-out membrane vesicles from MRP2 transfected HEK293 cells was linear for up to 3 
min (Fig 3.4B); uptake was more extensive than in vesicles from MRP3 transfected HEK293 
cells at 3 min (~23 vs. 5 nCi/μg protein) as shown in Fig. 3.4B.  Transport of Tc-99m 
mebrofenin by MRP3 was linear for up to 3 min, at which time 5 nCi/μg protein had 
accumulated and uptake began to plateau.   No significant transport activity was detected for 
membrane vesicles prepared from untransfected HEK293 cells. 
Several MRP2 and MRP3 substrates have been shown to be competitive inhibitors of 
MRP2 and MRP3 transport.  E217βG (100 μM) inhibited ATP-dependent MRP3-mediated 
transport of Tc-99m mebrofenin ~95% (Fig. 3.4C).  Unexpectedly, MRP2-dependent 
transport of Tc-99m mebrofenin was not inhibited by the same concentration of E217βG, 
possibly due to a higher affinity of MRP2 for Tc-99m mebrofenin than E217βG.   MRP2 
transport of Tc-99m mebrofenin was inhibited (~88% of control) by MK571 (50 μM), an 
LTD4 receptor antagonist commonly used as an MRP family inhibitor.   
Pharmacokinetic modeling of the disposition of Tc-99m mebrofenin in healthy subjects; 
disease state and drug interaction simulations: 
The model depicted in Fig 3.2 was suitable for describing Tc-99m mebrofenin disposition in 
all subjects.  The goodness of fit of this model to representative data from subject 4 is shown 
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in Fig 3.5.   The parameter estimates and associated coefficients of variation for k10, k12, k21, 
k20 and Vc are reported in Table 3.1 together with the administered dose and the amounts of 
Tc-99m mebrofenin excreted into bile and urine, which were used as input for the 
pharmacokinetic modeling studies (10).  The model clearly supports the hypothesis that a 
fraction of hepatic Tc-99m mebrofenin is effluxed back into sinusoidal blood and is available 
for urinary excretion or reuptake by the liver.  In all subjects, the ratio between the 
canalicular (k20) and basolateral (k21) efflux rate constants exceeded 2 (k20/k21 = 3.5±0.8, 
mean ± SD), suggesting that once in the liver, the predominant process that determines Tc-
99m mebrofenin fate is excretion into bile.  The small volume of distribution for the central 
compartment (Vc) suggests that this represents the blood pool; differences in the Vc among 
subjects were reduced when volumes were weight-normalized (0.09-0.15 L/kg).   
Simulations were performed using the mean values for the rate constants obtained 
from modeling the data from the four healthy (Fig 3.6).  The percentage of the dose predicted 
to remain in blood and to be excreted into urine was very similar to clinical data reported for 
Tc-99m mebrofenin (32).   Based on these simulations, ~22% of the dose remained in blood 
10 min after dose administration, which was consistent with a mean value of 17% reported in 
the literature.  The simulated percentage of the dose recovered in urine at 3 hr was ~0.6 %, 
which was similar to the average urinary excretion of 0.4-2.0% of the dose reported in 
previous clinical studies.  
Alterations in the disposition of Tc-99m mebrofenin due to pathophysiological abnormalities 
occurring in hyperbilirubinemia, Dubin-Johnson syndrome, cholestatic patients and possible 
drug-drug interactions were examined using mathematical simulations.   
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In the four healthy subjects enrolled in this clinical study, Tc-99m mebrofenin renal 
clearance was 5-13 mL/min.  In vitro protein binding studies revealed that the unbound 
fraction of Tc-99m mebrofenin in plasma was ~10%.  For a compound with these 
characteristics, the expected renal clearance would be 12 mL/min if glomerular filtration was 
the predominant process determining renal elimination.  Therefore, it can be concluded that 
Tc-99m mebrofenin elimination into urine is a passive process driven primarily by filtration.  
Since Tc-99m mebrofenin renal excretion is minimal and due to glomerular filtration, only 
liver uptake and efflux processes were assumed to be modified by pathologies and 
interactions with other drugs.    
Fig 3.7 depicts the changes in blood Tc-99m mebrofenin concentrations in the presence of 
pathologies affecting liver transport processes or drug interactions.   Impaired hepatic uptake 
of Tc-99m mebrofenin due to either elevated plasma bilirubin (Fig 3.7A) or drug-interactions 
(Fig 3.7C gemfibrozil, cyclosporin A), caused an elevation in Tc-99m mebrofenin blood 
concentrations, with slow removal by the kidneys; elevation in blood concentration also was 
predicted when hepatic basolateral efflux was induced by phenobarbital treatment (Fig 3.7C, 
PB x10 and PB x100).  For pathologies in which biliary excretion processes were obliterated, 
however, the concentrations in blood remained elevated for a much more prolonged period of 
time (Fig 3.7B) because of the extensive hepatic accumulation of Tc-99m mebrofenin 
increased the driving force for excretion of Tc-99m mebrofenin back into blood via MRP3.    
Hepatic accumulation is depicted in Fig 3.8.  Impaired hepatic uptake of Tc-99m mebrofenin 
would, as expected, lower the exposure of this organ to the drug (Fig 3.8A and 3.8C).   
Induction of MRP3 transport due to phenobarbital treatment also diminished hepatic 
exposure.  Inhibition of the hepatic uptake rate constant due to drug interactions delayed the 
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Cmax in the liver (Fig 3.8C).  On the other hand, impaired biliary excretion due to absence or 
downregulation of MRP2 resulted in sustained hepatic accumulation of Tc-99m mebrofenin 
over time (Fig 3.8B).   
The renal and biliary excretion of Tc-99m mebrofenin predicted from these 
simulations varied greatly in response to elevated blood and liver concentrations, as well as 
changes in hepatic transport protein expression and function.  The cumulative Tc-99m 
mebrofenin excretion in urine at 3 hr was predicted to be 0.6% of the dose in normal 
subjects; this value increased to 1.5, 2.9 and 5.3 % of the dose when hepatic uptake (k12) was 
decreased 2.5-, 5- and 10-fold, respectively.  Cumulative urinary excretion at 3 hr was 
predicted to be high in cholestasis (1.5% of the Tc-99m mebrofenin dose), and in patients 
with Dubin-Johnson syndrome (2.2% and 4.6% when accompanied by hyperbilirubinemia).  
Finally, all drug-drug interactions examined in the simulations enhanced urinary excretion 
(cyclosporin A, 3.1%; phenobarbital x10, 1.6%; phenobarbital x100, 7.4%; gemfibrozil, 
2.9%).  Simulated cumulative amounts of Tc-99m mebrofenin excreted into bile decreased: 
hyperbilirubinemia decreased biliary excretion from 86% to 83%, 77% and 65% of the dose.  
As expected in patients with Dubin-Johnson syndrome, less than 2% of the dose was 
predicted to be excreted into bile.  Cholestasis decreased the biliary excretion of Tc-99m 
mebrofenin to 46% of the dose.  Cyclosporine A and the highest dose of phenobarbital 
significantly changed the cumulative biliary excretion of Tc-99m mebrofenin to 54% and 
48% of the dose. 
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DISCUSSION  
This series of studies was designed to develop a model to describe the polyexponential 
disposition of Tc-99 mebrofenin in blood as observed during a clinical study in healthy 
volunteers.  An integral part of the study was the characterization of the transport proteins 
involved in liver uptake and excretion of this compound.  Since changes in expression of 
hepatic transport proteins are common in hepatobiliary disease, pharmacokinetic modeling 
and simulations were employed to investigate the effects of disease states and drug 
interactions on Tc-99m mebrofenin disposition.   
The OATP family is responsible for the uptake of a very broad range of substrates, 
preferentially anionic amphipathic compounds such as bile acids, bilirubin and other 
compounds/metabolites with high molecular weight that bind to plasma albumin and are 
ultimately excreted into bile (40, 41).  Tc-99m mebrofenin has a high molecular weight and a 
negative charge, accordingly it was not surprising to find that OATP1B1 and OATP1B3 are 
involved in the transport of this compound.  In the liver, OATP1B1 also is responsible for 
basolateral uptake of bilirubin and its glucuronide metabolites (38, 42), elevated plasma 
bilirubin concentrations may impair hepatic uptake and enhance urinary excretion of Tc-99m 
mebrofenin by competing for OATP-mediated transport into the liver.  The finding that Tc-
99m mebrofenin can be excreted into bile by MRP2 and effluxed from the liver into blood by 
MRP3 is in good agreement with clinical observations in patients with Dubin-Johnson 
syndrome, as well as experiments in TR- rats.  In the liver, MRP2 mediates the efflux of 
endogenous and exogenous organic anions and conjugates into bile (12, 43, 44).  The 
basolateral transport protein MRP3 shares tissue distribution and substrate specificity with 
MRP2, and these transporters have a complementary role in hepatic detoxification so that, in 
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disease states where MRP2 is absent or down-regulated, MRP3 is induced several fold (12, 
43, 45).   
The findings from the in vitro experiments, coupled with the results of the pharmacokinetic 
modeling, were used in simulation studies to predict the effect of disease states or drug 
interaction on Tc-99m mebrofenin disposition due to alterations of expression or activity of 
hepatic transport proteins.  The pharmacokinetic model described all data sets from the four 
healthy subjects well.  There was low variability associated with parameter estimates in all 
subjects.  Data sets from Subjects 1 and 3 were most affected by experimental error and, as 
expected, the model performed slightly worse in fitting these data sets when compared to the 
remaining subjects.  In Subject 1, the actual administered dose was not known, and a small 
leak of Tc-99m mebrofenin, below the balloon occluding the intestine, prevented complete 
quantitative recovery of the probe over the 3 hr study period.  Subject 3 did not respond 
completely to CCK-8 and, for this reason, the amount of the Tc-99m mebrofenin dose 
excreted into bile was the least certain, since it was based primarily on the mathematical 
correction for EF.  As previously demonstrated in dogs (6), Tc-99m mebrofenin is 
transported into bile and can be excreted from the hepatocyte back into blood.  The terminal 
phase of the Tc-99m mebrofenin blood activity-time profile may be due to egress into blood 
by the efflux transport protein MRP3, located on the basolateral membrane of hepatocytes.  
This excretory process is required in the pharmacokinetic model (k21).  The in vitro findings 
in this study demonstrated that OATP1B1, 1B3 and MRP2 and MRP3 play a role for the 
hepatobiliary disposition of Tc-99m mebrofenin in humans.  In vitro observations together 
with the predictions from the simulation exercise support the clinical observation that high 
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bilirubin concentrations in blood would cause, at least in part, the elimination route of this 
compound to shift from biliary to urinary excretion.  
Drug elimination by the kidney is the result of glomerular filtration, active secretion 
and active reabsorption (when transport processes are involved).  This differs from hepatic 
elimination of drugs that relies heavily on the uptake (active or passive) of compounds into 
the hepatocyte.  The renal clearance in the four subjects enrolled in this study was within the 
range of normal glomerular filtration when Tc-99m mebrofenin plasma protein binding was 
taken into account.  Therefore, modifications of active tubular secretion and reabsorption as a 
consequence of disease states or drug interactions would play a minor role in Tc-99m 
mebrofenin urinary excretion.  
Tc-99m mebrofenin simulated blood mass-time profiles, revealed that patients 
affected by Dubin-Johnson syndrome and obstructive cholestasis would exhibit significant 
differences in the blood pharmacokinetics of this agent, compared to patients with 
hyperbilirubinemia caused by other diseases.  In addition, simulations indicated that Tc-99m 
mebrofenin blood concentrations change minimally over the first hour post administration in 
patients lacking MRP2, therefore, sparse blood sampling coupled with gamma scintigraphy 
scans might be sufficient to diagnose Dubin-Johnson syndrome.  This diagnostic tool could 
be especially useful in children in whom liver biopsy would be considered very invasive.   
Additionally, the pharmacokinetic modeling and simulations provided important information 
on the distribution of Tc-99m mebrofenin within the liver.  Typically, it is not possible to 
quantify liver exposure to drugs in humans, but changes in hepatic accumulation due to 
disease state or drug interactions could be an important cause of hepatotoxicity.   The 
simulations were particularly useful in examining the impact of impaired hepatic uptake and 
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biliary efflux processes and in appreciating the differences when both processes are inhibited.  
The liver exposure to Tc-99m mebrofenin in the presence of cyclosporin A (k12 diminished 
5-fold and k20 diminished 2-fold) differed considerably from the predicted hepatic exposure 
in the presence of gemfibrozil (k12 diminished 5-fold).  These differences in hepatic 
accumulation may be relevant in cases where the drug affected by this interaction has 
hepatotoxic potential when liver exposure is prolonged.  Additionally, hepatotoxicants that 
are handled by the liver in a manner similar to Tc-99m mebrofenin may cause significant 
toxicity in patients with impaired MRP2 function or in patients with cholestasis. 
The importance of changes in systemic and hepatic exposure illustrated by these 
pharmacokinetic simulations may be considerable for drugs that are administered in larger 
doses and have toxic potential.  For example, cases of fatal rhabdomyolysis caused the 
withdrawal of cerivastatin from the market (46); these adverse events were related later to 
concomitant administration of gemfibrozil.  Other studies have shown that cerivastatin 
hepatic uptake can be inhibited by cyclosporin A (47), resulting in increased systemic 
exposure, as predicted for Tc-99m mebrofenin (48).  These data suggest that this compound 
could be used as an in vivo probe to investigate potential drug-drug interactions due to 
hepatic transport proteins. 
In conclusion, these studies identified the transport proteins involved in the 
hepatobiliary disposition of Tc-99m mebrofenin.  Utilizing pharmacokinetic modeling and 
simulations, the impact of changes in the hepatic uptake or excretion on the systemic and 
liver exposure, as well as the biliary and renal excretion of Tc-99m mebrofenin was 
demonstrated.  Pharmacokinetic studies with Tc-99m mebrofenin may be a useful in vivo 
 97
clinical tool to identify genetic polymorphisms and assess the potential impact of drug-drug 
interactions at the hepatic transport level as well as mechanisms of liver toxicity. 
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TABLES 
Table 3.1: Biliary and urinary recovery of Tc-99m mebrofenin after IV administration 
to 4 healthy human volunteers (10).  The biliary recovery was corrected for the degree of 
gallbladder contraction in response to pharmacological stimulation, thereby correcting the 
amount of drug recovered in bile for the residual amount remaining in the gallbladder.  The 
individual parameter estimates and associated variability for the first-order rate constants (see 
Fig. 3.2 legend for parameter definitions) and the volume of the central compartment (Vc) 
were obtained from pharmacokinetic modeling of Tc-99m mebrofenin disposition data.  
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Table 3.1 
 Subject 1 Subject 2 Subject 3 Subject 4 Mean S.D. 
*Dose (μCi) 2188a 2072 2282 2476 2255 171 
*Urinary Recovery  
(% of dose) 
0.7 0.5 0.8 0.5 0.6 0.2 
*Biliary Recovery corrected for EF 
 (% of dose ) 
70.9 89.1 91.9 84.9 84.2 9.3 
 
Parameter Estimate  
(CV%) 
K12 (min-1) 0.11 
(10.1) 
0.17 
(10.9) 
0.22 
(17.0) 
0.23 
(7.9) 
0.18 0.06 
K21 (min-1) 0.0019 
(26.5) 
0.0051 
(21.9) 
0.0034 
(64.6) 
0.0032 
(25.5) 
0.0034 0.0013
K20 (min-1) 0.0073 
(0.75) 
0.013 
(0.91) 
0.015 
(1.3) 
0.011 
(0.55) 
0.012 0.003 
K10 (min-1) 0.00065 
(11.8) 
0.00063 
(17.4) 
0.0015 
(21.8) 
0.00087 
(18.5) 
0.0009 0.0004
Vc (L)  13.6 
(9.84) 
10.1 
(10.8) 
8.73 
(18.7) 
5.79 
(9.27) 
9.56 3.25 
Ratio K20/K21 3.8 2.6 4.5 3.5 3.5 0.8 
 
a Only theoretical dose available 
* From (10)
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FIGURES 
Fig 3.1: Structure of Tc-99m mebrofenin.  This hepatobiliary imaging agent consists of 
two molecules of mebrofenin chelating a central atom of Tc-99m. 
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Fig 3.2: Scheme of the pharmacokinetic model describing the disposition and 
elimination of Tc-99m mebrofenin in humans. X0 represents the IV bolus dose.  Cc  is the 
concentration of Tc-99m mebrofenin in the central compartment (blood) and  Vc  the central 
compartment volume. All other compartments were modeled as amounts [in urine (Xurine), in 
liver (Xliver)  and in duodenal bile corrected by EF (X bile)]. All rate constants were assumed to 
be first-order: k12 represents hepatic basolateral uptake, k21  hepatic basolateral egress, k20  
hepatic canalicular excretion, and k10  represents the rate constant for renal elimination. 
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Fig 3.3:  Tc-99m mebrofenin uptake in Xenopus laevis oocytes expressing human 
OATP1B1 and 1B3.  Uptake was measured at room temperature with a Tc-99m mebrofenin 
concentration of 9-10 μCi/mL.  Results are expressed as a percentage of untreated oocytes 
expressing the same protein.  Bars and data points represent mean (± SEM) of 5-8 oocytes in 
a single experiment.  Similar results were obtained in an additional independent experiment.   
(A)  Time course of Tc-99m mebrofenin uptake by uninjected oocytes (control, z), 
OATP1B1 (V) and OATP1B3 () expressing oocytes.   
(B)  Inhibition of OATP1B1 and OATP1B3 uptake of Tc-99m mebrofenin by rifampicin.  
Oocytes expressing OATP1B1 and OATP1B3 were incubated for 60 min with Tc-99m 
mebrofenin in the presence (open bar) and absence (closed bar) of rifampicin (50 μM).  
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Fig 3.4:  Tc-99m mebrofenin uptake in inside-out membrane vesicles prepared from 
HEK293 cells transiently transfected with MRP2 or MRP3.  
(A)  [3H]E217βG uptake by membrane vesicles prepared from untransfected, MRP2 and 
MRP3 transfected HEK293 cells. ATP-dependent uptake was measured at 3 min after 
incubating the membrane vesicles with [3H]E217βG  (0.4 μM, 120 nCi). Bars represent mean 
(± SD) of a triplicate incubation in a single experiment.  
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(B) A time course of Tc-99m mebrofenin ATP-dependent transport by control (z), 
MRP2(V) and MRP3 () vesicles.  Uptake was measured at 37ºC with a Tc-99m 
mebrofenin concentration of 50 μCi/mL.  Data points represent mean (± SD) of a triplicate 
incubation in a single experiment.  
(C) Inhibition of MRP2- and MRP3-mediated ATP-dependent transport of Tc-99m 
mebrofenin. Membrane vesicles were incubated for 3 min with Tc-99m mebrofenin in the 
presence (open bar) and absence (closed bar) of E217βG (100 μM) for MRP3 inhibition, and 
MK571 (50 μM) for MRP2 inhibition. Results are expressed as a percentage of untreated 
membrane expressing the same protein.  Bars represent mean (± SD) of a triplicate 
incubation in a single experiment. 
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Fig 3.5: Tc-99m mebrofenin disposition in Subject # 4.  The solid curve represents the fit 
of the pharmacokinetic model depicted in Fig 3.2 to the data.  The blood concentration-time 
profile (¡) is shown on a log-linear scale (left axes), while bile (z) and urine (S) amount 
vs. time profiles are plotted on a Cartesian scale (right axes). Symbols represent actual data 
points while lines represent fit of the model to the clinical observations.  
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Fig 3.6: Simulation of blood, liver, bile and urine mass-time profiles for an “average” 
healthy subject after administration of an IV bolus of Tc-99m mebrofenin.  
The blood mass-time profile is plotted on a log-linear scale on the left axis, while liver, bile 
and urine mass-time profiles are plotted on a Cartesian scale on the right axis. 
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Fig 3.7: Effects of modifications in hepatic uptake and efflux processes on the blood 
concentrations of Tc-99m mebrofenin.  Solid line represents the simulated profile in 
normal healthy volunteers in all panels. 
(A) Inhibition of hepatic uptake of Tc-99m mebrofenin with a 2.5-, 5- and 10-fold 
impairment in k12 (mild, intermediate and severe bili).  These simulations predict 
modifications due to elevated plasma bilirubin concentrations. 
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(B) Simulation of changes in MRP2 and MRP3 caused by Dubin-Johnson syndrome (k21 
induced 7-fold and k20 reduced 100-fold, DJ), in the presence of elevated plasma bilirubin 
(k12 reduced 2.5-fold, DJ bili) are compared to normal volunteers and simulations of patients 
with obstructive cholestasis (k21 induced 5-fold and k20 reduced 3-fold, cholestasis).  
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(C) Simulated alterations in the disposition of Tc-99m mebrofenin in blood caused by drug-
drug interactions with concomitant administration of cyclosporin A (CsA, k12 reduced 5-fold 
and k20 reduced 2-fold), chronic administration of phenobarbital (PB x10 and x100, induction 
of k21 10- and 100-fold) and acute administration of gemfibrozil (k12 reduced 5-fold). 
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Fig 3.8: Effects of modifications in hepatic uptake and efflux processes on the hepatic 
accumulation of Tc-99m mebrofenin.  Solid line represents the simulated profile in normal 
healthy volunteers in all panels. 
(A) Inhibition of hepatic uptake of Tc-99m mebrofenin with a 2.5-, 5- and 10-fold 
impairment in k12 (mild, intermediate and severe bili).  These simulations predict 
modifications due to elevated plasma bilirubin concentrations. 
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(B) Simulation of changes in MRP2 and MRP3 caused by Dubin-Johnson syndrome (k21 
induced 7-fold and k20 reduced 100-fold, DJ), in the presence of elevated plasma bilirubin 
(k12 reduced 2.5-fold, DJ bili) are compared to normal volunteers and simulations of patients 
with obstructive cholestasis (k21 induced 5-fold and k20 reduced 3-fold, cholestasis).  
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(C) Simulated alterations in the disposition of Tc-99m mebrofenin in liver tissue caused by 
drug-drug interactions with concomitant administration of cyclosporin A (CsA, k12 reduced 
5-fold and k20 reduced 2-fold), chronic administration of phenobarbital (PB x10 and x100, 
induction of k21 10- and 100-fold) and acute administration of gemfibrozil (k12 reduced 5-
fold). 
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CHAPTER 4 
 
 
 
DETERMINATION OF THE BILIARY EXCRETION OF PIPERACILLIN AND 
METABOLITES IN HUMANS USING A NOVEL METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter was submitted to The British Journal of Clinical Pharmacology and is 
presented in the style of that journal. 
INTRODUCTION 
The biliary clearance of drugs in healthy human volunteers has been evaluated by 
several groups with varying degrees of success [1-4].  Major challenges in developing an 
accurate method to quantify biliary clearance include the complex anatomy of the human 
hepatobiliary system, as well as the intermittent and incomplete expulsion of bile from the 
gallbladder. Pharmacological contraction of the gallbladder has been employed in an attempt 
to collect as much bile stored within the gallbladder as possible [4].  However, gallbladder 
response to pharmacological contraction can vary considerably among human subjects, and is 
influenced by a variety of factors, including prolonged fasting [5].  Unless the degree of 
gallbladder contraction is considered, the estimated extent of biliary excretion of the drug of 
interest may be inaccurately low and inter-subject variability may be exaggerated [5, 6].   
Recently, we developed a technique to quantify biliary clearance of compounds in 
humans that couples gamma scintigraphy with a specially designed oroenteric catheter [7]. 
This catheter is equipped with an inflatable occlusive balloon that facilitates periodic 
collection of duodenal fluids and bile. The gallbladder ejection fraction (EF) is determined by 
administering a hepatobiliary imaging agent (Tc-99m mebrofenin). Tc-99m mebrofenin is a 
gamma emitting diagnostic agent used in nuclear medicine to evaluate the patency of the 
hepatobiliary tract.  Tc-99m mebrofenin is taken up in a rapid and selective manner by the 
hepatocyte and excreted into bile unchanged [8].  In humans, the majority of the Tc-99m 
mebrofenin administered dose is found in bile three hours after administration [7].  This 
imaging agent allows visualization of the gallbladder before, during and after 
pharmacological contraction.  Administration of a gamma emitter that is excreted into bile 
also aids in the identification of bile leakage beyond the occlusive balloon in the duodenum.   
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ABSTRACT 
Aims: To evaluate the applicability of a novel method to determine the biliary excretion of 
piperacillin, a low biliary clearance drug, and metabolites in healthy volunteers.  
Methods: Healthy volunteers were administered 2 g piperacillin IV. Duodenal aspirates were 
collected via a custom-made oroenteric catheter; blood and urine also were collected. 
Gallbladder ejection fraction (EF) was determined by gamma scintigraphy using Tc-99m 
mebrofenin as an imaging agent. Piperacillin and metabolites were quantified by LC-UV and 
LC-MS. Relevant pharmacokinetic parameters were calculated using noncompartmental 
analysis. Formation of metabolites also was investigated in vitro using human liver 
microsomes. 
Results: The fraction of the piperacillin dose excreted unchanged into bile was 1.1±0.3% 
(biliary clearance corrected for EF=0.032±0.008 mL/min/kg).  Desethylpiperacillin and its 
glucuronide conjugate were detected in bile and urine; these metabolites also were formed in 
human liver microsomal incubates. This is the first report of glucuronidation of piperacillin.  
Conclusions: This methodology can be used to determine biliary clearance of drugs and to 
identify metabolites as soon as they are excreted from the gallbladder, thereby minimizing 
the exposure of labile compounds to the intestinal environment. Although a prolonged 
intubation influences negatively gallbladder contractility, normalization of biliary clearance 
for EF significantly reduces inter-subject variability of this parameter. 
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The primary goal of the present series of investigations was to assess the versatility of 
our approach by applying it to piperacillin, a drug expected to exhibit low biliary clearance. 
Piperacillin is a third-generation, broad-spectrum, penicillin derivative.  This bactericidal 
drug is used commonly in the treatment of intra-abdominal infections and prophylactically 
for gastrointestinal and biliary tract procedures [9].  Studies performed in patients with bile 
duct drainage reported recovery of 0.7-2% of the administered piperacillin dose in bile and 
43-53% in urine, [10, 11] while only 0.08% of the dose was recovered in duodenal fluids of 
healthy volunteers [10].  
A second goal was to evaluate the effect of prolonged intubation on gallbladder 
contractility and on the biliary clearance of drugs.  The recovery of Tc-99m mebrofenin  in 
this study was compared to the recovery of this probe in our previous study [7] to evaluate 
the effect of the intubation time and prolonged presence of the inflated balloon in the 
duodenum on the variability of gallbladder response to CCK-8. 
The characterization of metabolic pathways that are unique to humans is very 
important in the drug development process.  Accordingly, a third goal was to use mass 
spectrometry to evaluate whether sampling bile immediately upon secretion into the intestine 
would enable identification of potentially unstable drug metabolites.  Although the 
metabolite desethylpiperacillin has been recovered in human urine and is formed in human 
liver homogenates [12, 13], the enzymes involved in the formation of this metabolite have 
not been elucidated and excretion of desethylpiperacillin into bile or faeces has not been 
demonstrated to date.  Therefore, the excretion pattern of piperacillin metabolites was 
evaluated in vivo and compared to metabolites generated in vitro.  
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This work demonstrated the utility of a novel clinical protocol and oroenteric tube to 
directly quantify drug and metabolites in bile of healthy subjects.  Results established that 
incorporation of the EF factor in the biliary clearance calculation provides a method to 
account for inherent variability associated with the determination of this parameter in healthy 
volunteers.  
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METHODS 
Clinical Studies:  
Clinical Protocol:  Three male volunteers (23-40 years of age) within 20% of their ideal body 
weight completed the study.  All study subjects were in good health as documented by 
medical history, physical examination, EKG and routine laboratory testing. Subjects were 
asked to abstain from any medications for 2 weeks prior to the study, and to abstain from 
caffeine and alcohol during the study.  The Clinical Research Advisory Committee and the 
Committee on the Protection of the Rights of Human Subjects at the University of North 
Carolina (UNC) at Chapel Hill School of Medicine approved all procedures. Subjects 
provided written informed consent prior to participation in the study.  
Subjects were admitted to the General Clinical Research Centre at UNC Hospitals 12 
hr prior to the procedure.  To stimulate gallbladder contraction, subjects were given a high-
fat, caffeine-free meal consisting of ~1150 kcal (45% fat, 16% protein) upon admission and a 
high-fat snack (48% fat, 18% protein) 5 hr later.  After an overnight fast, a custom-made 
oroenteric tube was passed through the mouth and positioned in the upper portion of the 
duodenum with the aid of dynamic fluoroscopic radiography.  The oroenteric tube used in 
these studies was a silicone multi-lumen extrusion (4.5 mm diameter; 128 cm length, 
Dentsleeve, Wayville, Australia) and was described in detail previously [7].  The distal end 
of the tube was fitted with a polyethylene balloon, which was inflated to occlude the intestine 
during bile collection.  
To determine relevant pharmacokinetic parameters for piperacillin, subjects were 
administered 2 g of piperacillin (generous gift of American Pharmaceutical Partners) as a 15-
min IV infusion via an arm vein, and blood samples were collected at 15, 30, 45, 60, 75, 90, 
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120, 150, 180, 210, 240, 270, 300, 330, 360, 480, 600 min. To visualize the gallbladder, 2.5 
mCi of Tc-99m mebrofenin (Choletec®, Bracco Diagnostics, Princeton, NJ) was 
administered as an IV bolus 2 hr post piperacillin, to allow time for hepatic uptake and 
accumulation of piperacillin.  At this time, subjects were positioned under a gamma camera 
(E-CAM Dual Head Gamma Camera, Siemens) and anterior planar gamma scintigraphic 
images of the abdomen were acquired at 1-min intervals for the remaining 4 hr of the study. 
Gallbladder contraction was induced with cholecystokinin-8 (CCK-8, Sincalide, Kinevac®, 
0.02 μg/kg) administered as an IV infusion over 30 min, 4 hr after piperacillin 
administration.  If CCK-8 failed to contract the gallbladder, 10-20 mL of half milk/half 
cream were delivered into the stomach ports of the catheter to stimulate endogenous CCK 
secretion with the presence of partially digested proteins and fats in the small intestine [14, 
15].  In one case, orange zest was used as an olfactory stimulant to promote gallbladder 
contraction upon failure of the previously described methods.  Duodenal aspirates and 
continuous images of the abdominal region were collected for a total of 6 hr.  Urine and 
blood samples were collected for a total of 10 hr.  Piperacillin was quantified in plasma, bile 
and urine as described under Analytical Methods.  Radioactivity was quantified in blood, bile 
and urine as described previously  [7].  
Analytical Methods: 
Bilirubin Determination: Bilirubin was quantified in the duodenal aspirates to demonstrate 
the presence of bile. The Total Bilirubin Kit (CATACHEM, Bridgeport, CT) was used with 
modifications. Bilirubin (Sigma-Aldrich, St. Luis, MO) was dissolved in 0.01 M NaOH and 
25 μL of samples or standards (range 1.4-35 mg/dL) were added with 200 μL of Total 
Bilirubin Working Reagent.  Following incubation at 22°C for 4 hr, samples were analyzed 
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at 540 nm using a microplate reader FL600 (Bio-Tek Instruments Inc., Winooski, VT). 
Preliminary kinetic studies demonstrated that the colorimetric reaction reached a plateau after 
240 min.  
Piperacillin quantification in plasma and urine: Piperacillin was quantified in plasma and 
urine by HPLC-UV using an HP1050 HPLC-UV system (Agilent, Germany) equipped with a 
Phenomenex Luna column (C18, particle size 5 μm, 250 x 4.60 mm).  The flow rate was 1.5 
mL/min, detection wavelength 254 nm, and dynamic range 1-200 μg/mL.  Samples were 
analyzed with a 14-min reverse phase gradient using sodium acetate 10 mM, pH 5.2, and 
acetonitrile.  For plasma, the gradient started at 18% acetonitrile and increased to 25% over 7 
min.  For urine, the gradient started at 13% acetonitrile and increased to 25% over 9 min.  
Prior to analysis by HPLC, the internal standard cefoxitin (final concentration 20 μg/mL) 
was added to 300 μL of plasma.  Proteins were precipitated with 100 μL of saturated solution 
of ammonium sulphate. Samples were then added to 600 μL of acetonitrile, incubated at 
room temperature for 15 min, centrifuged at 15,000 g for 10 min, and the supernatant was 
collected, evaporated, and reconstituted in sodium acetate (10 mM pH 5.2).  Urine samples 
were diluted with mobile phase containing internal standard.  The method was evaluated in 
both matrices in terms of accuracy, intra-day and inter-day variability (coefficient of 
variation, CV%).  Accuracy ranged between 83 and 119% for the plasma and urine assays. 
The inter-day and intra-day CV% was ≤ 11% for both matrices. 
Determination of Piperacillin and metabolites in bile and urine: Bile and urine were analyzed 
for piperacillin and metabolites using HPLC-MS-MS.  Bile and urine samples were diluted 
1:7 with methanol containing cefazolin (4.5 µg/mL) or cimetidine (0.5 µg/mL) as the internal 
standards.  The HPLC system was an HP1100 (Agilent, Germany), it was coupled to an 
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Applied Biosystems API4000 mass spectrometer with a TurboIonSpray source (Foster City, 
CA).  All components were controlled by Analyst software (version 1.3, Foster City, CA).  
Mobile phases consisted of water and methanol with 0.5% formic acid in each.  A methanol 
gradient was used to elute the analytes from an Aquasil (C18, particle size 5.0 µm, 50x2.1 
mm) analytical column (ThermoElectron, West Palm Beach, FL) at room temperature with a 
flow rate of 0.75 mL/min.  The gradient was held at 95% water for 0.5 min, then water was 
decreased to 10% over 2 min and was held for 1 min.  The system was returned to 100% 
water at 3.5 min.  The total run time was 4 min.  The dynamic range of this method was 1-
100 μM.  Accuracy was in the range of 89-99% and the inter-day and intra-day CV% was 
≤17.2%. An analytical standard was available only for piperacillin; therefore 
desethylpiperacillin and desethylpiperacillin glucuronide concentrations were estimated 
qualitatively and expressed as internal standard peak area ratios. 
User controlled parameters were optimized for the detection of the parent-to-product 
transitions when analytical standards were available (piperacillin, cefazolin and cimetidine).  
For desethylpiperacillin and glucuronides, the most likely transitions were monitored.  For 
positive ion multiple reaction monitoring (MRM), the following transitions were used:  
piperacillin, 518.2→143.3; desethylpiperacillin, 490.0→115.0 and cefazolin, 455.0→156.2.  
For negative ion MRM, the following transitions were used:  piperacillin, 516.0→141.0; 
desethylpiperacillin, 488.0→113.0; piperacillin glucuronide, 692.0→516.0; 
desethylpiperacillin glucuronide, 664→488 and cimetidine 250.9→165.9.  For negative 
MRM, the relative concentrations of piperacillin, desethylpiperacillin, piperacillin 
glucuronide and desethylpiperacillin glucuronide were estimated by analyte: internal 
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standard peak-area ratio and amounts were expressed as the product of the area ratio and the 
volume collected.  
To confirm the presence of piperacillin and desethylpiperacillin glucuronides, 
samples prepared as described for the triple quadrupole analysis were injected onto an 
Agilent 1100MSD ion trap mass spectrometer.  Analysis was conducted in negative mode 
using autoMSn in which parent ions of sufficient intensity were subjected to fragmentation.  
All product ions were scanned; since both parent and glucuronidated compounds contained 
similar structural elements, they were expected to form similar fragments.   
Pharmacokinetic analysis: A gallbladder EF was calculated from anterior planar scintigraphic 
images obtained after Tc-99m mebrofenin administration, using ESOFT 2.5 software 
(Siemens) [16].  EF was determined as described below where GB represents the counts over 
the gallbladder region and the time in all formulas refers to the minutes after piperacillin 
administration.  The amount of piperacillin (Xbile) collected in bile during the time period 
used for the EF calculation was normalized by EF to account for the drug excreted into bile, 
yet remaining in the gallbladder due to incomplete contraction (XGB= Excreted dose). 
EF= ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
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GBGB  
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The amount of Tc-99m mebrofenin (XGB) collected in bile over 4 hrs was calculated and 
corrected by EF as follows in order to compare the recovery obtained in this study to results 
obtained previously with this technique [7].  
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Noncompartmental analysis was used to calculate pharmacokinetic parameters using 
WinNonlin (Pro version 4.2; Pharsight, Mountain View, CA). The area under the plasma 
concentration-time curves (AUC) was calculated using the linear trapezoidal rule, and where 
appropriate, extrapolated to infinity using the slope obtained from linear regression of the last 
3 to 6 time points; AUC0-Tlast was calculated up to 6 hr. Total clearance (Cltotal) was 
calculated as the ratio of the administered dose to AUC0-∞. Biliary clearance (Clbiliary) was 
calculated as the ratio of the cumulative amount of drug recovered in bile at the end of the 
experiment and the AUC0-Tlast.  The biliary clearance corrected by gallbladder EF (in vivo 
Clbiliary) was calculated as the ratio of the Excreted Dose (XGB) and the AUC0-Tlast. 
In vitro metabolism studies: 
Phase I metabolism of piperacillin: To determine whether piperacillin was metabolized by 
microsomal enzymes, incubations were performed in triplicate using human liver 
microsomes [17].  Human liver microsomal proteins (2.5 mg/mL mixed-gender pooled 
human liver microsomes from XenoTech, LLC, Lenexa, KS) were incubated with a 
concentration of piperacillin (Sigma-Aldrich) within the range of the observed clinical Cmax 
(200 μΜ) in 100 mM potassium phosphate buffer (pH 7.4) and 3.3 mM MgCl2. After pre-
warming for 5 min at 37°C the reactions were initiated by the addition of 1 mM β-NADPH 
(Sigma-Aldrich); a control incubation without β-NADPH was included. Aliquots of 
incubation mixtures were removed at 0, 5, 15, 30, 60 and 90 min and the reaction was 
stopped with an equal volume of ice-cold acetonitrile containing internal standard (0.5 
µg/mL cimetidine).  Samples were centrifuged (3500xg for 5 min) to precipitate the protein, 
and the supernatant was analyzed immediately by positive ion HPLC/MS triple quadrupole 
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mass spectrometry, as described for bile and urine.  The same experiments also were 
performed using human liver S9 and cytosolic fractions (XenoTech, LLC, Lenexa, KS).  
Phase II metabolism of piperacillin: To demonstrate piperacillin and desethylpiperacillin 
glucuronidation in vitro, piperacillin was subjected to microsomal incubations in the presence 
of UDPGA.  Microsomal incubations, performed in duplicate, contained human liver 
microsomal protein (2.5 mg/mL mixed-gender pooled human liver microsomes from 
XenoTech, LLC, Lenexa, KS), 100 mM potassium phosphate buffer (pH 7.4), 3.3 mM 
MgCl2, 50 µg alamethicin/mg protein, 5 mM saccharolactone and 500 μΜ piperacillin. 
Samples were pre-warmed for 5 min at 37°C and the reactions were initiated by the addition 
of 2 mM β-NADPH (to allow for the formation of desethylpiperacillin) and 5 mM UDPGA.  
Reactions were terminated at 0, 5, 15, 30, 60, and 90 min by removing 50 µL of the 
incubation mixture and quenching with an equal volume of ice-cold 80:20 (v/v) acetonitrile: 
1% acetic acid containing internal standard (0.5 µg/mL cimetidine).  Samples were 
centrifuged to precipitate the protein, and the supernatant was analyzed immediately by 
negative ion HPLC triple quadrupole mass spectrometry, as described for bile and urine.  
Appearance of an analyte with an exact mass 176 amu greater than either piperacillin or 
desethylpiperacillin confirmed the glucuronidation of these compounds. 
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RESULTS 
Evaluation of gallbladder contractility and recovery of Tc-99m mebrofenin:  
The overall duration of intubation and the fasting time between the intubation and the 
administration of Tc-99m mebrofenin and CCK-8 in this study were modified from the 
design adopted previously [7] to account for the longer elimination half-life of piperacillin. 
These modifications seemed to affect the gallbladder contractility.  The gallbladder ejection 
fraction of the 4 subjects enrolled in the previous study (where three out four subjects had an 
EF ≥ 0.82, [7]) differed considerably from the healthy volunteers enrolled in this study 
(Table 4.1).  As expected, all subjects reported intestinal cramping in response to CCK-8.  
However, only four out of the seven healthy volunteers enrolled in these two studies 
demonstrated normal gallbladder contraction by the end of the study [18].  Since CCK-8 did 
not completely contract the gallbladder of any of the subjects enrolled in the current study, 
these volunteers were administered 10-20mL half milk/half cream at approximately 160 min 
post Tc-99m mebrofenin administration.  Subject A demonstrated satisfactory gallbladder 
contraction (EF=0.82) following fatty food (milk/cream) administration, while Subjects B 
and C did not. Due to complete lack of response to both CCK-8 and half milk/half cream, 
Subject C was asked to smell orange zest at 200 min post Tc-99m mebrofenin administration 
in an attempt to stimulate gallbladder discharge.  Regardless of differences in gallbladder 
contraction, the overall Tc-99m mebrofenin dose recovered in bile corrected for EF was very 
high, and comparable to our previous results [7] (84.2 ± 9.3% versus 60.9 ± 14.9% in the 
current study, mean ± SD).  Urinary recovery of Tc-99m mebrofenin was extremely low in 
both studies as well (0.6 ± 0.2% versus 0.8 ± 0.2% in the current study, mean ± SD). 
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To further demonstrate that Tc-99m mebrofenin accumulation and excretion into bile 
was not affected by the study design, but that the gallbladder contractility in response to 
CCK-8 administration was adversely affected by prolonged intubation, gamma scintigraphic 
images of representative subjects from the previous and current studies are shown in Figure 
4.1.  These images were captured at the times specified in the figure, which refers to the time 
after administration of the radiotracer Tc-99m mebrofenin. Images and duodenal secretions 
were collected for an extra hour post CCK-8 administration during the current piperacillin 
study (Subject B).  Tc-99m mebrofenin rapidly accumulated in the liver, hepatobiliary tree 
and gallbladder of both subjects (Figure 4.1, 10 and 45 or 43 min).  Within 60 minutes, the 
radiotracer was cleared out of the liver and excreted into bile.  At the time of CCK-8 
administration (120 min), both subjects displayed similar Tc-99m mebrofenin disposition, 
with almost all radioactivity contained within the gallbladder.  However, the gallbladder 
response to CCK-8 differed between subjects.  In Subject 2, who was representative of other 
subjects from the Tc-99m mebrofenin study, CCK-8 stimulated almost complete contraction 
of the gallbladder (total EF=0.86) and expulsion of radioactive bile into the intestine (Fig 
4.1).  However, CCK-8 failed to completely contract the gallbladder in Subject B and the 
partial EF calculated from 120-150 min after Tc-99m mebrofenin administration was only 
0.21.  Additionally, Subject B exhibited only a minimal response to fatty food administration 
(partial EF calculated from 160-240 min after Tc-99m mebrofenin administration was 0.08). 
As visible in Figure 4.1, at the end of the imaging time, more radioactivity remained within 
the gallbladder of Subject B.  The duodenal region was effectively isolated and occluded by 
the terminal balloon in both cases, as demonstrated by the confinement of radioactive bile 
within the hepatobiliary tree and duodenum.  Regardless of these differences, use of EF to 
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correct for incomplete gallbladder contraction improved the estimate of the amount of Tc-
99m mebrofenin excreted into bile by decreasing inter-subject variability.   
Piperacillin pharmacokinetics and biliary excretion:  
Piperacillin pharmacokinetics in all subjects in this study were similar to previously 
published data [19, 20].  The mean plasma concentration-time profile and individual 
cumulative biliary excretion plots for Subjects A, B and C are presented in Fig 4.2, and 
pharmacokinetic parameters are listed in Table 4.1.  Piperacillin biliary recovery was 
minimal (0.41 ± 0.32% of the dose), with the majority of the dose excreted as unchanged 
drug in urine (72 ± 13%).  Correction for incomplete contraction of the gallbladder decreased 
inter-subject variability improving the estimate of the amount of piperacillin excreted in bile 
(1.1 ± 0.3% of the dose) by accounting for the amount that would have been excreted in bile 
if the EF had been complete.  Likewise, the calculated biliary clearance of piperacillin was 
less variable among subjects when corrected for the gallbladder EF (Clbiliary 0.012 ± 0.011 
mL/min/kg vs. in vivo Clbiliary 0.032 ± 0.008 mL/min/kg).  
To establish whether the appearance of piperacillin in the duodenum coincided with 
bile discharge, the time-course of piperacillin and bilirubin in the duodenal aspirates was 
plotted (Figure 4.3).  To normalize for inter-individual variability, these values were 
expressed as a percentage of the maximal amounts recovered in the aspirates. The majority of 
piperacillin was excreted upon gallbladder contraction, as illustrated by simultaneous peaks 
of maximal piperacillin and bilirubin commencing at 240 min post piperacillin administration 
(the time of CCK-8 administration) for Subjects A and B.  Subject C did not have gallbladder 
contraction until olfactory stimulation with orange zest at 300 min; a peak in both piperacillin 
and bilirubin was detected readily in the duodenal samples at this time. Interestingly, some 
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piperacillin was found in duodenal secretions at early time points, especially in Subjects A 
and C.  These duodenal aspirates did not contain bilirubin, supporting the hypothesis that 
piperacillin is not only excreted into bile, but also is secreted actively into the intestinal 
lumen. 
Characterization of piperacillin metabolism in humans: 
Piperacillin is excreted primarily unchanged in urine and bile.  However, a metabolite unique 
to humans has been identified in human urine and in incubates of human liver homogenates 
[13, 21].  The comparison of samples from a clinical study analyzed using a bioassay and an 
HPLC method revealed that an active metabolite of piperacillin was detected in bile and 
urine [10].  Mass spectrometric detection allowed for structural identification of two 
metabolites of piperacillin in the clinical samples obtained in the present study. 
Desethylpiperacillin and the glucuronide conjugate of desethylpiperacillin were identified in 
urine and bile of all subjects.  No measurable concentrations of piperacillin glucuronide were 
detected. While dealkylation of piperacillin has been observed previously [12, 22], the 
conjugated metabolite is a novel finding of the present study.  The relative amounts of 
piperacillin, desethylpiperacillin and desethylpiperacillin glucuronide, expressed as the peak 
area ratios corrected for the volume of aspirate collected in the duodenal aspirates and in 
urine fractions analyzed by LC-MS-MS in negative ionization mode, are plotted in Figure 
4.4.  The presence of desethylpiperacillin glucuronide was investigated further. Bile samples 
were incubated with bovine β-glucuronidase (Sigma-Aldrich 4000 units/mL, pH 5, 37°C, 
over 24 hours).  As expected, the desethylpiperacillin glucuronide peak was sensitive to 
enzymatic degradation (results not shown).  Secondly, the structure of the phase II metabolite 
(Figure 4.5, Panel A) was verified by HPLC-MS-MS, as shown in Figure 4.5 (Panel B).  The 
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fragmentation pattern of the desethylpiperacillin glucuronide peak (pseudomolecular ions of 
664 amu) was the same as that of the desethylpiperacillin peak.  
The products of phase I and II metabolism subsequently were examined in vitro using 
pooled human microsomes, liver cytosol and S9 fractions.  There was no turnover of 
piperacillin in the cytosolic fractions of human liver (data not shown), while metabolites 
were formed readily in microsomal incubations.  Panel A in Figure 4.6 depicts in vitro 
formation of desethylpiperacillin by incubation of piperacillin with pooled human liver 
microsomes in the presence of β-NADPH; the lack of desethylpiperacillin formation in the 
absence of β-NADPH confirmed that this oxidation is most likely a cytochrome P450-
mediated reaction.  The determination of the extent of metabolism in vitro through substrate 
depletion was not possible due to the low turnover of piperacillin.  Nevertheless, it was 
feasible to demonstrate that glucuronidation also took place in vitro, once the microsomes 
were made permeable with alamethicin.  Figure 4.6 (Panel B) illustrates that both piperacillin 
glucuronide and desethylpiperacillin glucuronide were formed over time upon incubation of 
the liver microsomes with piperacillin in the presence of β-NADPH and UDPGA.  Since 
desethylpiperacillin glucuronide formation was dependent upon the initial turnover of the 
parent drug into the phase I metabolite, the amount of this glucuronide formed in vitro was 
extremely small, yet detectable after a 15-min incubation, as shown in Figure 4.6 (Panel B 
insert). 
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DISCUSSION 
Investigating the mechanisms of biliary clearance of drugs in humans presents a 
number of challenges, some of which are impossible to overcome, such as complete bile 
collection utilizing a non-invasive technique.  However, as demonstrated in this study, a 
combination of tools can be used to obtain a reliable estimate of the biliary clearance of a 
drug in healthy humans.  Determination of the gallbladder ejection fraction and correction of 
the amount of Tc-99m mebrofenin excreted into bile by this value, diminishes the variability 
of the biliary clearance parameter.  For example, if this corrected amount is used for the 
calculation of the corrected biliary clearance of Tc-99m mebrofenin obtained in our previous 
study, 93% of the systemic clearance for this probe (17.3 ± 1.7 mL/min/kg, [7]) can be 
accounted for by biliary elimination (in vivo Clbiliary =16.1 ± 3.2 mL/min/kg vs Clbiliary 12.5 ± 
3.5 mL/min/kg) . 
Inconsistent contraction of the gallbladder in healthy volunteers after CCK-8 administration 
has not been extensively reported in the literature, but has been observed by our group during 
the development of the current methodology [23].  The lack of responsiveness to CCK-8 for 
two of the three subjects involved in the present study may be attributed to prolonged fasting, 
which was 4 hours longer than in the previous study [7], or to the prolonged presence of the 
tube and the inflated balloon in the duodenum, which may have altered gastrointestinal 
motility.  It is well documented in animals that the duodenum is important in maintaining 
sphincter of Oddi response to CCK [24]. In the present study, the pressure exerted by the 
inflated balloon in the intestinal lumen may have modified response to CCK-8 and 
gallbladder emptying. 
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Piperacillin biliary excretion estimates in this study are highly consistent with 
Westphal and Brogard’s published results [10, 11], and clearly demonstrate that piperacillin 
is only marginally eliminated into bile in humans.  The correction of the excreted dose of 
piperacillin for the gallbladder ejection fraction greatly diminished inter-subject variability 
and yielded estimates for the fraction of dose excreted into bile similar to previously reported 
values in T-tube patients [10].  In contrast, the biliary excretion of piperacillin in animal 
models is extensive, making the extent of biliary elimination in humans more difficult to 
predict from preclinical studies; ~15% of the piperacillin dose was recovered in rat bile after 
single-pass isolated perfused liver experiments, [25] and 37% of the dose was recovered in 
recirculating rabbit isolated perfused livers [26].  The importance of biliary clearance and the 
difficulty in predicting this value from preclinical species, has been recognized recently [27]. 
The present clinical data establish the utility of this oroenteric tube and clinical protocol to 
accurately quantify the biliary clearance of drugs that exhibit low biliary clearance values in 
humans, in addition to drugs like Tc-99m mebrofenin, which are extensively excreted into 
human bile.  
Interestingly, upon administration of CCK-8, duodenal aspirates were collected 
through the more proximal ports of the oroenteric catheter indicating that either the tube 
slipped further along the GI tract or that the intestinal segment contracted.  This phenomenon 
was observed in all subjects and corresponded to CCK-8 administration, suggesting that it 
could be related to CCK-8 action on the gastrointestinal tract. The pH of the duodenal 
aspirates was variable (results not shown), and secretions with a pH of 7 or more were 
obtained upon discharge of gallbladder bile, perhaps due to stimulation of bicarbonate 
secretion [28].  The observation that the pH varied greatly among fractions collected was not 
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unexpected, although this should be taken into consideration when drugs sensitive to pH are 
studied, given that compound degradation could occur, confounding final results.  
The lack of complete overlap between piperacillin and bilirubin appearance patterns 
in the duodenal aspirates provides evidence that, in addition to biliary excretion, piperacillin 
may be secreted actively into the gastrointestinal lumen.  Previous studies of piperacillin 
distribution and excretion suggest that intestinal secretion may explain the lack of mass 
balance observed [11].  Piperacillin intestinal excretion could account for a percentage of the 
dose found in the duodenum, while hepatic metabolism explains the lack of mass balance at 
the end of our studies.  The quantification of bilirubin in the duodenal aspirates can therefore 
be used to overcome a limitation of the current methodology in discriminating between 
intestinal and biliary secretion.  
Quantification of desethylpiperacillin and desethylpiperacillin glucuronide was not 
possible because analytical standards of these metabolites were not available. Thus, only 
relative amounts of piperacillin and its metabolites, as determined by LC-MS-MS in negative 
ionization mode, were expressed as the internal standard area ratio multiplied by the volume 
of urine or duodenal aspirates collected.  As analyte ionization also can be affected by the 
biological matrix analyzed, the trend in the excretion pattern in urine and bile was examined, 
rather than a strict comparison.  From the quantitative analysis (Table 4.1), as well as from 
this comparison of relative amounts, piperacillin was primarily excreted into urine. In fact, 
piperacillin was the most abundant analyte in urine; the opposite held true for the duodenal 
aspirates, where the trend showed that desethylpiperacillin and desethylpiperacillin 
glucuronide were the more prevalent analytes found (Figure 4.4).   This observation could be 
explained by differential affinities for transport proteins in the liver [e.g. the apical and 
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basolateral members of the MRP (multidrug resistance associated protein) family], which 
may determine the major route of hepatic elimination of each species. 
 The liver specific metabolism of piperacillin into desethylpiperacillin has been reported 
previously [13], however, no mechanistic details were elucidated.  In vitro studies 
demonstrated that this N-dealkylation reaction is a microsomal, NADPH-dependent pathway, 
most likely involving a cytochrome P450 enzyme.  Additional studies in the presence of 
UPDGA and β-NADPH demonstrated that piperacillin and its metabolite, 
desethylpiperacillin, undergo glucuronidation in vitro.  The in vitro glucuronidation reaction 
in the present studies relied on the initial conversion of piperacillin by phase I metabolism 
into desethylpiperacillin, because the purified metabolite was not available.  Piperacillin has 
been reported to inhibit AZT glucuronidation [29]; however, no literature reports document 
phase II metabolism of this antibiotic in vitro or in vivo.  Although piperacillin glucuronide 
was detected in the in vitro incubations, it was not detected in the clinical samples, perhaps 
due to degradation of this labile metabolite in bile and urine.  The identification of these 
glucuronides leads to an intriguing hypothesis that other drugs (e.g. penicillin G [30]), that 
have been shown to “activate” Mrp2, but are not transported directly, may be metabolized to 
glucuronide conjugates.  It is well known that MRP2 generally transports phase II 
metabolites, such as glucuronides, into bile.  Due to the relative instability of these 
metabolites, the conjugates could degrade immediately and only the parent drug would be 
detected in bile.  If this hypothesis is correct, the contribution of phase II metabolism as a 
clearance mechanism may be underestimated for numerous drugs.   
 In conclusion, the results of this study extend the applicability of this technique to drugs 
that exhibit a low biliary clearance. This approach also could be useful to characterize 
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metabolic processes for new chemical entities in development, in particular when the 
metabolic pathways are exclusive to humans.  This study led to the identification of a novel 
metabolite of piperacillin in duodenal aspirates and urine, and illustrated the potential use of 
this method to compare the relative importance of different excretion routes for specific 
compounds.  Although these findings are not likely to have any impact on the clinical use of 
piperacillin, the experimental design developed in the present study could be applied to other 
drugs in development, not only to determine the extent of biliary clearance, but also to 
identify and thoroughly characterize drug metabolism.  This information could be obtained 
with a small number of healthy volunteers, and may be a strategic tool in the early stages of 
clinical research to unveil elimination pathways unique to humans. 
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TABLES 
Table 4.1: Summary of individual and mean pharmacokinetic parameters, biliary 
recovery and urinary recovery of piperacillin and ejection fraction for Subjects A, B 
and C.  
 
Parameter Subject A Subject B Subject C Mean SD 
 
Administered Dose (mg) 
 
1700 
 
1764 
 
1586 
 
1683 
 
90 
Biliary Recovery (% dose) 0.77 0.32 0.14 0.41 0.32 
Urinary Recovery (% dose) 72 85 60 72 13 
Ejection Fraction 0.82 0.28 0.07 0.39 0.39 
Recovery of Excreted Dose 
(% dose) 
0.87 1.1 1.4 1.1 0.3 
CLtotal (mL/min/kg) 3.2 2.5 2.9 2.9 0.3 
CLbiliary (mL/min/kg) 0.025 0.008 0.004 0.012 0.011 
in vivo CLbiliary (mL/min/kg) 0.028 0.028 0.041 0.032 0.008 
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Fig 4.1: Planar gamma scintigraphic frontal images from Subject 2 and Subject B. 
Images illustrate Tc-99m mebrofenin accumulation in the liver, hepatobiliary tree and 
discharge into the duodenum after CCK-8 administration (specified time refers to the min 
post Tc-99m mebrofenin administration in both subjects). Radioactive bile was collected 
from the portion of the intestine occluded by the distal balloon, which prevented visualization 
of lower parts of the gastrointestinal tract. 
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 Fig. 4.2:  Piperacillin plasma concentration-time profile for Subjects A, B and C and 
individual piperacillin cumulative biliary recoveries. 
 Piperacillin plasma concentration-time profile for Subjects A, B and C are plotted on the left 
axis (mean ± SD). Individual piperacillin cumulative biliary recoveries expressed as a 
percentage of the maximum recovery are plotted on the right axis. CCK-8, fatty food (milk) 
and orange zest were administered at 240, 280 and 320 min post piperacillin administration 
(arrows). 
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Fig 4.3:  Time-course of bilirubin and piperacillin excretion in duodenal aspirates.  
The amounts of bilirubin and piperacillin recovered in the duodenal aspirates are expressed 
as a percentage of maximum recovery. CCK-8, fatty food (milk) and orange zest (to Subject 
C only) were administered at 240, 280 and 320 min post piperacillin administration (arrows). 
 
 
0
20
40
60
80
100
0
100
200
300
400
0
20
40
60
80
100
Bi
lir
ub
in
 (%
 m
ax
)
Tim
e p
ost
 pip
era
cilli
n (m
in)
       Piperacillin (%max)
Subject A
Subject B
Subject C
CCK8
Milk
Orange
 149
Fig 4.4:  Relative amounts of piperacillin, desethylpiperacillin and desethylpiperacillin 
glucoronide in urine and duodenal aspirates. 
Relative amounts of piperacillin (PIP), desethylpiperacillin (DEP) and desethylpiperacillin 
glucuronide (DEPG) in urine (left ordinate axis) and duodenal aspirates (right ordinate axis). 
Relative amounts are expressed as the mean ± SD of the internal standard (IS) area ratio 
multiplied by the collected volume.  
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 Fig 4.5: Structure and Structural identification of piperacillin and metabolites. 
A) Structure of piperacillin, desethylpiperacillin and desethylpiperacillin glucuronide.   
B) Auto MSn of [M+H] = 664, the predicted pseudomolecular ion of desethylpiperacillin 
glucuronide, and Auto MSn of [M+H] = 488, the pseudomolecular ion of 
desethylpiperacillin. A glucuronide specific neutral loss of 176 amu was observed 
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Fig 4.6: Piperacillin metabolism in human liver microsomal incubations. 
A) Desethylpiperacillin formation (mean ± SD) over time in the presence and absence of 
NADPH.  NADPH incubations were performed in triplicate. 
B) Desethylpiperacillin (DEP), desethylpiperacillin glucuronide (DEPG) and piperacillin 
glucuronide (PIPG) formation over time in the presence of NADPH and UDPGA.  All 
incubations were performed in duplicate and the mean value is reported. Insert shows the 
formation of desethylpiperacillin glucuronide over time on an enlarged scale. 
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CHAPTER 5 
 
 
 
UTILITY OF SANDWICH-CULTURED HUMAN HEPATOCYTES TO PREDICT 
HEPATOBILIARY DRUG DISPOSITION IN HUMANS 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to The Journal of Clinical Investigation and is presented in 
the style of that journal. 
ABSTRACT  
The complexities of hepatobiliary drug disposition, coupled with species-dependent 
differences in metabolism and transport of drugs, make predictions regarding the extent of 
hepatobiliary clearance and interactions with endogenous and exogenous substances in 
humans very challenging. Sandwich-cultured human hepatocytes are an in vitro tool used to 
estimate the biliary clearance of drugs (Clbiliary).  However, information on the predictive 
capabilities of this model are lacking due to the absence of systematic in vivo studies in 
healthy volunteers. Recently, a reliable method was developed to quantify the Clbiliary of 
drugs in healthy humans.  Using this methodology, Tc-99m mebrofenin (MEB) and 
piperacillin (PIP) were determined to exhibit high and low Clbiliary, respectively.  In the 
present study, the  Clbiliary of Tc-99m sestamibi (MIBI), calculated as the ratio of the mass in 
bile corrected for gallbladder ejection fraction, to the area under the blood concentration-time 
profile was determined in healthy subjects (5.5±1.2 mL/min/kg). Additionally, in vivo Clbiliary 
values were compared to predicted Clbiliary values obtained in sandwich-cultured human 
hepatocytes. The rank order of predicted Clbiliary corresponded well with measured in vivo 
Clbiliary values for MEB (7.44 vs 16.1 mL/min/kg), MIBI (1.2 vs 5.5 mL/min/kg) and PIP 
(0.0028 vs 0.0032 mL/min/kg), indicating that sandwich-cultured human hepatocytes may be 
a useful model to predict hepatobiliary drug clearance. 
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INTRODUCTION 
The prominent role of the liver in the biotransformation and elimination of 
xenobiotics in animals and humans is well recognized.  Many in vitro tools as well as animal 
models have been established to study processes involved in the metabolism and 
hepatobiliary disposition of drugs (1, 2).  Despite the availability of in vitro models to 
estimate the biliary clearance of compounds in vivo, there is little information on the 
predictive accuracy of these methods due to the absence of systematic studies measuring the 
biliary clearance of xenobiotics in humans.  These values are needed to compare in vitro and 
in vivo systems (3, 4).  However, due to the complexities of the procedures needed to 
measure hepatobiliary clearance of compounds in humans, as well as species-dependent 
differences in hepatic metabolism and transport, it is very challenging to predict the biliary 
clearance of drugs and the potential for interactions in biliary clearance with endogenous and 
exogenous substances in humans (5, 6).  This often translates into costly failures of drugs at 
late stages in development, due to unexpected liver toxicity or drug interactions at the hepatic 
enzyme and transporter level (7-9).      
The anatomy of the human hepatobiliary system, as well as the intermittent and 
incomplete expulsion of bile from the gallbladder, must be considered when developing an 
accurate method to quantify biliary clearance of drugs in humans.  Recently, we developed a 
novel clinical methodology to determine the extent of biliary excretion of drugs that 
improves the recovery of biliary secretions and corrects for incomplete gallbladder 
contraction (10).  After administration of the drug of interest, bile secreted into the duodenum 
is collected with an oroenteric catheter while temporarily occluding the intestine with an 
inflatable balloon.  Additionally, the degree of gallbladder response to pharmacological 
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stimulation, and any escape of bile distal to the balloon due to partial occlusion of the 
intestine, are evaluated by administering an imaging agent that is excreted into bile.   In 
previously published clinical studies, the biliary clearance of two probes (Tc-99m 
mebrofenin and piperacillin) exhibiting extensive and minimal biliary excretion, respectively, 
was determined (10, 11).  In order to obtain a wide range of biliary clearance values for 
comparison with in vitro determinations, Tc-99m sestamibi was selected for investigation; 
Tc-99m sestamibi was expected to display an intermediate extent of elimination into bile.  
Tc-99m sestamibi is a cationic complex of technetium-99m (Tc-99m 2-
methoxyisobutylisonitrile) that distributes into the heart in proportion to blood flow and 
myocardial viability, and is used in nuclear medicine to assess myocardial perfusion (12, 13).  
A significant portion of the administered dose is excreted into bile (14), with over 27% of the 
dose recovered in urine and 33% in feces within 48 hours after administration (15).   
Biliary excretion of drugs can be investigated in vitro using various model systems 
with different degrees of complexity (5).  Primary rat hepatocytes cultured between two 
layers of gelled collagen in a sandwich configuration have been well characterized.  
Similarly, sandwich-cultured human hepatocytes repolarize, form canalicular networks, 
express and properly localize relevant, functional drug transport proteins, and can be used to 
characterize uptake and efflux of xenobiotics by the liver (16, 17).  Using this system, it is 
possible to determine the biliary excretion of drugs by disrupting the tight junctions via 
modulation of calcium in the medium (16, 18-20).   
In the present study, the predicted biliary clearance values of three probe compounds 
were estimated from data generated in sandwich-cultured human hepatocytes (SCHH) and 
these values were compared with in vivo biliary clearance values measured in humans in 
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order to determine how well this in vitro model predicted the hepatobiliary clearance of drugs 
in humans. 
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RESULTS 
Tc-99m sestamibi disposition in healthy volunteers:  
Tc-99m sestamibi (2.5 mCi, IV bolus) was administered to seven healthy males, and relevant 
pharmacokinetic parameters, including renal and biliary clearance, were determined (Table 
5.1).  The individual Tc-99m sestamibi blood concentration-time profiles are shown in Fig 
5.1A. Tc-99m sestamibi quickly distributed out of the blood compartment as demonstrated 
by a rapid decline in blood concentrations during the 15-min distributional phase. Tc-99m 
sestamibi disposition was similar in all subjects. A small secondary peak was noticeable in 
the plasma concentration-time profile of all volunteers at 40 min; this peak accounted for less 
than 3.4% of the overall exposure to Tc-99m sestamibi.  The radioactivity-time profile of Tc-
99m sestamibi appearing in duodenal aspirates, after correction of the mass collected in bile 
post CCK-8 administration for gallbladder ejection fraction (EF), is shown in Fig 5.1B.  In 
subjects 2 and 3, small amounts of radioactivity appeared in the duodenum at early time 
points, probably due to spontaneous partial emptying of the gallbladder.  Six out of the seven 
volunteers enrolled in this clinical study responded to the pharmacological action of CCK-8 
(Table 5.1).   
The renal clearance of Tc-99m sestamibi was 4.6±1.2 mL/min/kg; biliary clearance was 
similar to renal clearance.  Correction of biliary clearance (Clbiliary ) for EF diminished the 
inter-subject variability in this pharmacokinetic parameter (Clbiliary=3.9±2.0 mL/min/kg vs in 
vivo Clbiliary=5.5±1.2 mL/min/kg).  The gamma scintigraphy images also confirmed that the 
disposition and elimination of Tc-99m sestamibi were similar in all subjects. Representative 
images from subject 4 are shown in Fig 5.2.  Tc-99m sestamibi quickly accumulated in the 
gallbladder (12 min) and, at the same time, was excreted extensively into urine (the kidneys 
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were visible throughout the experiment, and the urinary bladder filled with radioactivity over 
time; Fig 5.2).  Additionally, radioactivity rapidly appeared in the upper and lower regions of 
the gastrointestinal tract (Fig 5.2, arrow A throughout all time frames). At early time points, 
Tc-99m sestamibi intestinal secretion was visible more clearly in the lower part of the small 
intestine (Fig 5.2, arrow A, 12 min).  Subsequently, the radioactivity descended along the 
intestine until it reached the colon where it accumulated, presumably due to fecal 
compaction. There was no visible discharge of bile and no radioactivity was recovered in 
duodenal secretions until 120 min post dose when CCK-8 was infused intravenously.  These 
observations suggest that the radioactivity visible in the GI tract was distal to the balloon 
occlusion and was related to intestinal secretion rather than biliary excretion.  At 120 min, 
CCK-8 was administered, resulting in contraction of the gallbladder and discharge of 
radioactive bile into the duodenum.  Radioactivity was aspirated rapidly and removed via the 
oroenteric tube; complete intestinal occlusion and aspiration of the duodenal fluids was 
confirmed by the observation that no additional radioactivity appeared in the lower parts of 
the GI tract (Fig 5.2, arrow B).   
In vitro biliary excretion of model probes in SCHH:  
The in vitro biliary excretion of Tc-99m mebrofenin, Tc-99m sestamibi and 
piperacillin was measured in SCHH.  As a positive control, taurocholate cellular 
accumulation and the biliary excretion index (BEI) were evaluated.  The BEI of taurocholate 
ranged from 50% to 66% in the four SCHH preparations; cellular accumulation and biliary 
excretion were similar among preparations (Fig 5.3).  Consistent with the previously reported 
in vivo Tc-99m mebrofenin hepatobiliary disposition data (10), the uptake of this agent into 
SCHH was very rapid with up to ~ 25% of the dose accumulating in cells+bile over 10 min 
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(Fig 5.4, Panel A).  In addition, biliary excretion of Tc-99m mebrofenin in vitro was rapid, as 
represented by a BEI of 20-54 % at 10 min.  In contrast, the hepatic uptake of Tc-99m 
sestamibi was modest; less than ~2.9% of the administered dose of Tc-99m sestamibi 
accumulated in the SCHH at 10 min (Fig 5.4, Panel B).  The BEI of Tc-99m sestamibi 
ranged from 23 to 40% at 10 min.  The incubation time of SCHH with piperacillin in the in 
vitro experiments was prolonged to 30 min to allow adequate cellular accumulation of 
piperacillin to detect biliary excretion.  The BEI for piperacillin in SCHH after the 30 min 
incubation ranged from 9-27% (Fig 5.4, Panel C).  Less than 0.32% of the piperacillin dose 
accumulated in SCHH during this time interval; however, in all preparations a detectable 
amount of piperacillin was excreted into the canalicular networks.  The hepatocytes used in 
these studies were obtained from four different donors; the demographic characteristics of 
these donors are summarized in Table 5.2.  The extent of bile canalicular network formation 
was donor-dependent and differed widely as evidenced by the microscopic images (Fig 5.5).  
Sandwich-cultured hepatocytes from Liver 2 exhibited the least canalicular network 
formation (Fig 5.5A); bile canaliculi were limited in size and did not entirely surround the 
hepatocytes.  In contrast, sandwich-cultured hepatocytes from Liver 4 developed extensive 
canalicular networks (Fig 5.5B) with bright belt-like structures between hepatocytes.  The 
biliary excretion index of the probes corresponded to the degree of canalicular network 
development (the BEI for taurocholate, Tc-99m mebrofenin, Tc-99m sestamibi and 
piperacillin was higher in SCHH from Liver 4 than for Liver 2).  
Comparisons of in vitro-in vivo biliary clearance: 
Intrinsic in vitro biliary clearance values (in vitro Clbiliary) were calculated for the three probes 
investigated in these studies and for taurocholate (Table 5.3) and scaled to mL/min/kg as 
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described in the methods. Additionally, the well-stirred model for hepatic disposition was 
used to estimate a biliary clearance value (predicted Clbiliary) from in vitro Clbiliary obtained in 
SCHH.  The biliary clearance values determined from the clinical studies were corrected for 
gallbladder EF to account for variable and incomplete contraction of the gallbladder.  This 
corrected in vivo biliary clearance value is a more reliable estimate of biliary clearance in 
humans and can be considered the true in vivo Clbiliary.  The in vivo Clbiliary values for the three 
probes determined utilizing our clinical methodology were compared to the predicted Clbiliary 
values from the SCHH data (Table 5.4).  The in vitro model consistently predicted a lower 
biliary clearance than the observed value in vivo.  The relationship between in vivo Clbiliary 
and predicted Clbiliary values is plotted in Fig 5.6.  Inspection of Fig 5.6 reveals that the 
“estimated” value from in vitro data was correctly ranked with the “measured” Clbiliary in vivo 
for the three compounds investigated in these studies.  
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DISCUSSION 
The clinical protocol employed in this study to investigate the hepatobiliary disposition of 
Tc-99m sestamibi yielded numerous pharmacokinetic parameters, including the biliary and 
renal clearance of this agent.  Tc-99m sestamibi is less than 1% bound to plasma proteins 
(15) and, in this study, the total renal clearance of this agent was determined to be 4.6±1.2 
mL/min/kg, which is higher than the glomerular filtration rate (1.7 mL/min/kg), and 
consistent with the observation that this compound is a substrate for efflux transporters 
present in the kidney such as P-glycoprotein (P-gp/ABCB1).  Interestingly, the radioactivity 
associated with the presence of Tc-99m sestamibi in the GI tract observed in the images,  was 
distal to the occlusive balloon, suggesting that Tc-99m sestamibi also undergoes intestinal 
secretion, presumably due to intestinal P-gp activity.  P-gp expression is low in the upper part 
of the intestine, but increases in the lower gastrointestinal tract in humans (21).  This may 
explain why no radioactivity was collected via the catheter in the upper part of the duodenum 
in the majority of the subjects until after gallbladder contraction was induced by CCK-8. This 
conclusion also is supported by the gamma images at very early time points depicting 
radioactivity in the ileum and colon when the gallbladder was slowly filling.  The blood 
activity-time profiles in the seven subjects were comparable to other studies (22); the small 
secondary peak noticeable in the plasma profiles could be due to some entero-enteric 
recirculation of this compound.  It is unlikely that enterohepatic recirculation could account 
for this secondary peak since the duodenal occlusive balloon was inflated and no 
radioactivity was collected until 120 min in 5 out of 7 subjects.  Even though Tc-99m 
sestamibi is a large cationic molecule, a small portion of the dose excreted into the intestine 
might be reabsorbed along the gastrointestinal tract.  It is not possible to differentiate 
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between intestinal and biliary secretions with this technique.  Thus, the radioactivity 
collected in duodenal aspirates from subjects 2 and 3 prior to administration of CCK-8 (Fig 
5.1B) may have been expelled from the gallbladder due to a spontaneous contraction, or may 
have appeared in the duodenal lumen following intestinal secretion. 
From the results of the current study and of the Tc-99m mebrofenin and piperacillin 
studies it can be concluded that this clinical methodology can be applied to determine biliary 
clearance of drugs that exhibit high, intermediate and low degrees of excretion into bile.  In 
all cases, the correction for EF reduced the inter-subject variability of the corrected biliary 
clearance estimate, accounting for incomplete bile and drug expulsion from the gallbladder.  
The ability to determine an important parameter such as hepatobiliary clearance in 
vivo allows for comparison of the results obtained with the SCHH model.  This in vitro 
system has been employed only recently to investigate the biliary excretion of drugs.  The 
intrinsic biliary clearance of a series of compounds determined in sandwich-cultured rat 
hepatocytes demonstrated a good correlation between “predicted” and “measured” values 
obtained in the same animal species (19).  Likewise, the results presented here suggest that 
SCHH can be used to correctly classify the biliary clearance of compounds in humans.  The 
rank order of the biliary clearance values predicted from in vitro data corresponded well with 
biliary clearance values measured in vivo.  The removal from sinusoidal blood of the model 
compounds utilized in these studies and elimination into bile is presumably handled by 
different transport proteins.  Thus, it is essential that the in vitro system maintains expression 
and function of hepatic drug transport proteins similar to the in vivo situation in order to 
correctly classify compounds with respect to biliary clearance (low, intermediate or high).  
The present data provide the first evidence that SCHH are capable of predicting the biliary 
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clearance of compounds in humans, and enables comparisons of drugs with different 
chemical structures and diverse mechanisms of hepatic uptake and biliary excretion.  
The predicted Clbiliary was consistently lower than the in vivo Clbiliary for the probes 
studied here.  These findings could be related to less extensive canalicular network formation 
in culture compared to liver tissue in vivo.  In the liver, adjacent hepatocytes form bile 
canaliculi at each cell-cell contact, and the interconnected canalicular spaces drain bile away 
from the hepatocytes and into small bile ducts.  When cultured in a sandwich configuration, 
primary human hepatocytes repolarize over time and form bile canaliculi (23); however, the 
extent of bile canalicular network formation varies from donor to donor, and is not as 
extensive as observed in the native tissue.  If less surface area per hepatocyte is occupied by 
bile canaliculi, then less drug would be excreted into bile in sandwich-cultured hepatocytes 
compared to in vivo.  Ideally, it would be possible to estimate the volume of the canalicular 
network in vitro and in vivo and adjust the predicted Clbiliary by this factor.  Additionally, the 
SCHH system is considered mildly cholestatic because the canalicular networks are sealed 
and cannot drain bile away from the cells.  This static system may reduce bile flow and the 
production of bile acids and, consequently, may influence the biliary excretion of drugs. 
Despite this, the SCHH system can clearly distinguish between drugs with different extents 
of hepatic clearance, and is capable of predicting whether a compound would be extensively, 
moderately or negligibly extracted by the liver and excreted into bile in vivo in humans. 
Undoubtedly, the ability to determine the biliary clearance of drugs in vitro and to 
predict the extent of hepatic excretion for an uncharacterized compound is important from a 
pharmacokinetic and toxicological perspective.  The application of this in vitro model to drug 
development could provide insight regarding the formation and hepatobiliary disposition of 
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potentially toxic metabolites, or could predict drug-drug interactions in a more complex 
system than microsomal incubations.  The three probes selected for investigation in the 
present study displayed almost ideal characteristics (intravenous administration, short half-
life, minimal or no metabolism) in order to simplify the execution of these proof-of-concept 
studies and minimize the length of the intubation time.  However, the same approach could 
be employed, with some modifications, to orally administered, metabolically unstable 
compounds, or drugs with longer elimination half-lives. Currently, new clinical studies are 
underway to investigate compounds with more diverse properties and to evaluate in vivo drug 
interactions with this methodology. The work presented here provides the foundation for 
exploring mechanisms of drug-drug and drug-metabolite interactions in hepatobiliary 
clearance in humans, both in vivo and in vitro.  The current work, which includes data from 
both clinical and in vitro studies, is the first report comparing predicted values for biliary 
clearance obtained in SCHH to in vivo determinations.  The excellent agreement obtained in 
these studies suggests that SCHH may be a useful model to predict hepatobiliary drug 
disposition in humans. 
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METHODS 
Clinical Study Conduct:  Seven volunteers (7 men, 21-41 years of age) within 20% of their 
ideal body weight completed the study.  All study subjects were non-smokers and in good 
health as documented by medical history, physical examination, EKG and routine laboratory 
testing.  Subjects were asked to abstain from any medication for 2 weeks prior to the study, 
and to abstain from caffeine and alcohol during the study.  The Clinical Research Advisory 
Committee and the Committee on the Protection of the Rights of Human Subjects at the 
University of North Carolina at Chapel Hill School of Medicine approved all procedures.  
Subjects provided written informed consent prior to participation in the study.  Volunteers 
consumed high-fat meals prior to insertion of the oroenteric tube to avoid overfilling and 
stimulate gallbladder emptying (10, 11).  After an overnight fast, a custom-made oroenteric 
tube was passed through the mouth and positioned in the upper portion of the duodenum with 
the aid of dynamic fluoroscopic radiography.  The oroenteric tube used in these studies was a 
silicone multi-lumen extrusion fitted at the distal end with a polyethylene balloon to occlude 
the intestine during bile collection; this tube has been described in detail previously (10).  
The extent of biliary excretion of Tc-99m sestamibi  (Cardiolite®, Bristol-Myers Squibb, 
New York, NY) was determined by positioning the subjects under a gamma camera (E-CAM 
Dual Head Gamma Camera, Siemens), and an IV bolus of ~2.5 mCi Tc-99m sestamibi was 
administered via an arm vein.  The duodenal balloon was inflated with ~ 30 mL of air, and 
blood and duodenal aspirates were collected at predetermined time points for 180 min.  
Anterior and posterior gamma scintigraphic images of the abdominal area were acquired at 1-
min intervals. Two hours following Tc-99m sestamibi administration, Cholecystokinin-8 
(CCK-8, Sincalide, Kinevac®, 0.02 μg/kg) was administered as an IV infusion over 30 min 
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to facilitate gallbladder contraction. Urine was collected at the conclusion of the sampling 
period (180 min).  
Pharmacokinetic analysis:  
The gallbladder EF was calculated from anterior planar scintigraphic images according to the 
procedure describe previously for Tc-99m mebrofenin using the following formulas:  
( )
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where GB represents the counts over the gallbladder region and the time in all formulas 
refers to the minutes after Tc-99m sestamibi administration, Xbile represents the amount of 
Tc-99m sestamibi collected in bile, and XGB  (excreted dose) represents the amount of Tc-
99m sestamibi collected in bile throughout the study corrected by EF to account for the drug 
that was excreted into bile, but remained in the gallbladder due to incomplete contraction. 
The area under the blood concentration-time curve (AUC0-∞) was calculated from the 
integration of a tri-exponential fit from non-linear least squares regression of the individual 
plasma profiles using SigmaPlot (SYSTAT Software, Point Richmond, CA), and AUC0-180 
was calculated with the linear trapezoidal rule using WinNonlin (version 4.2, Pharsight, 
Mountain View, CA).   Total clearance (Cltotal) was calculated as the ratio of the administered 
dose to AUC0-∞, renal clearance (ClR) as the  ratio of the cumulative amount of drug 
recovered in urine at the end of the experiment to AUC0-180min, biliary clearance (Clbiliary) as 
the ratio of the cumulative amount of drug recovered in bile at the end of the experiment to 
AUC0-180min, and the corrected biliary clearance (in vivo Clbiliary) as the ratio of the excreted 
dose (XGB) and AUC0-180min.  
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Chemicals and Reagents for In Vitro Studies: 
Insulin/transferrin/selenium (ITS+) was purchased from BD Biosciences (Bedford, MA, 
USA). Dexamethasone (DEX), piperacillin, sodium taurocholate, Hanks’ balanced salt 
solution (HBSS) and bovine serum albumin were purchased from Sigma Chemical Co. (St. 
Louis, MO). All other chemicals and reagents were of analytical grade and were available 
from commercial sources. [3H]Sodium taurocholate (1.19 Ci/mmol purity > 97%) was 
obtained from Perkin Elmer Life Sciences (Boston, MA, USA), Tc-99m mebrofenin 
(Choletec®, Bracco Diagnostics, Princeton, NJ) was prepared at the Nuclear Medicine 
pharmacy, UNC Hospital, and radiochemical purity evaluated by TLC using ITLS-SA 
(instant thin layer chromatography polysilicic acid) as the stationary phase and 20% sodium 
chloride as the mobile phase; solutions employed in the experiments had a radiochemical 
purity ≥ 90% (24).  Tc-99m sestamibi (Cardiolite®, Bristol-Myers Squibb, New York, NY) 
was purchased from Cardinal Healthcare (Research Triangle Park, NC) and the 
radiochemical purity of each lot was ≥ 95%.  
Isolation and Culture of Human Hepatocytes: 
Human liver tissue was obtained by qualified medical staff from the University of North 
Carolina, School of Medicine as waste from surgical resection.  Donor consent and IRB 
approval (Committee on the Protection of the Rights of Human Subjects) were obtained for 
all studies involving human liver tissue; these studies followed the tenets of the Declaration 
of Helsinki promulgated in 1964. 
Hepatocytes were isolated by a modification of the two-step collagenase digestion method 
(25).  Hepatocytes were cultured according to the methods described by Hoffmaster with 
modifications (26). Briefly, 1.5x106 hepatocytes/well were seeded on 6-well Biocoat™ pre-
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coated culture plates (BD Bioscience) in 1.5 mL of Dulbecco’s Modified Eagle’s Medium 
(DMEM, without phenol red) supplemented with 5% fetal bovine serum (FBS), nonessential 
amino acids (NEAA), L-Glutamine, penicillin/streptomycin and 1 µM dexamethasone 
(DEX), and allowed to attach for 2–6 h at 37°C in a humidified incubator with 95% air/ 5% 
CO2.  After cell attachment, culture plates were swirled gently and medium was replaced 
with DMEM containing 0.1% ITS+, penicillin/streptomycin, NEAA, L-glutamine and 0.1 
µM DEX.  Cells were overlayed 6-12 hours after seeding, using ice-cold medium containing 
0.25 mg/mL Matrigel™ (BD Bioscience).  In order to allow for formation of canalicular 
networks, human hepatocyte cultures were maintained for 6 days prior to experiments; 
culture medium was replaced every 24 h.  Cells were monitored daily for canalicular network 
development and the biliary excretion index (BEI) of [3H] taurocholate (1 μM, 100 nCi) after 
10 min accumulation was determined on day 6 as described below.  Only SCHH preparations 
that yielded a BEI value for [3H] taurocholate ≥50% were employed to study Tc-99m 
mebrofenin, Tc-99m sestamibi and piperacillin biliary excretion.  Additionally, on day 6, 
canalicular network formation was evaluated with phase contrast microscopy, and digital 
images were captured with a Zeiss Axiovert 100TV inverted fluorescent microscope (Carl 
Zeiss Inc., Thornwood, NY).  
Accumulation and Efflux studies in SCHH: 
Hepatocytes were rinsed twice with 2 mL of standard HBSS (37°C ) and pre-incubated in 2 
mL of either standard HBSS or Ca2+-free HBSS (in order to open the tight junctions and 
disrupt the canalicular networks).  Hepatocytes were incubated at 37°C in 1 mL HBSS 
containing the substrate of interest for 10 min ( [3H] taurocholate 1 μM, 100 nCi; 0.5 μCi/mL 
Tc-99m mebrofenin and 0.5-5 μCi/mL sestamibi) or 30 min (300 μM piperacillin) and 
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subsequently rinsed vigorously four times with 2 mL ice-cold standard HBSS to remove 
extracellular substrate and determine the accumulation of substrate in cells (with disrupted 
canalicular network) and cells+bile (with intact bile canaliculi).  For determination of 
accumulation of [3H] taurocholate, Tc-99m mebrofenin and Tc-99m sestamibi, hepatocytes 
were lysed with 1 mL of ice-cold 0.5% Triton-X 100 and aliquots were analyzed for 
radioactivity.  For piperacillin studies, hepatocytes were lysed with methanol/water 70/30 
(v/v) and piperacillin concentrations were determined by LC-MS-MS.  Nonspecific binding 
was accounted for by including a blank plate (BiocoatTM plus MatrigelTM overlay).  The 
accumulation of Tc-99m labeled compounds was corrected for decay (Tc-99m t1/2= 6.02 hr).  
Protein content in cell lysates was quantified with the BCA method (27) using BSA as the 
standard (0.2-1 mg/mL), and accumulation was normalized for the protein level. Due to 
incompatibility of the protein assay with methanol, the average protein content for standard 
HBSS or Ca2+-free HBSS incubations in the same liver preparation was used to normalize 
piperacillin content. 
The biliary excretion index (BEI) and intrinsic in vitro biliary clearance (in vitro 
Clbiliary) in SCHH were calculated using B-CLEAR® technology (Qualyst, Inc., Research 
Triangle Park, NC) based on the following equations:  
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Medium concentration was defined as the initial substrate concentration in the incubation 
medium corrected for non-specific binding to the plates for Tc-99m sestamibi and 
piperacillin, since preliminary experiments established that the drug concentration at the end 
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of the incubation did not differ by more than 10% from the initial concentration.  For Tc-99m 
mebrofenin, the concentration in the incubation medium was calculated as the average 
concentration between the beginning and the end of the incubation, to account for non-
specific binding to the plates and hepatocytes during the uptake experiment.   
Analytical Methods: 
Tc-99m mebrofenin and Tc-99m sestamibi were quantified in whole blood and sandwich-
cultured hepatocyte lysates by gamma counting (Quantum-8 Multichannel Analyzer, Oak 
Ridge, TN). Tc-99m sestamibi in bile and urine was analyzed by a CRC-15R dose calibrator 
(Capintec, Ramsay, NJ) as described previously (10). Taurocholate was analyzed by liquid 
scintillation spectroscopy (Packard Tricarb, Packard Corp., Meriden, CT, USA).  Piperacillin 
accumulation in SCHH was analyzed by LC-MS-MS; 100 μL of SCHH lysates was spiked 
with cimetidine (internal standard) at a final concentration of 0.5 μg/mL.  The LC-MS-MS 
method employed was described in detail previously (28).  
Calculation of intrinsic biliary clearance: 
The in vitro intrinsic biliary clearance (μL/min/mg prot) was scaled to kg of body weight 
assuming the following: 1 mg protein/1.5x106cells (the typical value obtained in all 
preparations), 107x106cells/g of human liver tissue (29), and 25.7g of liver tissue per kg of 
body weight (30). This value was used to obtain the predicted Clbiliary, based on the well-
stirred model of hepatic disposition, where  Q equals blood flow (21 mL/min/kg) for Tc-99m 
mebrofenin and Tc-99m sestamibi, and plasma flow [blood flow x (1-hematocrit)] for 
piperacillin, and in vitro Clbiliary is the intrinsic in vitro Clbiliary calculated as in equation 4 in 
the absence of protein binding and flow limitations (31-33)  
Predicted Clbiliary  
) in vitroQ(
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TABLES 
Table 5.1: Pharmacokinetic parameters for Tc-99m sestamibi.  
Parameter Subject 1 
Subject 
2 
Subject 
3 
Subject 
4 
Subject 
5 
Subject 
6 
Subject 
7 Mean SD 
Administered Dose (μCi) 2504 3384 3166 3182 3037 3563 3100 3134 331 
Biliary Recovery (% dose) 10.7 15.4 21.6 16.8 4.7 15.8 17.7 14.7 5.5 
Urinary Recovery (% dose) 25.3 7.3 16.3 19.3 22.1 17.4 22.9 18.7 5.9 
AEjection Fraction 0.47 0.63 0.90 0.64 0.16 0.83 0.79 0.65 0.27
BXGB Recovered (% dose) 22.5 23.0 22.1 26.2 16.8 17.8 22.3 21.5 3.2 
Cltotal (mL/min/kg) 15.8 20.2 24.2 19.3 17.7 18.2 19.0 19.2 2.6 
ClR (mL/min/kg) 4.6 2.0 5.4 4.6 5.5 5.4 5.0 4.6 1.2 
Clbiliary (mL/min/kg) 1.9 4.3 7.1 4.0 1.2 4.9 3.8 3.9 2.0 
In vivo Clbiliary (mL/min/kg) 4.1 6.4 7.3 6.2 4.2 5.5 4.8 5.5 1.2 
        
A EF calculated between 120 and 180 min 
B XGB= excreted dose as shown in Methods 
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Table 5.2: Demographics of human liver donors used for the in vitro experiments.  
All donors had no history of tobacco and alcohol use within the last two years. 
 
Liver Donor 
Identification 
Age 
(yr) Gender Race Co-medications Diagnosis 
Liver 1 47 Male Caucasian Glimepiride Hepatic Hemangioma 
Liver 2 63 Female Caucasian 
Labetalol, 
Lisinopril, 
Warfarin 
Metastatic 
Colon cancer 
Liver 3 53 Male Caucasian 
Aspirin, 
Colchicine, 
Omeprazole 
Metastatic 
Colorectal 
cancer 
Liver 4 68 Male Caucasian Lisinopril Metastatic Colon cancer 
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Table 5.3: Biliary excretion index and biliary clearance values of taurocholate, Tc-99m 
mebrofenin, Tc-99m sestamibi and piperacillin. Values were determined in sandwich-
cultured human hepatocytes (n=4 livers, in triplicate; Mean ± SD).  
 
 
In vitro Clbiliary Compound BEI % (μL/min/mg 
prot) (mL/min/kg) 
Predicted 
Clbiliary 
(mL/min/kg) 
Taurocholate 
(t=10 min) 56.9 ± 6.7 8.62 ± 2.45 15.8 ± 4.5 N.D. 
Tc-99m 
Mebrofenin 
(t=10 min) 
34.8 ± 14.0 6.36 ± 1.29 11.7 ± 2.4 7.44 ± 0.97 
Tc-99m 
Sestamibi 
(t=10 min) 
33.0 ± 7.7 0.700 ± 0.328 1.28 ± 0.60 1.20 ± 0.53 
Piperacillin 
(t=30 min) 18.8 ± 8.8 0.015 ± 0.011 0.028 ± 0.020 0.028 ± 0.020
 
 
 
 
 
 
 
 
 
 
 
 178
Table 5.4: Biliary clearance parameters. The in vivo biliary clearance of Tc-99m 
mebrofenin and piperacillin were determined in previous studies (10, 28).   
 
Compound Clbiliary 
(mL/min/kg)
*In vivo Clbiliary 
(mL/min/kg) 
Predicted Clbiliary
(mL/min/kg)  
Tc-99m Mebrofenin 
(n=4) 12.5  16.1  7.44 
Tc-99m Sestamibi 
(n=7) 3.90  5.51  1.20 
Piperacillin 
(n=3) 0.012  0.032  0.028 
  
* Clbiliary corrected for EF 
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Fig 5.1: Tc-99m sestamibi activity-time profiles in seven healthy subjects.  
Blood and bile concentration and mass time profiles, respectively are expressed in 
radioactivity units. 
A: Individual blood concentration-time profiles for Tc-99m sestamibi in healthy volunteers.   
B: Individual bile mass-time profiles for Tc-99m sestamibi in healthy volunteers.  Amounts 
of Tc-99m mebrofenin are expressed as μCi and were corrected by EF between 120 and 180 
min (CCK-8 was administered at 120 min).  
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 Fig 5.2: Gamma scintigraphic anterior abdominal images of Subject 4 after IV 
dministration of 2.5 mCi Tc-99m sestamibi.  In the 5 min frame, the spatial position of all a
major organs is indicated (HT=heart, SP=spleen, LV=liver, RK and LK=right and left 
kidney, BL=bladder). The BL was visible only upon filling with radioactive urine (99 min 
frame). The gallbladder, which started filling with radioactivity at 12 min post dose, 
overlapped with the RK.  A custom-made oro-enteric tube was used to aspirate bile from the 
duodenum as soon as it was expelled from the common bile duct; inflation of an occlusive 
balloon in the duodenum facilitated complete bile collection (dotted oval outline indicates the 
location of the balloon).  Intestinal secretion of Tc-99m sestamibi (arrow A) was visible in 
the lower part of the small intestine at 12 min, and the radioactivity moved down the intestine 
until it reached the colon (125 min). There was no visible discharge of bile until 120 min 
when CCK-8 was infused to contract the gallbladder; at this time, radioactive bile was 
suctioned rapidly from the duodenum via the oro-enteric tube and disappeared (arrow B). No 
additional radioactivity appeared in the GI tract below the balloon upon gallbladder 
contraction, indicating successful occlusion of the intestine.  
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Fig 5.3: Taurocholate accumulation in sandwich-cultured human hepatocytes.   
SCHH were incubated with [3H] taurocholate (1 μM, 100 nCi), and cellular accumulation 
(open bar) and cells+bile accumulation (solid bar) were measured at 10 min (mean ± SD in 
triplicate, n=4 livers). For each preparation the BEI value is reported.  
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Fig 5.4: Accumulation of Tc-99m mebrofenin, Tc-99m sestamibi and piperacillin in 
sandwich-cultured human hepatocytes. Bars represent mean ± SD of triplicate 
determinations in a single liver (n=4 livers).  For each preparation the BEI value is reported.  
Panel A: SCHH were incubated with Tc-99m mebrofenin (0.5 μCi/mL) and cells (open bar) 
and cells+ bile accumulation (solid bar) were measured at 10 min.  
Panel B: SCHH were incubated with Tc-99m sestamibi (0.5-5 μCi/mL) and cells (open bar) 
and cells+ bile accumulation (solid bar) were measured at 10 min.  
Panel C: SCHH were incubated with piperacillin (300 μM) and cells (open bar) and cells+ 
bile accumulation (solid bar) were measured at 30 min.  
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B: Tc-99m Sestamibi 
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Fig 5.5:  Phase contrast images of sandwich-cultured human hepatocytes at day 6 in 
culture. The bile canalicular network is visible as bright dots or belts between adjacent 
hepatocytes and is indicated by arrows.  
A) human liver #2 
 
20 μm 
 
B) human liver #4 
 
 
20 μm 
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Fig 5.6: Comparison of the in vitro and in vivo biliary clearance values for the three 
compounds investigated in these studies.  
(solid symbols represent data expressed as mean ± SD).                                     
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CHAPTER 6 
 
 
 
CONCLUSIONS AND FUTURE WORK 
  
The general focus of this dissertation research has been the development of novel in vivo and 
in vitro tools to study and characterize biliary clearance of drugs in humans.  The 
contribution of biliary excretion to systemic drug exposure or to intestinal toxicity has been 
recognized in the literature, at least for drugs like mycophenolic acid and irinotecan 
metabolites, respectively (1, 2).  However, biliary excretion studies are rarely conducted in 
humans and considerable work is still needed in this field to better elucidate and characterize 
the processes involved in hepatobiliary drug disposition.  This is especially true in light of the 
significant effects that alterations in hepatobiliary disposition of drugs due to disease states or 
drug interactions may have on pharmacological efficacy and/or toxicity.  The animal models 
most commonly used to investigate hepatobiliary disposition of drugs are rodents.  In vivo 
and ex vivo experiments with rats and mice are a very popular way to examine hepatic uptake 
and efflux mechanisms.  An in vitro model that may be used for the same purpose is rat 
hepatocytes cultured in a sandwich configuration.  This in vitro model has been shown to 
predict the hepatobiliary disposition of compounds reasonably well compared to results 
obtained in vivo in the same species (3).  However, species differences are an insurmountable 
limitation when performing animal studies.  As a result, this research project focused on 
models that were more relevant to the human species.  This dissertation research was 
designed to provide the basis for the development of an in vitro-in vivo correlation in biliary 
clearance based on data generated in sandwich-cultured human hepatocytes and in vivo in 
humans. 
The development of a technique to reliably determine biliary clearance of drugs in 
humans was the cardinal point of this dissertation.  In this study, a technique was developed 
to collect bile from the duodenum and account for the fraction of secreted bile remaining 
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within the gallbladder.  This has several advantages when compared to similar methods 
already reported in the literature.  Over the past 40 years, many approaches to aspirate 
pancreatic and biliary secretions have been described; several of these techniques also have 
been used to estimate the extent of biliary excretion of drugs (Chapter 1).  The anatomy of 
the human gastrointestinal and hepatobiliary tract does not allow easy access to liver or 
gallbladder bile.  In healthy volunteers, bile can be collected in a relatively non-invasive 
manner only after excretion into the intestine.  In all published approaches, a naso- or 
oroenteric tube has been used to withdraw bile from the duodenum.  Complete bile collection 
has been optimized in various ways by occlusion of the intestinal lumen with an inflatable 
balloon, to prevent bile flow down the duodenum, and by recovery of a non-absorbable 
marker perfused at steady-state into the intestinal segment of interest, to correct for 
incomplete recovery.  Perfusion with non-absorbable markers is technically challenging, and 
also relies on the assumption that the mixing of secretions and perfusate is complete.  This 
may not always be true due to the different density and consistency of these fluids, such a 
discrepancy could affect the accuracy of this approach.  For this reason, and to simplify the 
execution of the clinical studies, we chose to occlude the duodenum with an inflatable 
balloon and assess occlusion by monitoring the gamma images of the lower part of the small 
intestine.  Any escape of bile distal to the occlusion would spread radioactivity throughout 
the intestine after administration of a gamma emitting hepatobiliary imaging agent such as 
Tc-99m mebrofenin.  However, during the clinical study designed to characterize piperacillin 
biliary excretion, it became apparent that a prolonged intubation, and the presence of the 
inflated balloon in the duodenum, may have a negative influence on gallbladder 
responsiveness to pharmacologically induced contraction.  In future studies, it would be 
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advisable to shorten the bile collection period and keep the balloon inflated for no longer 
than 3-4 hours.  If the collection period cannot be shortened, this issue could be overcome by 
deflating the balloon for cycles of 10-30 min during collection.  This only would be possible 
when any gallbladder contraction and bile discharge into the intestine could be excluded 
using the gamma images. 
An important aspect of the developed method, not previously addressed in the calculation of 
drug biliary clearance, is the ability to account for variability in the response to CCK-8 by 
correcting the fraction of dose excreted into bile for the gallbladder ejection fraction.  In 
previous studies, bile was collected over several hours, and typically there was no attempt to 
expel bile from the gallbladder using a pharmacological approach.  However, lack of control 
over the extent of gallbladder contraction yields highly variable results and unexpectedly low 
values for biliary clearance.  This conclusion is exemplified for digoxin.   When measured 
with the same technique in 3 different studies, digoxin biliary clearance varied widely [72-
163, 79-343, 58-142 mL/min (4-7)] and the inter-subject variability was very high.  This 
variability is a major problem when in vivo biliary clearance values are compared to in vitro 
biliary clearance values.  One explanation for this variability may be that the collection of the 
digoxin excreted into bile was not complete.  In these studies, is was assumed that the 
gallbladder remained contracted throughout the experiment due to duodenal perfusion with 
5% glucose and a mixture of amino acids.  If this was true, all the bile containing digoxin 
would have flowed directly from the liver into the intestine, allowing calculation of digoxin 
biliary clearance as the rate of excretion divided by the steady-state plasma concentration at 
the midpoint of the collection interval.  It is questionable whether the gallbladder remained 
contracted for the duration of the entire experiment, or whether there were changes in 
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intraductal pressure and the state of the sphincter of Oddi.  It is quite possible that the rate of 
digoxin excretion varied greatly during the experiment.  Therefore, the reported digoxin 
biliary clearance values may be grossly underestimated.  This could be confirmed by 
performing a small clinical study (n=4-6 subjects) using the technique developed in this 
thesis.  Digoxin is expected to exhibit an intermediate to low biliary clearance in the SCHH 
model based on pilot studies conducted at Qualyst, Inc. (Brandon Swift, personal 
communication).  Addition of digoxin to the developing in vitro in vivo correlation would be 
very beneficial.  
The model probes selected in the studies presented in this dissertation were 
administered intravenously and exhibited a short half life (to prevent prolonged intubations).  
However, the majority of drugs on the market are available only for oral administration.  To 
adapt this technique to a wider range of applications, additional modifications to the 
oroenteric catheter and optimization of the study design are required.  Modifications in the 
tube design would expand the technique to orally administered drugs. Oral administration of 
a tablet could potentially contaminate the duodenal contents with residual components from 
the dissolved tablet.  Thus, a solution of drug may be preferable with administration through 
a new port placed distal to the occluding balloon.  Moreover, when drugs with a long half-life 
are under investigation, the study design should be modified.  A parallel design which 
includes a group of patients intubated for a few hours immediately after drug administration, 
and other groups intubated at later time intervals would allow sampling over a sufficient 
period of time to characterize the processes involved in the elimination of the compound 
under study. 
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An important finding in one of the clinical studies, presented in this dissertation work, 
was the identification of desethyl-piperacillin glucuronide in human bile and urine samples. 
Even though the transformation of piperacillin into desethyl-piperacillin has been reported, a 
novel finding was the formation of desethyl-piperacillin glucuronide.  Clearly, the 
combination of access to duodenal bile and the application of a very sensitive analytical 
technique (LC-MS-MS) to the analysis of these biological samples was instrumental in the 
identification of this new metabolite. Comparing the relative amount of metabolite recovered 
in urine and bile, it may be concluded that piperacillin was excreted mostly into urine as the 
parent drug, while biliary excretion was more predominant for the metabolites.  The 
relevance of this novel finding is not expected to be clinically important because metabolism 
accounts for a very small percentage of piperacillin clearance.  However, identification of 
metabolites for new drugs after human administration could be very desirable.  In fact, the 
combination of this method with the sensitivity of the analytical techniques available today, 
would offer a new tool to quickly identify metabolites formed in humans that might not be 
predicted from preclinical studies.  The removal of bile containing drug as soon as it appears 
in the duodenum would preserve metabolites that are unstable in the intestinal environment, 
or that could be reabsorbed along the intestine. 
One additional application of this clinical methodology is in clarifying the relative 
contribution of enterohepatic versus enteroenteric recirculation in the overall disposition of 
drugs.  In recent years, other groups have attempted to establish the contributions of intestinal 
secretion and biliary excretion of drugs to overall disposition (8-10). Further characterization 
of transport protein expression along the gastrointestinal tract has shown clearly that efflux 
transporters such as P-gp, BCRP and MRP2 could play a role in the removal of drugs from 
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the bloodstream even after intravenous administration (exemplified by gamma images of 
intestinal secretion of Tc-99m sestamibi detailed in Fig 5.2, Chapter 5).  The relative 
contributions of enterohepatic and enteroenteric recirculation to the overall disposition of 
many drugs could be determined by combining the study design developed in this 
dissertation research to induce and monitor gallbladder contraction, with the technique cited 
above, which was designed to investigate intestinal metabolism, absorption and secretion,   
Other interesting applications of the in vivo technique developed here could address 
the effect of transport protein polymorphisms and/or pharmacological inhibition of transport 
proteins on the hepatobiliary disposition of model probes, such as Tc-99m mebrofenin.  As 
demonstrated in this research, Tc-99m mebrofenin is an excellent substrate for MRP2 and to 
a lesser extent for MRP3.  A clinical study is ongoing to determine whether ritonavir will 
inhibit Tc-99m mebrofenin biliary excretion in humans in a manner similar to that shown in 
vitro using inside-out membrane vesicles expressing MRP2 (Appendix C). Tc-99m 
mebrofenin is a unique probe that may be used to quantify biliary excretion and at the same 
time detect delays in hepatic uptake due to inhibition of basolateral transport proteins by 
examining gamma scintigraphy images.  Furthermore, gamma scintigraphy is a powerful tool 
that can be used to differentiate delays in excretion of Tc-99m mebrofenin from the liver into 
the gallbladder, and from the gallbladder into the duodenum.  It is reasonable to expect that 
polymorphisms in the MRP2 gene could influence either the affinity of this protein (Km) for 
Tc-99m mebrofenin, or the overall expression and localization of MRP2 at the canalicular 
membrane (Vmax).  Alterations in either Km or Vmax would be detected by alterations in the 
biliary clearance of this probe and may provide useful mechanistic information (as 
exemplified in the mathematical simulations of Tc-99m mebrofenin disposition in Chapter 
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3).  However, most importantly, liver and body exposure could be affected by inhibition of 
biliary excretion or basolateral uptake and efflux.  Many pharmacokinetic studies have been 
performed to evaluate the effect of drug-drug interactions in the intestine, liver and/or kidney 
with respect to P-gp inhibition using digoxin as a probe (4-8, 11-14).  Tc-99m mebrofenin 
could be used as an MRP2/MRP3 probe in vivo to study drug-drug interactions that affect 
hepatic uptake or excretion processes, since this probe has virtually no renal elimination and 
our technique prevents enterohepatic recycling (if any is present). 
Most of all, these interactions can be detected and predicted using the SCHH in vitro 
model.  An important goal of this research project was to investigate whether the SCHH 
model accurately predicts hepatobiliary disposition of xenobiotics in the human liver.  If so, 
SCHH could be used to characterize human liver uptake and excretion mechanisms, as well 
as the effect of interactions between novel compounds and xenobiotics or endogenous 
molecules.  SCHH express relevant transport proteins and qualitatively maintain vectorial 
transport of substrates such as taurocholate (15, 16).  In the current studies, the ability of 
SCHH to transport numerous probes from the incubation medium into bile was examined 
(Chapter 5).  Human liver tissue typically was obtained from living donors undergoing liver 
resection.  During the surgery, hepatic cancerous tissue was removed together with 
surrounding normal tissue; human hepatocytes were obtained following collagenase 
perfusion of only the healthy tissue.  These cancer patients are obviously a very different 
population from the healthy volunteers who participated in our in vivo studies, and their liver 
tissue has been exposed to a variety of medications prior to resection. For ethical reasons, 
human tissue from healthy subjects is obtained only from cadaver liver not suitable for 
transplantation.  Therefore, ischemic damage to this tissue may be considerable and 
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hepatocytes obtained from these sources often are not as viable as those obtained from fresh 
liver resections.  Despite the difference in sex, age and previous medication exposure of the 
four donors (see Table 5.2, Chapter 5), the hepatocyte preparations used in these studies 
behaved similarly in terms of accumulation and excretion of the four different probes 
investigated.  However, the morphology of the cells during culture and the extent of 
canalicular network formation varied from preparation to preparation. This affected the 
overall extent of excretion into canalicular spaces (Appendix D).  One approach to account 
for the differences in canalicular network formation would be to calculate the overall volume 
occupied by these “cylindrical” structures in each preparation, and to use this number as a 
correction factor for the amount of drug recovered in bile in the SCHH studies.  This 
correction might be useful when comparing the predicted Clbiliary obtained in this in vitro 
system to the in vivo Clbiliary measured in humans in order to minimize the differences in the 
bile canalicular volume. 
In the future, it would be of value to systematically evaluate the expression of 
relevant transport proteins and metabolizing enzymes after cell isolation and over days in 
culture in the SCHH.  A comparison between freshly isolated human hepatocytes and a time 
course of human hepatocytes in sandwich-culture using western blot analysis could be useful 
to understand whether anticancer and other medications that liver donors may have been 
exposed to and that are known to induce the expression of transport proteins and other 
metabolizing enzymes through nuclear receptors [i.e. microtubule-stabilizing anticancer 
agents such as paclitaxel and discodermolide are known to induce PXR-dependent pathways 
(17)] actually affect protein expression, and whether this induction is lost over time during 
culture in a sandwich configuration.  
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In addition, in the present studies, the cellular uptake experiments were performed in the 
absence of albumin in the incubation medium.  Of course, this is not completely 
representative of the in vivo situation for compounds that are highly protein bound.  Biliary 
clearance is defined as the volume of blood (or plasma) cleared of drug that is excreted into 
bile per unit time.  The apparent biliary clearance will represent the rate-limiting step in this 
process, which can be either clearance across the basolateral or the canalicular membrane.  
The true biliary clearance process is driven by intracellular unbound drug concentrations.  
Therefore, when considering protein binding, it may be appropriate to consider cytosolic as 
well as plasma protein binding.  Cytosolic fractions from pooled liver preparations (18) as 
well as plasma albumin or alpha 1- acid-glyco protein could be used to evaluate the impact of 
protein in the incubation medium on the in vitro biliary clearance.  
One characteristic of the SCHH model that makes it a particularly powerful tool is the 
metabolic capacity in addition to the transport capabilities of the human hepatocytes.  In the 
rat model culture conditions can influence the expression of Phase I and Phase II 
metabolizing enzymes(3).  The optimal culture conditions for drug transport experiments 
have not been investigated fully with respect to metabolic capacity.  In our in vitro studies, 
desethyl-piperacillin was formed in SCHH as early as 30 min post exposure (Appendix D), 
and in three out of four preparations, a modest degree of biliary excretion of this metabolite 
was observed, reproducing the clinical findings.  However, the Phase II metabolites 
recovered in human liver microsomal incubations and in the in vivo biological samples were 
below the limit of detection even after SCHH were incubated for 48 hr with the parent drug.   
The intracellular concentrations of piperacillin in SCHH were lower than in the microsomal 
incubations, this may explain why the metabolites were not formed at detectable levels.  
 196
Although no general conclusion can be drawn from these preliminary experiments, the 
maintenance of Phase II metabolic activity should be tested using compounds known to be 
extensively taken up and metabolized by the liver.  Even though additional experiments are 
needed to further define the abilities of this in vitro system to biotransform drugs, this feature 
is extremely desirable in an in vitro model that is also capable of transporting the metabolites 
in a manner similar to what is expected in vivo in humans.  This would make the SCHH a 
critical preclinical tool that can form metabolites unique to the human species and is able to 
handle these products in a physiological manner offering insight into possible mechanisms of 
hepatoxicity or drug-metabolite interactions otherwise only detectable during clinical studies, 
when a threat to human health is possible.  
Up until now, SCHH have been cultured as a cell monolayer between two layers of 
extracellular matrix.  In order to detect drug excretion into bile, the canalicular networks 
formed between the cells need to be extensive, and this has posed some challenges to scaling 
down the culture from 6-well plates to 24- or even 96- well plates in an effort to adapt this 
model to the requirements for high throughput and automated screening assays.  Human 
hepatocytes are very expensive, and their availability is and will always be limited.  
Therefore, it would be ideal to increase the number of cell-cell interactions in culture to 
obtain the largest canalicular network possible per number of cells.  This could be achieved, 
for example, by developing a novel carbohydrate biopolymer gel support to allow culturing 
of hepatocytes in a 3 dimensional sponge-like scaffold over which the cells would be seeded 
and allowed to penetrate by gravity.  This novel scaffold could provide two major 
improvements over the current collagen sandwich configuration.  It would allow hepatocytes 
to be cultured in a 3-D configuration in smaller wells (e.g. 24- or 96-well plates), and would 
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reduce the cost of the raw materials required per experiment.  In addition, by tailoring the 
molecular architecture of the polysaccharide gel, the pore size could be modified to 
determine whether bile canalicular network development and transport protein expression 
could be enhanced.  Galactose grafted chitosans have been shown to enhance attachment of 
hepatocytes and allow successful culturing of the cells (19-21).  Other biopolymers such as 
guar and locust bean gum should allow cell adhesion through galactose-cell interactions since 
they are naturally formed with a linear mannose backbone to which single sugar galactose 
branches are attached.  These polymers can be modified further by addition of other 
biopolymers such as xanthan, or crosslinked to form a variety of hydrated gels, which can be 
molded to any shape that is required.  Guar and locust bean biopolymers are commercially 
available at very affordable prices.  These polymers could be allowed to gel directly into 
culture plates (96-well plates) under aseptic conditions; the gels could be lyophilized in 
advance and only hydrated prior to cell seeding.  Another interesting approach to increase the 
number of cells per unit of well surface area occupying the entire volume of each 96-well 
plate would be to entrap primary hepatocytes within a double layer of extracellular matrix 
using electrospinning.  Although a thorough description of this technique is beyond the scope 
of this dissertation, electrospinning has been used extensively in tissue engineering research 
to obtain nano- and micro-fibers that mimic the composition and architecture of the native 
extracellular matrix (22).  Some blends of collagen and glycosaminoglycan have been 
successfully electrospun into fibers that are compatible with cell adhesion and proliferation 
(23, 24).   With this technique, it is also possible to entrap living cells within the electrospun 
fibers.  Therefore, it would be very exciting to prove that hepatocytes could be “electrospun” 
as a chain of cells and entrapped in these filaments.  This would create a sandwich within 
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each strand and the strands could be woven into 3-D balls containing millions of cells, these 
agglomerates could loosely sit in plastic wells bathed and surrounded by culture or 
incubation medium.  Of course, the most important prerequisite would be that “electrospun” 
hepatocytes correctly polarize in this environment and form canalicular spaces at each cell-
cell contact.  A robot could be used for the feeding and accumulation studies;  moving these 
agglomerates into new wells containing fresh medium or HBSS at appropriate times could all 
be automated. 
The sandwich-cultured hepatocyte model can be adapted for co-culturing with other 
cell types since hepatocytes represent only 60-80% of the entire cell population of the liver 
(25).  In vivo, cholangiocytes also play an important role in influencing the composition of 
bile, once hepatocytes have removed drugs and endogenous substances from the blood and 
transported them across the canalicular membrane into bile.  Recently, the role of 
cholangiocytes in bile formation has been investigated by several groups (26, 27).  These 
cells express a variety of transport proteins and are thought to play a role in the reabsorption 
of bile components, modifying the concentration of bile salts and possibly of drugs in bile 
(28). It would be interesting to develop a co-culture of hepatocytes and cholangiocytes that 
would more closely mimic hepatic function and biliary excretion. 
In conclusion, this project laid the foundation for the development of a correlation 
between the biliary clearance of drugs measured in vivo in humans and biliary clearance 
values obtained in vitro in the SCHH system.  The ramifications of this project have 
implications not only for the determination and prediction of biliary clearance of drugs, but 
also in understanding alterations in biliary clearance due to drug-drug or metabolite 
interactions.  
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EXPRESSION OF BASOLATERAL AND CANALICULAR TRANSPORT 
PROTEINS IN HEPG2 CELLS: 
EFFECT OF DAYS IN CULTURE AND CULTURE CONFIGURATION 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
This work was presented in the form of a poster at the AAPS Annual Meeting, Salt Lake 
City, Utah, 2003
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INTRODUCTION 
Culturing hepatocytes between two layers of gelled collagen in a sandwich configuration is a 
well-established technique to maintain liver-specific functions including albumin secretion, 
cytochrome P-450 expression, as well as bile acid and xenobiotic vectorial transport (1, 2).  
Sandwich-cultured hepatocytes form extensive bile canalicular networks over time in culture; 
transport proteins are expressed and functional (3).  However, due to the limited availability 
of freshly isolated human hepatocytes, evaluation of alternative cells is a major focus of 
current research. HepG2 cells are a human-derived hepatoma cell line frequently used in 
toxicology studies.  Hepatic transport proteins are expressed at lower levels in HepG2 cells 
relative to human hepatocytes (4).  HepG2 cells do not express all of the cytochrome P-450 
enzymes at the same levels as human hepatocytes; however, they are capable of synthesizing 
the majority of liver-specific proteins (5).  Previous studies had demonstrated that culturing 
HepG2 cells between two layers of collagen improved the phenotype, increasing albumin 
synthesis (6). 
The present studies evaluated the influence of culture configuration (polystyrene 
uncoated petri dishes, polystyrene dishes coated with rat tail type I collagen gel, and collagen 
gel substratum with collagen overlay or sandwich-cultured) on basolateral and canalicular 
transport proteins involved in hepatic transport of xenobiotics in HepG2 cells over days in 
culture.  Specifically, expression of the canalicular transport proteins multi-drug resistance 
associated protein (MRP2; ABCC2), P-glycoprotein (P-gp; ABCB1),  breast cancer-
resistance protein (BCRP; ABCG2), and the basolateral transport protein MRP3 (ABCC3), 
as well as the function of MRP2, were examined.  
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METHODS 
Cell Culture  
HepG2 cells were seeded at a density of 1x105/cm2 onto 60-mm polystyrene dishes (uncoated 
or rat tail type I collagen coated).  Dishes coated with collagen (1.5 mg/mL final 
concentration) were prepared by neutralizing 4 mL rat tail type I collagen, 4 mL deionized 
water and 1 mL 10x DMEM with 1 mL 0.2 N NaOH (final pH ~7.4).  To obtain the 
sandwich configuration, cells were overlaid with a second rat tail type I collagen layer 48 hr 
after seeding.  Cells were maintained in DMEM-F12 containing 1% insulin/ transferrin/ 
selenium (ITS+), 50 U/mL penicillin, 50 μg/mL streptomycin, and 0.1 μM DEX. Cells were 
cultured up to 10 days, and medium was changed daily.  
MRP2 Functional Assay  
On each day, starting at 72 hr post seeding, MRP2 function was determined.  Cells were 
rinsed 3 times with warm HBSS (Hank’s Balanced Salt Solution, pH 7.4), then incubated at 
37ºC for 10 min in HBSS containing 2 µM 5-(and 6) carboxy-2’,7’-dicholorofluorescein 
(CDF) diacetate, quickly rinsed 4-5 times with warm buffer and light and fluorescence 
images were captured with a fluorescence microscope (Zeiss, Axiovert) to evaluate the 
excretion of CDF into apical vacuoles.  
Western Blot 
Cells were lysed with phosphate buffer (pH 7.4) containing 1% sodium dodecyl sulfate 
(SDS), Dithriothretol (DTT) and protease inhibitor cocktail (Complete, Roche).  Human liver 
tissue was homogenized and protein was solubilized into Tris-HCl buffer containing protease 
inhibitor cocktail.  Samples were loaded onto a 4-12% Bis-Tris gel (total protein loaded 30-
45 μg).  Proteins were transferred onto PVDF membranes and probed with specific 
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antibodies.   Anti-MRP2 primary monoclonal antibody (Alexis M2III-6), anti-MRP3 primary 
monoclonal antibody (Alexis M3II-9), anti-P-gp primary monoclonal antibody (Alexis 
C494), and anti-BCRP primary monoclonal antibody (Oncogene Ab-1) were incubated with 
antimouse secondary antibody linked to horseradish peroxidase and detected by Supersignal 
West Dura chemiluminescence reagent kit.  Membranes were stripped and reprobed with 
mouse anti-actin antibody.  
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RESULTS 
MRP2 and MRP3 Expression 
Expression of MRP2 was not influenced by the different culture configurations investigated 
(Fig A.1).  Once normalized for actin content, the slight induction of MRP2  that was 
observed over time in culture was not significant (< 2-fold).  Expression of MRP3 was 
maintained over days in culture by all three culture configurations (Fig A.2).  When MRP3 
expression was evaluated over days in culture, the optical density of the MRP3 bands 
detected by western blot analysis remained constant when normalized for actin. 
MRP2 Functional Assay 
An apical vacuole was present in HepG2 cells.  After passive diffusion of CDF diacetate into 
the cells and cleavage of the diacetate moiety, the MRP2 substrate CDF was actively pumped 
by these cells into the apical vacuole.  The number of vacuoles increased over days in 
culture, and was higher in cells cultured on uncoated polystyrene dishes when compared to 
the other two configurations.  After 10 days in culture, some of the vacuoles became enlarged 
and migrated towards each other only in cells cultured on uncoated dishes (Fig A.3).  As 
evidenced by the light and fluorescent images none of the culture configurations sustained 
the formation of a functional canalicular network between adjacent cells. 
P-gp and BCRP Expression 
P-gp and BCRP were expressed in HepG2 cells; expression was not influenced by culture 
configuration at 3 days after seeding.   After actin normalization, the three culture conditions 
did not differ significantly (< 2-fold increase, Fig A.4). 
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CONCLUSIONS 
MRP2, P-gp, BCRP and MRP3 expression was maintained in HepG2 cells in all the culture 
conditions investigated in this study.  It was interesting to note based on inspection of 
Western blots that these transport proteins exhibited a slightly different molecular weight in 
HepG2 cells than in the human liver sample investigated.  MRP2 and MRP3 expression was 
maintained over days in culture, and was not affected by culture configuration.  MRP2 
function was preserved, as evidenced by CDF excretion into apical vacuoles over days in 
culture.  The apical vacuoles increased in number and size near cell-cell contacts, and were 
more visible in HepG2 cells cultured on uncoated polystyrene dishes than in any other 
culture condition. 
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FIGURES  
Fig A.1:  Western Blot of MRP2 protein in HepG2 cells cultured in different 
configurations over time. The band for MRP2 in HepG2 cells showed a slightly higher 
molecular weight than that of the human liver control.  (HL: human liver; Ctrl: uncoated 
dishes; Coll: collagen coated dishes; SC: collagen sandwich configuration). 
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Ctrl     Coll SC
Day 3 Day 4 Day 6
 
 
 
 
Fig A.2:  Western Blot of MRP3 protein in HepG2 cells cultured in different 
configurations over time. The double band pattern observed for MRP3 in liver was 
consistent with bands observed in HepG2 cells.  In this cell line, the double band was at a 
lower molecular weight.  (HL: human liver; Ctrl: uncoated dishes; Coll: collagen coated 
dishes; SC: collagen sandwich configuration). 
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Fig A.3 :  CDF fluorescence demonstrating functional activity of MRP2 in HepG2 cells 
(Days 3, 4, 6 and 10 after seeding) cultured in three different configurations. (Panel A: 
uncoated polystyrene dishes. Panel B: collagen coated dishes. Panel C: collagen sandwich 
configuration).  Light micrographs are shown to indicate the cell density at each time point. 
(Magnification 200x). 
Panel A: 
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Panel B: 
 
 
 
 
 
 
 
 
 
 
 
Panel C: 
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Fig A.4:  P-gp and BCRP expression in HepG2 cells in three different culture 
configurations 3 days after seeding. In both cases, the transport proteins in the HepG2 cells 
migrated at a higher molecular weight than in the human control liver.  (HL: human liver; 
Ctrl: uncoated dishes; Coll: collagen coated dishes; SC: collagen sandwich configuration). 
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Appendix B 
 
 
 
Tc-99 MEBROFENIN DISPOSITION IN WILD-TYPE AND TR- RATS: 
DEVELOPMENT OF ANALYTICAL TECHNIQUES AND IN VITRO AND IN VIVO 
INVESTIGATIONS  
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INTRODUCTION 
Tc-99m mebrofenin disposition was investigated in healthy human volunteers in Specific 
Aim #1.  In Specific Aim #2a, a pharmacokinetic model was developed to characterize the 
processes involved in the elimination of this substrate, and the model was used to simulate 
the effect of impaired function of the canalicular transport protein MRP2.  Ideally, a clinical 
study designed to investigate the impact of impaired MRP2 function on the hepatobiliary 
clearance of Tc-99m mebrofenin would have validated the predictions obtained with the 
simulation.  However, it was not possible to recruit a large enough number of patients with 
Dubin-Johnson syndrome to the UNC Hospitals in a reasonable time frame.  A rodent model 
of the disease is readily available in our laboratory (TR- rats).   Therefore, the disposition of 
Tc-99m mebrofenin in the wild-type and mutant rat was investigated.   Specific Aim #4 
proposed to study the disposition of this probe in sandwich-cultured human hepatocytes.  The 
use of day 4 sandwich-cultured hepatocytes from wild-type and Mrp2-deficient rats was 
proposed as a tool to optimize experimental conditions for the subsequent in vitro studies 
using sandwich-cultured human hepatocytes.  Additionally the pharmacokinetic model 
developed in Aim #2a was based on a series of assumptions regarding the transport proteins 
involved in the uptake from sinusoidal blood and efflux into bile of Tc-99m mebrofenin.  In 
vitro tools such as Xenopus Laevis oocytes and HEK293 cell membrane vesicles 
injected/transfected with uptake or efflux transporters, respectively, were proposed to 
investigate which protein was responsible for Tc-99m mebrofenin disposition in the liver. 
In appendixes B.1, B.2 and B.3, the work undertaken to accomplish these goals is described 
in detail. 
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Appendix B.1 
THE USE OF TECHNETIUM-99 VERSUS TECHNETIUM-99M TO LABEL 
MEBROFENIN AND SESTAMIBI FOR THE IN VITRO STUDIES 
 
INTRODUCTION 
The main goal of this work was to be able to determine the kinetic parameters (Vmax and Km) 
for the transport proteins under investigation as proposed in Specific Aim #2 (Xenopus laevis 
oocytes expressing OATP1B1 and 1B3, and membrane vesicles from MRP2 and MRP3 
HEK293 transfected cells).  These studies required large amounts of mebrofenin complex, 
which could pose safety issues if Technetium 99m was used to label mebrofenin, since 
unacceptably high levels of radioactivity would be associated with the complex. Technetium-
99 (Tc-99) is a beta emitter with lower energy and a longer decay half-life than Tc-99m.  The 
use of Tc-99 allows measurement of the actual concentrations of chelate in solution (on the 
order of μM) when performing in vitro studies.  Initially, it was assumed that the 
radiochemical purity of the Tc-99 complex was high (>85-90%); hence, all the beta energy 
measured during scintillation counting was assumed to be associated with the Tc-99 
mebrofenin complex.  Tc-99 mebrofenin was used initially as a model for other chelates such 
as Tc-99 sestamibi, since unlabeled sestamibi is not commercially available.  
Tc-99m labeled mebrofenin and sestamibi are technetium-essential compounds in that 
these complexes have a unique disposition, which is different from either Tc-99m 
pertechnetate or the ligand alone.  The formation of Tc-99m labeled mebrofenin and 
sestamibi chelates requires technetium to be in a specific oxidation state, which is not 
necessarily a stable state since the bonds formed with the ligand molecules will stabilize even 
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particularly unstable oxidation states of Tc.  The most stable form of Tc-99m, TcO4- 
(pertechnetate, oxidation state +7), is obtained readily as sodium-pertechnetate.   This is the 
form that is added to radiopharmaceutical kits to obtain the radiopharmaceuticals of interest. 
All Tc-99m radiopharmaceuticals are provided in a ready-to-label sterile kit to which Tc-99m 
sodium-pertechnetate is added.  These kits are lyophilized powders containing the ligand 
(mebrofenin or sestamibi) and stannous chloride, which functions as the reducing agent for 
TcO4- , and other adjuvants (1). 
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METHOD DEVELOPMENT AND RESULTS 
Tc-99 mebrofenin Labeling and Counting Protocols 
The CholetecTM kit (Bracco Diagnostic) was reconstituted with 5mL of sterile water (water 
was purged with nitrogen for 30 min to remove oxygen in order to avoid oxidation of 
stannous ions in the kit).  Aliquots (1 mL) of this reconstituted mebrofenin solution were 
frozen immediately and stored at -80ºC until needed.  On the day of the experiment, 0.5 mL 
of a sterile stock solution of Tc-99 sodium pertechnetate (79 mg/L or 0.8mM) was added to 1 
mL of reconstituted mebrofenin and the labeling reaction took place at room temperature for 
15 minutes.  Radiochemical purity of the chelate formed was evaluated with a TLC method 
using ITLS-SA (instant thin layer chromatography polysilicic acid) as the stationary phase 
and 20% sodium chloride as the mobile phase; solutions were employed in the experiments 
only when the radiochemical purity was ≥ 90% (1). 
A new counting protocol for scintillation counting of Tc-99 was established and a 
quench curve was evaluated.  Tc-99 has a maximal energy peak at 290 keV.  Therefore, a 
lower window was set between 0 and 400 keV and an upper window was set between 0 and 
2000 keV with a counting time of 5 min.  
Liquid scintillation detection is a process that converts the energy emitted by 
radioactive decay into photons of light.  It is imperative to control for any factor present in 
the samples that could cause quenching of the beta emissions.  The different matrices used in 
the in vitro and in vivo experiments could attenuate the photons of light, and this effect could 
be accounted for once a quench curve for Tc-99 was established.  Chloroform is a known 
chemical quencher that is used to prepare quench curves. The transformed spectral index of 
the external standard (t-SIE) is a method used to measure the quench of solutions.  An 
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external 133Ba gamma source is positioned under each sample vial and causes a Compton 
spectrum to be produced in the cocktail solution; the t-SIE parameter is calculated from this 
spectrum.  The t-SIE decreases when the sample is quenched.  By comparing the t-SIE 
parameter associated with experimental samples to those obtained in a quench curve, it is 
possible to establish whether a sample is quenched, and also to correct the cpm for the actual 
efficiency and transform the cpm into dpm for any given sample.  A quench curve was 
obtained by adding increasing amounts of chloroform to a known amount of Tc-99. Five 
milliliters of scintillation cocktail (Biosafe II) was added to 17 μL of saline stock solution of 
Tc-99 pertechnetate (concentration 79 ng/μL) and the counting efficiency was calculated in 
the presence/absence of quencher. Blank samples were prepared with scintillation cocktail 
and chloroform as indicated in Table B.1.1.   A quence curve was generated as shown in Fig 
B1.1 by plotting the percent counting efficiency (cpm/dpm x100) versus the tSIE. 
The counting efficiency for Tc-99 is very high as exemplified by the following calculations: 
Activity = λ*N 
λ = ln 2 / decay t1/2 
where N = 6.022*1023 atoms/mole 
Tc-99 MW = 99 
t1/2 = 2.1*105 years = 66.23*1011 sec 
Therefore there are 6.096*1015  atoms/μg of Tc-99. The theoretical activity of 17μL  Tc-99 
solution (concentration 79 ng/μL) would be:  
A= [0.693/(66.23*1011 sec)] * [1.343μg*(6.096*1015 atoms/μg)] 
A= 857 dps= 51,389 dpm 
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From Table B.1.1 it can bee seen that the efficiency for an unquenched sample of Tc-99 is 
95%   Therefore, the cpms approximate the dpms for Tc-99. 
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FIGURES AND TABLES 
Table B.1.1 Quench curve of a sample of Tc-99 sodium pertechnetate (Tc-99) in 5mL of 
scintillation fluid, and scintillation fluid alone (blank), obtained after adding increasing 
volumes of chloroform. 
  Chlorform μL cpm tSIE Efficiency% 
Blank 0 34.8 496  
Tc-99 0 48664.4 478 95 
Blank 10 37.2 431  
Tc-99 10 47957.5 432 94 
Blank 30 39 362  
Tc-99 30 47654.8 360 93 
Blank 60 34.8 290  
Tc-99 60 47234.8 288 93 
blank 100 40 230  
Tc-99 100 46510.2 228 91 
blank 200 39.4 150  
Tc-99 200 44929.7 154 88 
blank 300 31 109  
Tc-99 300 42782.4 114 84 
blank 400 38 85.3  
Tc-99 400 41237.4 89.1 81 
blank 500 39.2 67.9  
Tc-99 500 39120.8 73.2 77 
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Figure B.1.1: Efficiency versus tSIE plot. The efficiency was not markedly different over 
the range of tSIE values observed in the in vitro preparations (tSIE=470-350 for SCRH 
experiments, tSIE=480-320 in rat IPL experiments, tSIE=440 for TLC radiochemical purity 
assays).  Therefore, results were not corrected for quenching and data were expressed as cpm 
in all experiments.  
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Appendix B.2 
Tc-99 MEBROFENIN  ACCUMULATION IN SANDWICH-CULTURED RAT 
HEPATOCYTES 
INTRODUCTION 
Naturally occurring mutants of the Wistar strain that lack functional Mrp2 are called TR- rats.  
A similar phenotype is encountered in humans affected by Dubin-Johnson syndrome.  Tc-
99m HIDA, an analog of Tc-99m mebrofenin, is transported into bile to a lesser extent in 
Mrp2-deficient compared to wild-type rats (2).  
Evaluation of the effect of this disease state on Tc-99 mebrofenin disposition in TR- 
rats can be valuable information to integrate with the predicted modifications in Tc-99m 
mebrofenin disposition that have been obtained for Dubin-Jonhson syndrome patients using 
pharmacokinetic simulations (Aim #2.a).  In order to accomplish this, in vitro experiments to 
determine Tc-99 mebrofenin BEI and biliary clearance values were performed using primary 
hepatocytes from Wistar and TR- rats cultured in a sandwich configuration.  Additionally, 
some ex vivo experiments using the recirculating isolated perfused liver technique also were 
performed in the two rat strains.  An additional benefit of the in vitro experiments was the 
optimization of experimental conditions for cellular accumulation of Tc-99 mebrofenin in 
primary human hepatocytes.  
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METHODS 
Isolation and Culture of Sandwich-Cultured Rat Hepatocytes (SCRH) 
Wistar (wild-type or TR-) male rats were anesthetized prior to portal vein cannulation. 
Hepatocytes were isolated with a 2-step collagenase perfusion (3).  Livers were perfused with 
Ca2+ free Hank's buffer containing glucose (5.5 mM) and EGTA (1 mM) followed by 
perfusion with buffer containing collagenase type I (150-200 U/mL); 1 min later, 0.5 mmol 
CaCl2 was added.  After collagenase digestion (~10 min), the liver was removed, immersed 
in ice-cold medium [Dulbecco’s modified Eagle’s medium (DMEM) with 5% fetal bovine 
serum (FBS), 50 U/mL penicillin, 50 μg/mL streptomycin, 4 mg/L insulin, 1 μM 
dexamethasone (DEX)], and the capsule surrounding the liver was torn gently to release 
hepatocytes, which were filtered through 70-µm mesh and centrifuged (50xg, 2 min, 4°C). 
The pellet was resuspended in equal parts medium and isotonic Percoll® and centrifuged 
(70xg, 5 min, 4°C) to separate nonviable cells.  The pellet was resuspended in medium and 
centrifuged (50xg, 2 min, at 4°C).  Hepatocytes were counted in a hemocytometer, and 
viability (>90%) was determined by trypan blue exclusion.  Cells were resuspended in 
medium and diluted to 1x106 cells/mL.  Cells were seeded onto 6-well polystyrene dishes 
(Nalgen Nunc, Rochester, NY) coated with collagen (1.5 mg/mL final concentration) 
prepared by neutralizing 4 mL rat tail type I collagen, 4 mL deionized water and 1 mL 10x 
DMEM with 1 mL 0.2 N NaOH (final pH ~7.4).  Unattached cells were removed 1-2 hr after 
plating by replacing the plating medium with DMEM containing 5% FBS, 50 U/mL 
penicillin, 50 μg/mL streptomycin, 4 mg/L insulin,  and 0.1 μM DEX.  Medium was 
aspirated 24 hr after plating, and cells were overlaid with 0.1 mL rat tail collagen type I 
solution (1.5 mg/mL, pH 7.4) in order to obtain a ‘sandwich’ configuration.  After collagen 
 224
overlay, insulin/transferrin/selenium (ITS+) cell culture supplement replaced FBS/insulin in 
the medium.  Medium was changed daily. SCRH were maintained for 4 days before 
performing experiments.  
Accumulation and Efflux Studies in SCRH 
Rat hepatocytes were cultured in a collagen-sandwich configuration in 6-well dishes, as 
described above.  Hepatocytes were rinsed twice with 2 mL warm standard Hanks’ balanced 
salt solution (HBSS) and pre-incubated for 10 min in 1.5 mL of either standard HBSS or 
Ca2+ free HBSS (in order to allow the tight juctions that seal the canalicular lumen to open). 
Subsequently, hepatocytes were incubated in 1.5 mL HBSS containing 15 μM Tc-99 
mebrofenin for 30 min and then washed 4 times with 1.5 mL ice-cold standard HBSS to 
remove extracellular substrate.  On one occasion, WT rat SCRH were incubated with 0.5 
μCi/mL of Tc-99m mebrofenin.  Hepatocytes were lysed with 1 mL of ice cold 0.5% Triton-
X 100 by shaking (20 min at room temperature).  An aliquot (0.7 mL) of lysate was analyzed 
for Tc-99 mebrofenin content by scintillation counting, in the case of Tc-99m mebrofenin, 
0.5 mL were analyzed by gamma counting and corrected for decay.  All values for Tc-99 
mebrofenin uptake into cell monolayers were corrected for nonspecific binding to the 
collagen by subtracting Tc-99 mebrofenin uptake determined in the appropriate control 
dishes in the absence of cells.  Uptake data were normalized to the protein content and 
expressed as mean ± S.D. from three separate preparations of hepatocytes.  The biliary 
excretion index (BEI) and biliary clearance in SC hepatocytes were calculated as follows:  
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 Cytotoxicity Assay  
The commercially available formulation of mebrofenin contains methylparaben and 
propylparaben as preservatives, and these compounds have been shown to exhibit toxicity 
when applied to suspended rat hepatocytes.  Toxicity experiments were performed using 
SCRH to establish that the maximum dose (containing preservatives) used in these 
experiments was non-toxic. (4, 5) 
The release of lactate dehydrogenase (LDH) from hepatocytes after toxic insult is 
proportional to cell damage.  The toxicity of methyl- and propyl-paraben preservatives  to 
SCRH was measured using the CytoTox-ONE™ Homogeneous Membrane Integrity Assay 
Kit (Promega) according to the manufacturer’s instructions.  Briefly, these compounds were 
dissolved in DMSO and added to day 3 SCRH in standard HBSS buffer (DMSO≤ 0.1%) to a 
final concentration of 9.12 mM methyl-paraben and 0.12 mM propyl-paraben (the maximum 
concentrations used in the accumulation studies with Tc-99m mebrofenin).  LDH levels in 
the medium (100 μL of HBSS) relative to untreated cells were measured after 2 hr exposure 
to these compounds. HBSS was removed and replaced with DMEM with ITS+.  The culture 
medium was sampled (100 μL) at 3 hr post treatment and assayed for LDH content.  
Recirculating Rat Isolated Perfused Liver Experiments 
To investigate the disposition of Tc-99 mebrofenin in an ex-vivo system, recirculating 
isolated perfused liver experiments were performed using wild-type Wistar rats (males, 300–
350 g; Charles River Laboratories, Inc., Wilmington, MA) and TR- rats (males, 300–350 g; 
in-house breeding colony obtained from Dr. Mary Vore, University of Kentucky, Lexington, 
KY).  Male Wistar rats (400 g) were used as blood donors.  Animals were maintained on a 12 
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hr light/dark cycle with ad libitum access to water and chow.  The Institutional Animal Care 
and Use Committee of the University of North Carolina at Chapel Hill approved all 
procedures, and a mixture of ketamine/xylazine (60/12 mg/kg i.p.) was used to induce deep 
anesthesia prior to any surgical procedure.  Upon cannulation of  the bile duct, the liver was 
perfused through the portal vein with Krebs-Henseleit buffer.  Subsequently, the liver was 
removed from the carcass and placed in a humidified, temperature-controlled chamber, and 
the perfusion was continued ex situ using 80 ml of recirculating Krebs-Henseleit buffer 
containing 20% (v/v) whole rat blood at a flow rate of 20 mL/min.  Perfusate was continually 
oxygenated with a Hamilton lung and perfusate pH was maintained at 7.4 by addition of 
sodium bicarbonate.  To maintain bile flow, taurocholate (30 μmol/h) was infused into the 
perfusate reservoir.  After initial liver acclimatization (10 min) experiments were initiated by 
adding a bolus dose of Tc-99 mebrofenin (~5 μM final concentration) to the reservoir.  
Livers used in these experiments had acceptable viability (portal pressure ≤15 cm of water, 
initial bile flow > 0.8 and 0.2 μl/min/g liver in wild-type and TR- rat livers respectively, and 
normal gross morphology).  Perfusate was sampled at 1, 2.5, 5, 7.5, 10, 15, 20, 25, 30, 35, 40, 
45, 50, 55, 60, 65, 70, 75, 80, 85 and 90 min, centrifuged and 150 μL of plasma was added 
with 5mL of scintillation fluid (Biosafe II) and analyzed with a scintillation counter. Bile was 
collected in toto at 5-min intervals through 90 min, and 5 μL was analyzed by scintillation 
counting.  
Statistical Analysis 
Multivariate analysis of variance (MANOVA) was used to compare Tc-99m mebrofenin 
accumulation in the presence or absence of canalicular spaces, and between the two types of 
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rats. This analysis accounts for the correlation between the accumulation of Tc-99 
mebrofenin with and without Ca2+ in the same set of hepatocytes. 
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RESULTS 
Cytoxicity of Preservatives 
No differences were observed in LDH levels in the culture medium at 3 hr post treatment 
with methyl- and propyl- paraben preservatives when compared to untreated cells.  
Sanwich-Cultured Rat Hepatocyte Experiments 
Tc-99 mebrofenin was taken up by SCRH and excreted into bile to a lesser extent than 
expected from the in vivo observations during the clinical studies.  No measurable BEI was 
observed at 10 min post dose, therefore, the incubation time was increased to 30 min to allow 
for more intracellular accumulation.  The BEI at 30 min calculated in wild-type rats was 
16.9%, and there was a significant difference between the mean Tc-99 mebrofenin 
accumulation in cells compared to accumulation in cells+bile (p<0.05).  In contrast, there 
was not a significant difference in mean accumulation in SCRH from TR- rats; the BEI was 
only 5.4%.   In addition, the mean accumulation of Tc-99 mebrofenin in cells or cells plus 
bile was not significantly different in SCRH from wild-type (WT) and mutant rats (Fig 
B.2.1).  The in vitro biliary clearance determined in SCRH from both WT and TR- rats was 
extremely small (Table B.2.1).  However, Tc-99 mebrofenin biliary clearance in WT SCRH 
was more than double the value determined in TR- SCRH. 
When the accumulation of Tc-99 mebrofenin in SCRH was expressed as a percentage of the 
medium concentration, ~ 15% of the administered dose accumulated in cells and cells+bile.  
An exception to this was a single experiment performed with WT rat SCRH incubated with 
Tc-99m mebrofenin (0.5 μCi/mL) for 30 min.  In this case, over 38% of the dose 
accumulated in the cells (Fig B.2.2). However, in this experiment the BEI for Tc-99m 
mebrofenin after a 30 min incubation was only 10%. 
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 Rat Isolated Perfused Liver Experiments 
Livers from WT and one TR- rat were perfused in these pilot experiments.  The disposition of 
Tc-99 mebrofenin was similar to that observed in SCRH. Over 70% of the administered 
radioactivity was recovered in bile of the WT rat, while only 30% of the radioactivity was 
excreted into bile in the TR- rat (Fig B.2.3). This experiment was repeated at a higher 
perfusion flow rate (30 mL/min) and the results were similar (data not shown).  
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FIGURES AND TABLES 
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Fig B.2.1: Accumulation of Tc-99 mebrofenin in SCRH from wild-type (WT) and Mrp2- 
deficient (TR-) rats. 
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Table B.2.1: BEI and in vitro intrinsic biliary clearance values for Tc-99 mebrofenin in 
SCRH from wild-type (WT) and Mrp2-deficient (TR-) rats. 
 
In vitro Clbiliary
 
 
 
 
 
BEI 
 
(ml/min/mg prot) (ml/min/Kg) 
WT rats 
 
16.9 0.000731 5.8 
TR- rats 
 
5.4 0.00026 2.1 
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Fig B.2.2: Accumulation of Tc-99m mebrofenin in WT SCRH (n=1). 
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CONCLUSIONS 
These experiments demonstrated that Tc-99 mebrofenin is an Mrp2 substrate in rats.  It is 
possible that another residual transport mechanism is present in TR- rats to explain the 
significant biliary excretion of Tc-99 mebrofenin in the absence of Mrp2.  These findings are 
consistent with the initial hypothesis that Mrp2 is the primary transport protein responsible 
for biliary clearance of this compound.  It was somewhat troublesome that 20-30% of the 
total administered radioactivity in the isolated perfused liver experiments remained in the 
perfusate at the end of the 90-min perfusion experiments.  This observation, together with the 
slower uptake into cells and excretion into bile of Tc-99 mebrofenin into SCRH when 
compared to the fast and almost complete elimination via the biliary route in the clinical 
study presented in Chapter 2, may be attributed to species differences between rat and 
human.  Another possible explanation could be that during the labeling of the Tc-99 
mebrofenin used for these studies, other radiochemical species were formed, and the complex 
administered had relatively low radiochemical purity.  This latter possibility was investigated 
further as reported in Appendix B.3, and the findings suggested that this was true, in part.  A 
considerable difference was observed between Tc-99 mebrofenin and Tc-99m mebrofenin 
accumulation in SCRH. While the BEI for Tc-99m mebrofenin at 30 min in SCRH was only 
10%, over 38% of the Tc-99m mebrofenin dose accumulated within the cells.  It is possible 
that in previous experiments with Tc-99 mebrofenin, the higher amounts in solution saturated 
uptake transporters and prevented cellular accumulation. 
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Fig B.2.3: Disposition of Tc-99 mebrofenin in plasma and bile of wild-type (WT) and Mrp2-
deficient (TR-) rats after a bolus dose of Tc-99 mebrofenin (5μM) into the perfusate 
reservoir. Solid symbols refer to plasma and open symbols to bile.  Data are expressed as a 
percentage of the total radioactivity administered (n=1 for both types of rats). 
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Appendix B.3 
DEVELOPMENT OF AN HPLC METHOD TO DETERMINE THE 
RADIOCHEMICAL PURITY OF TC-99 MEBROFENIN 
 
INTRODUCTION 
Results of the SCRH study and two pilot isolated perfused liver experiments in wild type and 
TR- rats raised doubts regarding the purity of the Tc-99 mebrofenin complex used in these 
studies.  It did not seem reasonable that a compound that is quickly taken up and excreted 
into bile in vivo in humans would be excreted in SCRH to a much lesser extent, and that 20-
30% of the administered radioactivity would still circulate in perfusate from the rat isolated 
perfused livers after 90 min. To investigate the hypothesis that the administered Tc-99 
mebrofenin used in these studies was radiochemically pure, a more sensitive method to 
determine radiochemical purity needed to be developed to prove that the compound 
administered was Tc-99 mebrofenin. As pointed out in Appendix B.1, the preparation of 
radiopharmaceuticals from ready-to-label kits relies upon the presence of reducing agents 
that will reduce Tc-99 pertechnetate to the desired oxidation state. To obtain Tc-99 labeled 
mebrofenin for our in vitro and in vivo studies, the radiochemical labeling procedure was 
modified in order to use micro-molar concentrations of the complex.  Despite the fact that the 
TLC assay results indicated high radiochemical purity, it is possible that the modifications 
made to the labeling procedure affected the amount of stannous ions present in solution, and 
thereby affected the reduction state of TcO4-, and/or too much Tc-99 pertechnetate was added 
causing the stochiometry of the reaction to be incorrect and the yield not quantitative. 
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HPLC METHOD DEVELOPMENT 
Literature on HPLC analysis of Tc-99m mebrofenin is very sparse. A recently published 
method reported using a C18 column and a 30 min linear gradient starting at 10% H2O (A) 
with 0.1% trifluoro acetic acid (TFA), and 90% acetonitrile (B) with 0.1%TFA, and ending at 
90% A / 10% B (6).  When tested with our HPLC system, this method performed poorly with 
extremely broad peaks.  To improve the peak shape, a sharper gradient was employed 
reducing the run time to 10 min and terminating the run with a 5-min hold at 90% of B.  
Since mebrofenin has a benzene ring, UV detection was performed at 254 nm; a Phenomenex 
Luna (C18, particle size 5 μm, 250 x 4.60 mm) column with a flow rate of 1 mL/min was 
used.  A fraction collector was set up in series with the UV detector, and fractions of 0.5 mL 
were collected every 30 sec for subsequent gamma and beta counting. These fractions were 
counted immediately with a bench top gamma counter (Tracon Northern TN-1750 
multichannel analyzer) and after decay (72 hr) they were analyzed for beta particles (Packard 
1600TR liquid scintillation analyzer) when appropriate. 
Mebrofenin, already reconstitued in sterile water as described in Appendix B.1, was 
labeled with only trace amounts of Tc-99m pertechnetate (solution A), Tc-99m and Tc-99 
pretechnetate in trace amounts (solution B), and Tc-99 pertechnetate only (solution C) in the 
same proportion as used in the in vitro and in vivo experiments. 
A solution of Tc-99m pertechnetate in saline (1 μCi/1 μL) was obtained from the 
nuclear medicine pharmacy at UNC hospitals.  This solution was diluted 1:4 in sterile saline.  
Tc-99m pertechnetate solution (100 μL) was added to 300 μL of mebrofenin stock solution in 
order to obtain solution A. Solution B was made by adding a mixture of 50 μL of Tc-99m 
pertechnetate and 50 μL of the Tc-99 pertechnetate stock (0.8 mM) to 300 μL of mebrofenin 
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aqueous solution. Finally, a beta only labeled complex (solution C) was obtained as 
previously done for the in vitro studies adding 150 μL  of the Tc-99 stock (0.8 mM) to 300 
μL of mebrofenin aqueous solution (solution C and all the solutions used in the in vitro 
studies developed a pink discoloration upon mixing). The gamma only, gamma/beta and beta 
only Tc-99m/Tc-99 mebrofenin complexes were allowed to form at room temperature over 
15 min and 100 μL of each solution was injected onto the HPLC system. Also Tc-99 
pertechnetate stock (100 μL) was injected. 
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RESULTS AND DISCUSSION 
LC-UV detection identified two sharp peaks in the Tc-99m and Tc-99 mebrofenin labeled 
solutions (solutions A, B and C, Fig B.3.1 panels a and b).   Upon gamma and beta counting, 
no peak was detected at a retention time (RT) of 8.4 min, this suggested that the first peak 
detected by UV was associated with unlabeled mebrofenin (monomer).  In contrast, almost 
all the radioactivity was associated with the second peak observed in the UV chromatogram 
(RT in UV 10.2 min), suggesting that this second peak was associated with the radioactive 
complex Tc-mebrofenin.  
The LC-UV analysis of Tc-99m only mebrofenin (solution A) and Tc-99m/Tc-99 
mebrofenin  (solution B) gave identical results.  Therefore, only one chromatogram is shown 
for both solutions in Fig B.3.1, panel a.  The LC-UV analysis of Tc-99 mebrofenin solution C 
(Fig B.3.1 panel b) also looked very similar to the chromatograms obtained for solutions A 
and B.  The peaks detected by UV had the same shape, height and area in all the samples, 
regardless of whether they were labeled with traces or a higher amount of Tc-99 sodium 
pertechnetate.  
Injection of the TcO4- stock solution demonstrated the presence of an unknown 
species eluting at 5.5-6 min, which was not detectable in solutions A, B or C (Fig B.3.1, 
panel c).  
Fig B.3.2 panels a, b, c and d refer to plots of relative cpms obtained upon radioactivity 
detection in the four solutions described.  Cpms were determined in each 0.5 mL fraction and 
then expressed as % of total cpms.  The peaks in the radioactivity-time profiles look broader 
than with UV detection.  The Tc-mebrofenin complex eluted at ~11 min in all the solutions 
tested, and the overall relative cpms associated with this peak were the same in solutions A 
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and B (when Tc-99m and Tc-99 were added in low amounts to mebrofenin acqueous 
solutions, Fig B.3.2 panel a, b, c).  Addition of the Tc-99m/Tc-99 pertechnetate mixture to a 
solution of mebrofenin yielded both Tc-99-mebrofenin and Tc-99m mebrofenin complexes, 
as expected, and as demonstrated by the presence of a single peak both in Fig B.3.2 panel b 
(gamma cpms) and panel c (beta cpms of the same solution B).  The purity calculated as the 
sum of the % cpms between 8 and 11.5 min, was 96% for solution A and 89% for solution B.  
A much lower yield of the Tc-99 mebrofenin complex was obtained when higher amounts of 
Tc-99 pertechnetate (in the same proportion used in the in vitro studies) were added to the 
mebrofenin solution, with a calculated purity equal to 67%.  This is in discordance with the 
TLC radiochemical purity test that was performed on all the solutions used in the in vitro 
studies, which indicated a purity of 90% or more. In Fig B.3.2 panel d, the beta cpms vs time 
profile obtained from HPLC fractionation of solution C (Tc-99 mebrofenin prepared as for 
the in vitro studies) and the Tc-99 pertechnetate stock solution are superimposed.  The 
presence of an overlapping peak at ~5.5 min indicates that in solution C, free Tc-99 
pertechnetate is present that did not quantitatively react with mebrofenin. Upon further 
investigation, it became clear that another complex also was formed (RT=8.5 min). It was 
quite surprising to notice that such a small ion would elute between 5.5-6 min.  A peak was 
detected at the same retention time in the Tc-99 pertechnetate stock solution also using UV 
detection, consistent with the hypothesis that another complex was present in the original 
stock solution. 
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CONCLUSIONS 
Upon development of a sensitive HPLC assay for technetium labeled mebrofenin, a 
discordance was noticed between the results of this method and the TLC method used to 
evaluate radiochemical purity during the execution of all the in vitro and ex vivo experiments. 
Unfortunately, due to the labile nature of the Tc-99 mebrofenin complex, it was not possible 
to evaluate a posteriori, by using this HPLC method, the purity of the solutions employed in 
the SCRH and IPL experiments.  All the solutions used in the in vitro studies exhibited a pink 
discoloration that only later was associated with an incomplete labeling reaction.  For these 
reasons, it is very difficult to present the data generated in the SCRH and the isolated 
perfused liver experiments as amounts of Tc-99 mebrofenin accumulated in the cells and 
canalicular spaces, and remaining in blood or excreted into bile.  The incomplete labeling 
reaction may be due to changes in the chemistry of the radiopharmaceutical kit for 
mebrofenin.  The transport of Tc-99m pertechnetate into bile canaliculi using SCRH also was 
assessed, and no difference was noticed in accumulation of substrate between cells+bile and 
cells.  It is likely that Tc-99 pertechnetate will behave in the same way.  The overall finding 
that Tc-99 mebrofenin is a Mrp2 substrate still holds true.  However, the expression of the 
data as amounts of Tc-99 mebrofenin complex in bile canaliculi from SCRH, perfusate and 
bile is not believed to be accurate, considering that other radioactive species probably were 
present.  For these reasons, all the remaining in vitro experiments were performed using only 
Tc-99m mebrofenin reconstituted as suggested by the manufacturer. 
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FIGURES 
Fig B.3.1: LC-UV analysis of Tc-99m mebrofenin (solution A) and Tc-99m/Tc-99 
mebrofenin (solution B) and Tc-99 mebrofenin (solution C) 
a) Solution A and B chromatograms were identical, as expected (these solutions were labeled 
with trace amounts of Tc-99m or Tc-99m and Tc-99, respectively) 
 
 
b) Solution C chromatogram (Tc-99 mebrofenin labeled as in the in vitro studies) did not 
show any significant difference from solutions A and B. 
 
 
c) Tc-99 pertechnetate stock solution LC-UV chromatogram 
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Fig B.3.2: Chromatograms obtained after gamma or beta counting of fractions collected after 
HPLC analysis of solutions A, B, C and the Tc-99 pertechnetate stock solution. 
a) Solution A: Gamma cpm vs time profile expressed as a % of total radioactivity.  
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b) Solution B: Gamma cpm vs time profile expressed as % of total radioactivity. 
Time (min)
0 2 4 6 8 10 12 14
G
am
m
a 
cp
m
 (%
 T
ot
al
)
0
20
40
60
80
100
 
 242
c) Solution B: Beta cpm vs time profile (note the perfect overalap with panel b) 
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d) Solution C and Tc-99 pertechnetate beta cpm vs time profiles. Solid line refers to solution 
C, dotted line to Tc-99 pertechnetate stock solution. 
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Appendix C 
 
 
 
IN VITRO INHIBITION OF TC-99M MEBROFENIN TRANSPORT BY 
RITONAVIR 
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 INTRODUCTION 
Tc-99m mebrofenin is an imino diacetic acid derivative (HIDA) commonly used in 
hepatobiliary scintigraphy that displays selective hepatic uptake and fast transit through the 
liver into bile. (1) This probe was used as described in Aim#1 during a clinical study to 
develop of a methodology to determine biliary clearance of drugs in humans (2).   
In vitro experiments we have demonstrated that hepatic uptake of Tc-99m mebrofenin 
is mediated, at least in part, by transport proteins belonging to the OATP family. Using 
inside-out membrane vesicles prepared from HEK293 cells transiently transfected with 
MRP2 or MRP3, it was also possible to show that Tc-99m mebrofenin egress from the liver 
into bile involves MRP2 and efflux into sinusoidal blood involves MRP3 (Chapter 3).  
Additionally, we were able to show that MRP2-dependent transport was inhibited to ~88% of 
control values by MK571 (50 μM), an LTD4 receptor antagonist commonly used as an MRP 
family inhibitor.   
Following the successful results obtained in Aim#1, an additional clinical study was 
designed to investigate the drug-drug interaction between ritonavir and Tc-99m mebrofenin 
in order to demonstrate that the methodology developed can detect changes in the biliary 
excretion of drugs. The effects of ritonavir (a known MRP2 inhibitor) on Tc-99m mebrofenin 
excretion into bile in healthy subjects was proposed. Here, the in vitro study supporting the 
hypothesis that ritonavir inhibits ATP-dependent transport of Tc-99m mebrofenin at 
physiologically relevant concentrations is reported. 
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METHODS 
Membrane preparation and transport experiments 
In order to evaluate the inhibition of MRP2-mediated transport of Tc-99m mebrofenin, 
inside-out membrane vesicles prepared from HEK293 cells transfected with MRP2 were 
used. 
HEK293 cells transiently transfected with MRP2 were prepared as reported in Chapter 3. 
Transport assays were carried out by a rapid filtration method as described in Chapter 3.  
Transport in the presence of AMP was subtracted from transport in the presence of ATP, and 
reported as ATP-dependent Tc-99m mebrofenin transport. The effects of ritonavir inhibition 
on Tc-99m mebrofenin transport were measured at a single time point of 3 min, using two 
ritonavir concentrations (5 and 50 μM). These concentrations were chosen to mimic the 
ritonavir Cmax in vivo after administration of a 200 mg tablet.  
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RESULTS 
Ritonavir inhibition of Tc-99m mebrofenin MRP2-dependent transport 
Inhibition of Tc-99m mebrofenin MRP2-mediated transport by ritonavir (5 and 50 μM) and 
by MK571 (50 μM) is plotted in Fig C.1. The ATP-dependent MRP2- mediated transport of 
Tc-99m mebrofenin was inhibited to ~88% of control values by the well-known general 
MRP inhibitor, MK571 (50 μM).  Ritonavir affected MRP2-dependent transport at both 
concentrations investigated. Tc-99m mebrofenin MRP2-dependent transport was decreased 
to ~68% and ~40% of control values by ritonavir 5 and 50 μM, respectively. 
 
CONCLUSIONS 
Concentrations of unbound ritonavir between 5 and 50 μM are sufficient to significantly 
inhibit Tc-99m mebrofenin transport by MRP2 in the inside-out membrane vesicle system. It 
is likely that these concentrations are reached within the hepatocyte after oral administration 
of 200mg ritonavir.  Thus, inhibition of biliary excretion of Tc-99m mebrofenin should be 
detectable during properly designed in vivo studies. 
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Fig C.1:  Tc-99m mebrofenin uptake in inside-out membrane vesicles prepared from 
HEK293 cells transiently transfected with MRP2 was inhibited in the presence of MK571 
(50 μM) and ritonavir (5 and 50 μM). Membrane vesicles were incubated for 3 min with Tc-
99m mebrofenin in the presence (open bar) and absence (closed bar) of inhibitor. Results are 
expressed as a percentage of untreated membrane expressing MRP2.  Bars represent mean (± 
SD) of triplicate incubations in a single experiment.  
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Appendix D 
 
 
 
PIPERACILLIN METABOLISM IN SANDWICH-CULTURED HUMAN 
HEPATOCYTES AND DIFFERENCES IN CANALICULAR NETWORK 
FORMATION IN DIFFERENT HEPATOCYTE PREPARATIONS 
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INTRODUCTION 
Primary human hepatocytes cultured in a sandwich configuration between a double 
layer of extracellular matrix have been used to investigate the hepatobiliary disposition of 
endogenous and exogenous substances and their metabolites as well as the hepatotoxicity of 
drugs (1-4).  However, the maintenance of metabolic capacity of this system has not been 
systematically investigated.  Recently, during a clinical study to quantify biliary clearance of 
piperacillin in humans, we identified two metabolites of this antibiotic in bile and urine 
samples.  Desethyl-piperacillin is formed by N-dealkylation of the parent drug; while this 
phase I metabolite had been identified previously in human urine and following incubation of 
liver homogenates (5, 6), the formation of desethyl-piperacillin glucuronide was not reported 
previously.  The characterization of metabolic pathways that are unique to humans is very 
important in the drug development process, and often the formation of human-specific 
metabolites can be predicted using microsomal incubations. Nevertheless, microsomes do not 
allow for mechanistic studies concerning the excretory route of these metabolites (canalicular 
vs basolateral excretion). In Chapter 4, we demonstrated that desethyl-piperacillin and its 
glucuronide were formed in vitro using human liver microsomes upon optimization of the 
experimental conditions.  The goal of this additional study was to investigate whether the 
SCHH model could be used to investigate the formation as well as the biliary excretion of 
these metabolites.   
The hepatobiliary disposition of taurocholic acid, Tc-99m mebrofenin, Tc-99m sestamibi and 
piperacillin was investigated in sandwich-cultured human hepatocytes obtained from 4 living 
donors affected by hepatic cancer (Chapter 5). Despite the difference in sex, age, race and 
previous medication exposure of these four donors, the hepatocyte preparations used in these 
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studies behaved in a similar manner with respect to hepatic accumulation of the investigated 
probes.  However, the morphology of the cells over days in culture, and the extent of 
canalicular network formation, varied from preparation to preparation affecting the extent of 
excretion of these compounds into canalicular networks.  The light micrographs of three of 
these sandwich-cultured human hepatocytes preparations after 6 days of culture are reported 
to illustrate these differences. 
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METHODS 
Isolation and Culture of Human Hepatocytes: 
Human liver tissue was obtained from liver resections procured through the Department of 
Surgery, University of North Carolina at Chapel Hill School of Medicine, with donor consent 
and approval of the UNC Hospitals Ethics Committee.  Hepatocytes were isolated by a 
modification of the two-step collagenase digestion method (7) and cultured according to the 
methods described previously in the Materials and Methods Section in Chapter 5.  In order to 
allow for formation of bile canalicular networks, SCHH were maintained for 6 days prior to 
experiments, and culture media was replaced every 24 h.  On day 6, canalicular network 
formation was evaluated with phase contrast microscopy, and digital images were captured 
with a Zeiss Axiovert 100TV inverted fluorescent microscope (Carl Zeiss Inc., Thornwood, 
NY, USA).  
Piperacillin Metabolism and Metabolite Excretion in SCHH: 
Hepatocytes were rinsed twice with 2 mL of standard HBSS (37°C) and pre-incubated for 10 
min in 2 mL of either standard HBSS (yielding cells + bile) or Ca2+-free HBSS (yielding 
cells).  After washing, hepatocytes were incubated at 37°C in 1 mL HBSS containing 500 
μM piperacillin for 30 minutes and subsequently rinsed vigorously four times with 2 mL ice-
cold standard HBSS to remove extracellular substrate.  Hepatocytes were lysed with 1 mL of 
ice-cold methanol/water 70/30 (v/v).  Nonspecific binding was accounted for by including a 
blank plate (BiocoatTM plus MatrigelTM overlay).  An aliquot of lysate was analyzed using 
LC-MS-MS as described below.  Due to incompatibility of the protein assay with methanol, 
the average protein content for standard HBSS or Ca2+-free HBSS incubations in the same 
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liver preparation was used to normalize piperacillin and metabolite content. Protein content 
in cellular lysates was quantified with the BCA method (8).  
The BEI in SCHH was calculated as follows:  
%100×−=
+
+
bilecells
cellsbilecells
onAccumulati
onAccumulationAccumulatiBEI     
Since none of the phase II metabolites were detected after 30 min incubation of Liver 1 
SCHH with piperacillin, additional experiments were performed with hepatocytes from 
Livers 2, 3 and 4.  Hepatocytes were incubated for 2 h in HBSS (Livers 2,3 and 4) and for 24 
and 48 hr (Liver 4 only) in maintenance medium containing 500 μM piperacillin in the 
attempt to increase intracellular concentrations of piperacillin and therefore of metabolites. 
LC-MS-MS analysis of Piperacillin and metabolites: 
Piperacillin and metabolite accumulation in SCHH was analyzed by LC-MS-MS: 100 μL of 
SCHH lysates were spiked with cimetidine (internal standard final concentration 0.5 μg/mL).  
To improve the sensitivity of the assay, samples were incubated for 2, 24 and 48h were dried 
and reconstituted in 1/10 of the original volume prior to analysis. 
The LC-MS-MS method employed has been described in detail in Chapter 4.  An analytical 
standard was available only for piperacillin; therefore desethylpiperacillin and 
desethylpiperacillin glucuronide concentrations were estimated qualitatively and expressed as 
internal standard peak area ratios per mg of protein. 
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RESULTS AND DISCUSSION 
Desethyl-piperacillin was formed within 30 min in all of the preparations of human 
hepatocytes used for these experiments. Accumulation in cells and cells+bile is shown in Fig 
D.1.  In SCHH prepared from Livers 1, 3 and 4, more desethyl-piperacillin was detected in 
cells+bile than in cells alone indicating measurable excretion of this metabolite into bile, in 
accordance with what was observed in the in vivo study. Unfortunately, actual quantification 
of this metabolite was not possible due to lack of an analytical standard.  For this reason, 
results are reported as the internal standard area ratio normalized for the protein content. 
The levels of desethyl-piperacillin glucuronide and piperacillin glucuronide were 
undetectable in all preparations after 30 min, 2, 24 or 48 hr incubation in the presence of 
piperacillin.  Although the piperacillin concentration in the medium was similar to the Cmax 
obtained in healthy volunteers in the clinical study (Chapter 4), the intracellular 
concentration of piperacillin in SCHH was very low (Chapter 5), and less than 1% of the 
dose was taken up by the hepatocytes in 30 min. In microsomal incubations, the formation of 
the phase II metabolites was detected only after increasing the piperacillin concentration in 
the incubation mixture to 500 μM.  This may explain why no glucuronidation was observed 
in the SCHH model. 
Images of the human hepatocytes cultured in a sandwich configuration from Livers 2,  
3 and 4 after 6 days in culture are shown in Fig D.2. Images for Liver 1 were not obtained. 
Taurocholate BEI values and in vitro Clbiliary were very similar between Livers 2 and 3 liver 
preparations.  However sandwich-cultured hepatocytes from Liver 4 hepatocytes taurocholate 
as well as all the other probes investigated in Chapter 5 into bile to a greater extent than the 
livers. This may be attributed to the more developed canalicular networks observed in images 
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of SCHH from Liver 4 compared to Liver 3 and especially Liver 2. This suggests that 
extensive formation of bile canaliculi detected by visual inspection of the sandwich-cultured 
hepatocytes correlates with more extensive excretion into the canalicular spaces.  However, 
since the major determinant of cellular and biliary accumulation is the expression of uptake 
and efflux transport proteins, visual inspection should be used in conjunction with functional 
assays, such as taurocholate accumulation and biliary excretion, when assessing the 
appropriate time in culture to perform accumulation experiments. 
 
CONCLUSIONS 
The results of these studies were encouraging, as SCHH were capable of forming desthyl-
piperacillin, most likely through a Cytochrome P450-mediated oxidative reaction. In three 
out of four liver preparations, it was possible to detect metabolite excretion into bile. 
The apparent lack of glucuronidation activity towards piperacillin and its metabolite may be 
due to the very low intracellular concentrations of these substrates.   Future studies should 
focus on the maintenance of phase I and II enzyme activity in SCHH using probe substrates 
with higher metabolic turnover rates.  Light microscopy images of the SCHH preparations on 
the day of the accumulation studies confirmed the formation of canalicular networks,  in 
most cases, network formation corresponded to greater extent of biliary excretion of the 
compounds under investigation. 
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FIGURES 
Fig D.1:  Accumulation and biliary excretion of desethyl-piperacillin in SCHH. SCHH were 
incubated with piperacillin (300 μM) and cell (empty bar) and cell+bile  (solid bar) 
accumulation were measured after 30 min. Bars represent mean (±SD) of triplicate 
determinations in a single experiment; four liver preparations were used in these studies. For 
each liver the individual BEI value is reported.  When cellular accumulation was higher than 
cell+bile accumulation, the BEI calculation was not possible (NA).  
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Fig D.2: Phase contrast images of SCHH preparations on day 6 in culture.  Bile canalicular 
networks were visible in all liver preparations, but were more extensive in Liver 4 than in 
Liver 2 or 3. Images were not available for SCHH from Liver 1.  Arrows indicate bile 
canalicular networks. 
 
UNC2 SCHH day 6 
 
 
 
 
 
 
 
 
 
20 μm
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UNC3 SCHH day 6 
 
 
 
 
 
 
 
 
 
20 μm
 
UNC4 SCHH day 6 
 
 
 
 
 
 
 
 
 
20 μm
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APPENDIX E 
 
 
 
RAW DATA FROM THE CLINICAL STUDIES  
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Tc-99m Mebrofenin study (Chapter 2) 
sub 01 
(actual 11)    
sub 02 
(actual 09)   
DOSE  
(μCi)    DOSE  (μCi)  
theoretical 2188   theoretical 2498  
Actual N.D.   Actual 2072  
Gallbladder EF (120-150min)  Gallbladder EF (120-150min) 
0.82    0.86   
BLOOD    BLOOD   
time (min) nCi/ml   time (min) nCi/ml  
0 0   0 0  
1 0.44   2 87.38  
2.5 30.09   2.75 137.59  
5 85.30   5.66 80.73  
7.5 80.72   7.5 55.23  
10 57.35   10 38.12  
20 16.29   20 17.59  
40 4.96   30 10.99  
60 3.38   40 4.39  
80 1.86   60 2.43  
100 1.33   80 1.95  
120 1.02   100 1.27  
140 0.87   120 1.27  
165 0.78   140 0.99  
180 0.76   165 0.93  
    180 1.31  
BILE    BILE   
time (min) actual  (μCi) 
EF corr  
(μCi)  time (min) 
actual  
(μCi) 
EF corr  
(μCi) 
0 0 0  0 0 0 
5 0 0  5 0.18 0.18 
10 0 0  10 0.55 0.55 
30 48.83 48.83  30 0.37 0.37 
50 30.14 30.14  50 0.18 0.18 
70 29.40 29.40  70 34.88 34.88 
90 65.71 65.71  90 227.20 227.20 
110 72.63 72.63  110 111.24 111.24 
130 57.07 62.00  130 816.80 886.97 
150 1004.15 1224.58  150 503.66 585.65 
180 125.53    180 51.73   
Cumulative 1433.47 1533.29  Cumulative 1746.81 1847.24 
       
URINE    URINE   
time (min) actual (μCi)   time (min) 
actual 
(μCi)  
0 0   0 0  
180 14.52   180 10.69  
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sub 03 
(actual 12)    
sub 04 
(actual 16)   
DOSE  
(μCi)    DOSE  (μCi)  
theoretical 1923   theoretical 2497  
Actual 2282   Actual 2476  
Gallbladder EF (120-150min)  Gallbladder EF (120-150min) 
0.03    0.86   
BLOOD    BLOOD   
time (min) nCi/ml   time (min) nCi/ml  
0 0   0 0  
2.166 159.81   1 166.39  
5 81.09   2.5 229.78  
7.5 97.93   5 167.04  
10 22.31   7.5 70.94  
19 6.98   10 43.53  
39.5 2.84   20 10.00  
60 1.84   40 6.03  
80 1.22   60 2.68  
100 0.82   80 2.51  
120 0.85   100 1.84  
140 0.77   120 1.51  
165 1.32   140 1.57  
    165 1.35  
    182 1.64  
       
BILE    BILE   
time (min) actual  (μCi) 
EF corr  
(μCi)  time (min) 
actual  
(μCi) 
EF corr  
(μCi) 
0 0 0  0 0 0 
5 0 0  5 0.16 0.16 
10 0 0  10 3.30 3.30 
30 174.95 174.95  30 132.18 132.18 
50 250.24 250.24  50 535.33 535.33 
70 90.31 90.31  70 114.22 114.22 
90 2.38 2.38  90 117.51 117.51 
110 1.47 1.47  110 48.62 48.62 
130 80.60 80.60  130 11.21 11.29 
150 44.88 1496.07  150 979.01 1138.39 
180 158.83    180 126.25   
Cumulative 803.66 2096.02  Cumulative 2067.80 2101.00 
       
URINE    URINE   
time (min) actual (μCi)   time (min) 
actual 
(μCi)  
0 0   0 0  
180 15.54   180 11.67  
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Tc-99m Sestamibi (Chapter 5) 
sub 01 (actual 23)   sub 02 (actual 25)   
DOSE  (μCi)   DOSE  (μCi)   
Actual 2503   Actual 3384   
        
Gallbladder EF (120-180min)  Gallbladder EF (120-180min)  
0.47    0.63    
BLOOD    BLOOD    
time (min) nCi/ml   time (min) nCi/ml   
0 0   0 0   
1 229.09   1 137.19   
2.5 82.24   2.5 82.18   
5 32.42   5 31.17   
7.5 20.35   7.5 16.50   
10 15.14   10 11.93   
20 9.30   20 8.11   
40 8.01   40 9.15   
60 4.71   60 5.31   
80 4.26   80 4.90   
105 3.51   105 4.02   
130 3.30   130 3.66   
150 2.87   150 3.56   
170 2.70   170 3.20   
180 2.65   180 3.59   
        
BILE    BILE    
time (min) 
actual  
(μCi) 
EF corr  
(μCi)  time (min) 
actual  
(μCi) 
EF corr  
(μCi)  
0 0 0  0 0 0  
5 1.85 1.85  5 0.00 0.00  
10 1.86 1.86  10 1.82 1.82  
30 11.15 11.15  30 49.18 49.18  
50 0.00 0.00  50 9.12 9.12  
70 1.86 1.86  70 5.49 5.49  
90 0.00 0.00  90 9.16 9.16  
120 1.86 1.86  120 3.67 3.67  
140 196.08 417.20  140 325.50 516.67  
160 59.76 127.15  160 106.87 169.63  
180 0.00 0.00  180 9.23 14.65  
Cumulative 274.43 562.93  Cumulative 520.03 779.38  
        
URINE    URINE    
time (min) 
actual 
(μCi)   time (min) 
actual 
(μCi)   
0 0   0 0   
180 634   180 246   
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sub 03 (actual 26)   sub 04 (actual 27)   
DOSE  (μCi)   DOSE  (μCi)   
Actual 3166   Actual 3182   
        
Gallbladder EF (120-180min)  Gallbladder EF (120-180min)  
0.9    0.64    
BLOOD    BLOOD    
time (min) nCi/ml   time (min) nCi/ml   
0 0   0 0   
1 102.31   1 275.24   
2.5 108.74   2.5 103.28   
5 48.13   5 36.29   
7.5 18.70   7.5 20.00   
10 13.47   10 12.27   
20 7.87   20 8.25   
40 7.70   40 7.15   
60 4.11   60 5.20   
80 3.94   80 4.29   
105 3.38   105 3.66   
130 3.10   130 4.78   
150 2.69   150 3.37   
170 2.97   170 3.12   
180 2.65   180 3.14   
        
BILE    BILE    
time (min) 
actual  
(μCi) 
EF corr  
(μCi)  time (min) 
actual  
(μCi) 
EF corr  
(μCi)  
0 0 0  0 0 0  
5 1.75 1.75  5 0.00 0.00  
10 5.26 5.26  10 0.00 0.00  
30 14.11 14.11  30 0.00 0.00  
50 10.61 10.61  50 0.00 0.00  
70 98.63 98.63  90 1.80 1.80  
90 45.82 45.82  120 3.57 3.57  
120 10.65 10.65  145 447.70 699.54  
140 448.44 458.37  160 78.83 123.18  
160 37.55 41.72  180 3.60 5.62  
180 12.54 13.93         
Cumulative 685.37 700.86  Cumulative 535.502349 833.703431  
        
URINE    URINE    
time (min) 
actual 
(μCi)   time (min) actual (μCi)   
0 0   0 0   
180 518   180 614   
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sub 05 (actual 28)   sub 06 (actual 29)   
DOSE  (μCi)   DOSE  (μCi)   
Actual 3037.05818   Actual 3563   
        
Gallbladder EF (120-180min)  Gallbladder EF (120-180min)  
0.16    0.83    
BLOOD    BLOOD    
time (min) nCi/ml   time (min) nCi/ml   
0 0   0 0   
1 111.99   1 84.98   
2.5 136.43   2.5 117.99   
5 41.46   5 27.96   
7.5 16.42   7.5 15.59   
10 12.76   10 13.68   
20 8.01   20 10.19   
40 9.22   40 12.60   
60 5.14   60 6.61   
80 4.60   80 5.53   
105 3.10   105 5.20   
130 3.09   130 4.90   
150 3.16   150 4.18   
170 2.68   170 4.18   
180 2.39   180 4.13   
        
BILE    BILE    
time (min) 
actual  
(μCi) 
EF corr  
(μCi)  time (min) 
actual  
(μCi) 
EF corr  
(μCi)  
0   0  0 0 0  
5 1.6481727 1.648172703  5 1.78329165 1.783291651  
10 1.6481727 1.648172703  10 3.59 3.59  
30 13.21 13.21  30 8.93 8.93  
50 11.57 11.57  50 10.73 10.73  
70 21.51 21.51  70 3.57 3.57  
120 23.24 23.24  90 5.36 5.36  
140 11.63 72.70  120 1.79 1.79  
160 51.79 323.66  140 433.46 522.24  
180 6.69 41.78  160 76.07 91.65  
       180 17.94 21.61  
Cumulative 142.93 510.97  Cumulative 563.21 635.50  
        
URINE    URINE    
time (min) actual (μCi)   time (min) actual (μCi)   
0 0   0 0   
180 671   180 621   
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sub 07 (actual 30)   
DOSE  (μCi)   
Actual 3100   
    
Gallbladder EF (120-180min)  
0.79    
BLOOD    
time (min) nCi/ml   
0 0   
1 212.66   
2.5 108.24   
5 38.28   
7.5 15.85   
10 13.80   
20 9.55   
40 11.50   
60 5.43   
80 4.76   
105 3.56   
130 3.30   
150 2.97   
170 2.62   
180 2.39   
    
BILE    
time (min) 
actual  
(μCi) 
EF corr  
(μCi)  
0 0 0  
5 1.69637594 1.696375941  
10 1.69963917 1.699639166  
120 23.93 23.93  
135 284.32 359.90  
160 217.86 275.77  
180 20.56 26.03  
       
       
       
       
Cumulative 551.768361 690.7228697  
    
URINE    
time (min) actual (μCi)   
0 0   
180 711   
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sub A (actual 19)   sub B (actual 20)   
DOSE  
(mg)    DOSE  (mg)   
Actual 1700   Actual 1764   
        
Gallbladder EF (120-150min)  Gallbladder EF (120-150min)  
0.82    0.28    
BLOOD    BLOOD    
time (min) mg/L   time (min) mg/L   
0 0   0 0   
15 127.96   15 109.02   
30 62.61   30 112.09   
45 39.99   45 73.00   
60 34.62   75 51.81   
75 23.00   112 35.25   
109 12.36   127 25.40   
152 5.33   150 21.13   
194 2.96   210 10.32   
262 1.43   270 5.93   
322 0.97   360 2.77   
352 1.34   600 1.46   
60 0.65   720 0.33   
720 0.54       
        
        
BILE    BILE    
time (min) EF corr  (ng) cumul %  time (min) 
EF corr  
(ng) cumul %  
0 0 0  0 0 0  
30 0.5 0  30 157.9 2.8  
60 1701.5 12.9  90 153.2 5.5  
90 336.1 15.5  120 100.4 7.3  
120 425.2 18.7  180 5.5 7.4  
180 562.8 23.0  240 32.1 8.0  
240 926.2 30.0  270 4058.0 80.1  
270 2073.4 45.8  300 320.5 85.7  
300 5162.8 85.0  360 802.4 100.0  
360 1973.4 100.0  cumulative 5629.9    
cumulative 13162.0        
        
        
URINE    URINE    
time (hr) actual (mg)   time (hr) actual (mg)   
0 0   0 0   
10 1227.00   10 1499.70   
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sub C (actual 21)   
DOSE  
(mg)    
Actual 1586   
    
Gallbladder EF (120-150min)  
0.07    
BLOOD    
time (min) mg/L   
0 0   
15 118.81   
30 68.42   
45 36.20   
75 36.74   
105 14.97   
151 7.95   
210 3.90   
270 1.77   
340 0.93   
360 0.09   
617 1.30   
720 0.33   
    
    
BILE    
time (min) EF corr  (ng) cumul %  
0 0 0  
30 19.3228973 0.891603168  
60 45.8984916 2.117862549  
90 12.69855641 0.58594076  
120 321.262461 14.82379291  
180 183.717926 8.47716998  
240 89.7457478 4.141076353  
270 219.64517 10.1349361  
300 81.26523258 3.749765768  
360 1193.651754 55.0778524  
cumulative 2167.208236    
    
    
URINE    
time (hr) actual (mg)   
0 0   
10 949.50   
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